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ABSTRACT
Stroke or cerebral vascular accident (CVA) is the 4th leading cause of mortality and the
principle cause of long-term disability in the United States. Unfortunately, current
reperfusion-based treatments (e.g. thrombolysis, tPA) cannot be administered to the
majority of patients presenting with ischemic stroke. Accordingly, new treatments for
ischemic stroke are desperately needed.
Reactive astrocytes perform key roles in tissue repair and remodeling following
stroke such as preservation and repair of the blood-brain barrier, modulation of immune
cell invasion, glutamate uptake and neuroprotection, and glial scar formation. The
proliferative subpopulation of reactive astrocytes found immediately adjacent to the
infarct core after stroke (known as the peri-infarct area) is particularly important for
protecting the brain parenchyma from ischemic damage and inflammation. Defining the
signaling network that controls reactive astrocyte formation and function has potential to
provide new treatment strategies for patients ineligible for reperfusion therapy.
Notch1 signaling is required for the proliferation of peri-infarct reactive astrocytes
after stroke. To identify downstream targets and potential functional effectors of Notch1
signaling in reactive astrocytes, we developed an ex vivo forward signaling screen. To
generate large quantities of adult reactive astrocytes, we employed adult Reactive
astrocyte-derived Neural Stem Cells (Rad-NSCs) isolated from the peri-infarct area of
mice after stroke. Astrocytes re-differentiated from Rad-NSCs (AstroRad-NSC) were then
exposed to immobilized Jagged-1, a Notch1 ligand. In response to Jagged-1, many genes
involved in reactive astrocyte-mediated tissue protection, metabolic regulation,
angiogenesis and glial scar formation were up-regulated. Of special interest, several
genes for proteins that regulate with glutamate uptake and metabolism were increased by
Jagged-1/Notch signaling, including the glial-specific GLutamate-ASpartate Transporter
(GLAST). With loss-of-function experiments, we determined that deletion of Notch1
decreased GLAST transcript and protein levels in cultured AstroRad-NSC. Furthermore, we
isolated reactive astrocytes directly from cerebral cortex after stroke and confirmed the
effects of Notch1 on GLAST in vivo. Our results suggest that treatments designed to
stimulate Notch1 signaling after stroke may promote glutamate uptake, thereby
decreasing excitotoxicity and neuronal cell death.
Binding of Endothelin peptides to the type B Endothelin receptor (ETBR) has
been shown to alter cell proliferation. Investigating a possible relationship between
Jagged-1/Notch1 and Endothelin signaling in reactive astrocytes, we determined that
Notch1 signaling regulated ETBR indirectly, by activating STAT3, an unidentified
transcriptional activator of ETBR. Using inducible transgenic astrocyte-specific
conditional knockout (cKO) mice (GFAP-ETBR-cKO), we found that specific deletion of
ETBR in reactive astrocytes phenocopied the defect in reactive astrocyte proliferation
observed in our previous work with GFAP-Notch1-cKO mice. Notably, the Notch1STAT3-ETBR axis we identified is likely to control reactive astrocyte proliferation in
most, if not all, forms of CNS injury.
The experimental results presented in this doctoral dissertation provide novel
insight into signaling mechanisms that may someday be exploited to improve care for
patients with stroke and other forms of CNS injury or disease.

CITATIONS
Material from this dissertation has been submitted for publication to Neuron (06/05/2014)
in the following form:
LeComte M.D., Shimada I.S., Sherwin C.J., and Spees J.L.. Notch1-STAT3-ETBR
signaling controls reactive astrocyte proliferation after brain injury.
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CHAPTER 1. COMPREHESIVE LITERATURE REVIEW.
1.1 Background and Impetus for the Study of Stroke
Stroke or “cerebrovascular accident” (CVA) is clinically defined as the acute onset of a
neurological deficit caused by inadequate blood flow to the central nervous system.
Based on 2009 statistics from the Centers of Disease Control (CDC), every year since
1998 an average of ~795,000 people in the United States has experienced a stroke. Stroke
is the fourth leading cause of death in the United States, accounting for approximately 1
in 18 deaths, and is only superseded in morality by heart disease, malignant neoplasms
and chronic lower respiratory diseases (Towfighi and Saver, 2011; Heron, 2013).
Recent efforts of researchers and clinicians have lowered stroke mortality in the
United States. The age-adjusted mortality rate due to stroke was lowered 37% in 10
years: from 61.6 per 100,000 deaths in 1999 to ~34 per 100,000 in 2010 (Kissela et al.,
2012). However, the trend for decreased stroke mortality is now threatened by an upward
swing in the prevalence of stroke risk factors like obesity and type 2 diabetes (Mitka,
2012).
Secondary to mortality, the majority of the disease burden of stroke is attributed
reduced neurologic function. As of 2012, the number of Americans suffering from
disability after stroke is approximately 7,000,000 and it remains the leading cause of
serious long-term disability in the United States (Roger et al., 2012). Approximately,
45% of stroke patients have moderate to severe disabilities. In the 2004 National Nursing
Home Survey, 11.7% of nursing home residents had a primary diagnosis upon entry of
“Acute cerebrovascular disease”.
1

(http://www.cdc.gov/nchs/data/nnhsd/Estimates/nnhs/Estimates_Diagnoses_Tables.pdf Table33b).
The quality of life is decreased amongst stroke survivors due to their disabilities
and the economic impact of cardiovascular disease and stroke is substantial. In 2008, the
healthcare system spent 18.8 billion dollars in direct costs due to stroke and 15.5 billion
in estimated indirect costs due to morality and loss of productivity. Notably, home health
care costs for stroke surpassed 5.5 billion (Roger et al., 2012). By comparison, hospital
expenditures for acute myocardial infarction (MI) amounted to 51.1 billion dollars and
post-MI patient home care expenditures were 7.9 billion dollars (Roger et al., 2012).
1.2. Challenges to the Treatment of Stroke
Stroke has a broad etiology. The most common cause is infarction, or blockage, of a
cerebral blood vessel by a fibrin clot. Known as an ischemic stroke, this type of stroke
accounts for 80% of stroke cases. Symptoms and signs can vary widely from minor
neurological deficit to major physical disability and death. The location of the infarct
dictates the area of the brain that becomes ischemic and thus, the forms of neurological
deficits that occur. Of the major vessels in the cerebral vascular system, the middle
cerebral artery (MCA) is the largest, supplying a vast area of the cerebral cortex. Within
the vascular territory of the MCA on the dominant hemisphere are areas involved in
motor control, sensation and speech. Notably, the MCA is the vessel most often occluded
in stroke (Goldstein et al., 2011).
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Current treatments for stroke are based on reestablishing blood flow with 1)
Enzymes that accelerate disruption of the offending blood clot (a.k.a. thrombolytic
therapy), or 2) Devices inserted into the arterial lumen to physically remove the clot, (e.g.
MERCI devices). Recombinant tissue Plasminogen Activator (tPA, Alteplase) was the
first thrombolytic therapy for stroke. Although clinical trials have demonstrated benefit
from tPA treatment, it does not decrease the overall morality of stroke (Lees et al., 2010).
As a stroke treatment, tPA has specific and stringent administration criteria. It is
estimated that only 2% to 3% of patients with acute ischemic stroke receive IV tPA
(Kleindorfer et al., 2008). The low treatment rate for tPA is attributable to its narrow time
window for administration after the onset of neurological deficits due to stroke. Patients
who receive tPA at 90 minutes or earlier after the onset of symptoms experience
significant neurological recovery. However, few patients who receive tPA beyond 4
hours from the onset of symptoms will have significant neurological recovery (Lees et
al., 2010; Gursoy-Ozdemir et al., 2012). Notably, the administration of tPA is not without
risk: 6% of patients experience edema and hemorrhage after thrombolysis (Donnan et al.,
2011).
1.3. The Need for Safe and Effective Therapies for Ischemic Stroke
Despite decades basic science research in the area of CNS injury, medical science has not
been able to provide a clinically relevant therapy for ischemic stroke. To date, numerous
compounds and biologics aimed at providing neuroprotection, vasoprotection, antiinflammation, or enhanced elimination of free radicals have not helped patients recover
from stroke. A recent search of the National Institute for Health’s (NIH) clinical trials
3

database (http://clinicaltrials.gov) produced over 292 records for ongoing or completed
clinical trials investigating treatments for acute ischemic stroke in adults. These
treatments included surgical interventions, cellular therapies, small-molecule drugs,
thrombolytics and cerebral cooling interventions, amongst many others. The following is
a representative list of therapies that have been investigated in large, double-blind,
placebo-controlled clinical trials that failed to confer benefits to patients: the neuroprotectant and antithrombotic Piracetam (Ricci et al., 2012), fibrinogen depleting agents
(Hao et al., 2012), the antioxidant NXY-059 (Savitz and Fisher, 2007; Diener et al.,
2008) and corticosteroids (Qizilbash et al., 2002; Sandercock and Soane, 2011).
Thrombolytic therapies continue to improve, but are still far from ideal (Sandercock et
al., 2012). Trials examining surgical decompression for cerebral edema by
hemicraniectomy following large cerebral infarcts have yielded favorable outcomes
(Cruz-Flores et al., 2012). However, this intervention requires removal of part of the
skull, allowing the brain to expand out of the cranial vault and is only indicated for very
large cortical infarcts that would otherwise lead to brain herniation and death. Surgical
decompression also requires a facility capable of performing the surgery and providing
post-operative care.
1.4. The Pathophysiology of Stroke
Understanding the evolution of CNS injury is essential for creating new therapies for
stroke. The stepwise response to injury of the mammalian central nervous system (CNS)
has a similar pattern across many modes of injury that include stroke, trauma, and tumor
invasion (Pekny and Nilsson, 2005). For focal cerebral ischemia, the pathological
4

progression begins with an infarct that either decreases blood flow or stops it entirely. In
patients, imaging that employs time-of-flight contrast computed tomography (CT) has
been useful for identifying the infarct core, an area directly downstream of the infarct
where cerebral blood flow (CBF) can drop from ~50 ml per 100 grams of brain tissue per
minute to 15–18 ml/100g/minute (Bramlett and Dietrich, 2004); this flow is insufficient
to maintain the metabolic demands of the tissue. Collateral flow creates an area around
the infarct core, known as the ischemic penumbra or peri-infarct area. For this reason, the
rescue of peri-infarct tissue at risk of damage from ischemia is the goal of many stroke
treatments (Back, 1998; Fisher and Bastan, 2012).
Cell death in the infarct core is mediated by both apoptosis and necrosis (Back,
1998). During stroke, glutamate-dependent excitotoxicity occurs as glutamate remains in
synaptic clefts. This causes prolonged calcium influx into neurons through Nnitrosodimethylamine (NMDA) channels/receptors, which then trigger pro-apoptotic
events (Mark et al., 2001). Production of oxidative and nitrate radicals by multiple cell
types also cause damage to the brain parenchyma (Gursoy-Ozdemir et al., 2012).
Furthermore, as platelets in the thrombus activate and release vasoactive and
inflammatory mediators (e.g. ADP, thromboxane, Nitric Oxide) the endothelium
becomes increasingly pro-thrombotic and the downstream microcirculation begins to clog
with secondary thrombi (Gursoy-Ozdemir et al., 2012).
At this point, a few hours may have elapsed since the initial thrombotic event
(Bramlett and Dietrich, 2004). The tight junctions of endothelial cells that maintain the
blood brain barrier become disrupted, in part due to proteolytic cleavage of these proteins
5

in the cell membrane as well as the extracellular matrix. Plasma proteins are then free to
leak into the parenchyma of the brain. The plasma proteins are followed by molecules of
water, resulting in cerebral edema (Gursoy-Ozdemir et al., 2012). After stroke, local
inflammation in the brain is mediated by cytokine and chemokine release by endothelial
cells, astrocytes, pericytes and microglia (resident CNS macrophages) (Back, 1998).
Acute immune invasion, primarily by neutrophils and macrophages, marks the secondary
phase of damage to the brain parenchyma and additional immune-mediated neuronal
apoptosis (Bramlett and Dietrich, 2004; Jaerve and Muller, 2012).
1.5. Reactive Astrogliosis
1.5.1 Introduction
Reactive astrogliosis occurs in most central nervous system injuries including:
penetrative injuries, contusions, hemorrhages, infections of all etiologies and tumors
(Graham, 1996). In the case of cerebral ischemia, within 6 hours after occlusion,
astrocytes residing near the ischemic infarct core begin a series of stereotyped molecular
and morphological changes in response to tissue injury. These changes are collectively
known as reactive astrogliosis. The ubiquity and stereotypy of reactive astrogliosis in
CNS injury suggests a critical role for this process in protecting the CNS from immunemediated damage, spreading of cytotoxic substances from areas of tissue damage and
secondary neuronal death.
Reactive astrogliosis resolves in to a glial scar: a persistent collection of
extracellular matrix and cells that impedes axonal re-growth from injured neurons
6

(Eddleston and Mucke, 1993; Pekny and Nilsson, 2005; Sofroniew, 2009). Since the time
of Ramon y Cajal, the glial scar was considered maladaptive and an impediment to CNS
regeneration after injury. Based on research performed in the last two and a half decades,
the glial scar is now considered the resolution of an important protective acute response
by proliferating astroglial.
Reactive astrogliosis occurs in tissue surrounding a CNS injury when astrocytes
become hypertrophic and increase their expression of various intermediate filament (IF)
proteins such Glial Fibrillary Acid Protein (GFAP), vimentin and nestin (Eddleston and
Mucke, 1993). The intensity of the reactive astroglial response is directly related to the
severity of CNS damage (Sofroniew, 2009). However, at either end of the injury
continuum, the resolution of astrogliosis can be vastly different, ranging from fully
healed CNS parenchyma with no evidence of glial scarring to the formation of a large
and persistent glial scar that contains new-born astrocytes and fibro-meningeal cells
(Sofroniew, 2009; Burda and Sofroniew, 2014). Strokes large enough to cause
neurological symptoms in humans elicit reactive astrogliosis that leads to glial scarring.
To date, only a few studies have been published that successfully determined cell
signaling mechanisms or other molecular mediators of reactive astrogliosis in vivo. The
role of reactive astrocytes in tissue preservation, repair and remodeling after CNS injury
has largely been achieved through experiments with various strains of transgenic
knockout mice designed to 1) delete intermediate filaments proteins such as GFAP,
thereby inhibiting reactive astrocyte (RA) formation, 2) deplete proliferating reactive
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astrocytes, or 3) delete important transcription factors in astrocytes such as STAT3 and
SOCS3 (Okada et al., 2006; Herrmann et al., 2008).
1.5.2. Inhibition of Neuronal Plasticity by Reactive Astrogliosis
Evidence for the deleterious effects of reactive astrogliosis has been well-documented
(reviewed in Silver and Miller, 2004; Pekny and Nilsson, 2005). Many of the deleterious
effects of reactive astrocytes are attributed to the inhibition of axon sprouting and
guidance and, general suppression of neuronal plasticity by the glial scar. Histological
evidence for the inhibitory effects of glial scarring on axon regeneration and outgrowth
can be found in the work of Ramon y Cajal (Silver and Miller, 2004). He described and
named the so-called “dystrophic endbulbs”, newly sprouted axons that appeared to stall at
the edge of the glial scar. The chondroitin and keratan sulfate proteoglycans produced by
reactive astrocytes within the glial scar are now known as the inhibitors of axonal
regeneration (Silver and Miller, 2004).
Menet et al. (2003) reported improved functional recovery after spinal cord
lesions in double knockout GFAP-/- vimentin-/- mice compared with recovery in control
animals (Menet et al., 2003). Citing many studies that obtained histological and
functional data for weeks and months after injury, Pekny and Nilsson (2005) suggest a
biphasic model for reactive astrogliosis: “The effect of reactive astrocytes after CNS
trauma has two stages: reactive astrocytes play a beneficial role in the acute stage after
CNS injury, but later act as inhibitors of CNS regeneration”.
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1.5.3. Protective roles of Reactive Astrogliosis
Astrocytes are necessary for tissue protection and repair during the acute phase of CNS
injuries like spinal cord injury and stroke. Pekney and others (1999) performed some of
the first experiments to elucidate the protective and reparative role of reactive astrocytes
in the acute phase of CNS injury. They found that knockout of the GFAP and vimentin
genes in mice increased immune cell infiltration and the persistence of acute
inflammation cells in the injury area; this correlated with a reduced rate and degree of
astroglial scar formation (Pekny et al., 1999). Targeted ablation of proliferating reactive
astrocytes in vivo produced phenotypic results similar to IF deletion, and disrupted repair
of the BBB (Bush et al., 1999). Notably, ablation of reactive astrocytes increased
neuronal apoptosis (Faulkner et al., 2004; Myer et al., 2006) and worsened functional
outcomes relative to control animals (Faulkner et al., 2004).
Reactive astrocytes protect neurons from excitotoxicity by uptake of glutamate
(Rothstein et al., 1996) and from reactive oxygen species after injury through a
glutathione-dependent mechanism (Pekny and Nilsson, 2005). They also mitigate postinfarct edema by up-regulating the expression of aquaporin proteins that provide
transmembrane water channels (Hirt et al., 2009). Reactive astrocytes also support
neurovascular remodeling after injury, which is important for tissue repair/remodeling
and recovery of motor function after focal ischemia (Hayakawa et al., 2010).
The inflammatory response following stroke is necessary for clearance of necrotic
and dying cells, but also causes the disruption of the BBB and secondary CNS injury
mediated by cells of the innate immune system (reviewed in Iadecola and Anrather,
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2011).

Reactive astrocytes secrete both pro- and anti-inflammatory cytokines to

modulate the immune response to injury (Iadecola and Anrather, 2011). Most
importantly, proliferating reactive astrocytes create physical barrier the injury area and
close off infiltrating innate immune cells from the parenchyma (Voskuhl et al., 2009;
Wanner et al., 2013).
In all, these studies show that the astroglial response to CNS injury is necessary
for tissue protection and repair during the acute phase of injury, and greatly out-weights
any long-term inhibitory effects on neural plasticity.
1.5.4. Comparative Astrogliosis: Restricted Regeneration of CNS tissue in Mammals
CNS tissue damage and regeneration have been well researched in cold-blooded animals.
Amphibians (Xenopus laevis) and Teleost fish such as zebrafish (Danio rerio) have an
amazing ability to regenerate the CNS after injury (Del Rio-Tsonis and Tsonis, 2003).
Sean Carroll’s recent book “Endless Forms Most Beautiful: The New Science of Evo
Devo” illustrates the stark differences between mammals and fish in response to retinal
damage. In brief, Müller glia (retinal astrocytes) in fish respond to retinal injury by
proliferating, forming a scar and then generating neuroblasts that repopulate the damaged
retina. Remarkably, healing of the CNS in these animals is both structurally and
functionally complete. In mice, the response to retinal damage is arrested at glia scar
formation, leaving the mice blind (Carroll, 2005) (see Del Rio-Tsonis and Tsonis [2003]
for a peer-reviewed article on this subject).
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1.6. Neural Stem Cells
1.6.1. Adult Neural Stem Cells
A neural stem cell is a specific type of stem cell that can divide symmetrically to make
two identical daughter cells, or asymmetrically to create a daughter cell and a neural
progenitor cell. Neural progenitor cells give rise to precursor cells with restricted
potential to differentiate into one of the three cell types in the neural lineage: neurons,
oligodendrocytes or astrocytes. Therefore, neural stem cells are said to possess the
property of self-renewal, i.e. they create identical daughter cells that maintain their
capacity for multipotent differentiation through multiple cell divisions and over time.
Adult neural stem cells (NSC) were first isolated from mice and cultured in the
early 1990’s (Reynolds and Weiss, 1992). Up to that point, NSCs could only be obtained
from embryonic neuroepithelium. To date, specialized “niches” that contain NSCs have
been identified in the adult CNS of many different mammalian species including rats,
mice, and man (Yao et al., 2012).
1.6.2. Adult Neurogenic Niches
Adult NSCs reside in two niches in the brain, the sub granular zone (SGZ) of the
hippocampal dentate gyrus and the subventricular zone (SVZ) of the lateral ventricle.
Both niches support a population of self-renewing stem/progenitor cells that give rise to
neuroblasts and nascent neurons, as well as glial precursors. The SGZ generates neurons
that integrate within the network of the dentate gyrus/CA3 region of the hippocampus to
facilitate learning and memory (Bonaguidi et al., 2012). The SVZ creates migratory
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neuroblasts that travel to the olfactory bulb where they differentiate into GABAergic
interneurons (inhibitory neurons) that integrate into the mitral layer and the granular layer
to refine odorant discrimination (Breton-Provencher and Saghatelyan, 2012).
The SVZ provides an environment that supports self-renewing adult NSCs in the
mammalian forebrain (Morshead et al., 1994). The SVZ NSC niche consists of several
different cell types that facilitate adult neuro- and gliogenesis. Doetsch and colleagues
(2002) proposed a model that ascribes the labels “A”, “B” and “C” to different cell types
in the neurogenic niche. Type B cells are the putative stem cell and have astrocyte-like
morphology and have processes that contact microvessels and the cerebral spinal fluid in
the lumen of the lateral ventricle. They express multiple proteins characteristic of NSCs:
Sex determining region Y-box 2 (Sox2), GFAP, nestin, and CD15/SSEA-1 (Ihrie and
Alvarez-Buylla, 2011). Transit amplifying progenitor cells, or Type C cells, arise from
asymmetrical divisions of Type B cells. Type C cells express the EGF receptor and the
transcription factor MASH1 (Doetsch et al., 2002); these cells divide rapidly to produce
Type A cells (neuroblasts). The Type A cells are destine to become neurons and express
markers of early neural lineage cells (neuroblasts): polysialylated neural adhesion
molecule (PSA-NCAM), doublecortin (DCX), and β-tubulin III (Tuj1). When removed
from the SVZ and cultured in basic fibroblast growth factor (bFGF) and EGF, Type C
cells create self-renewing, multipotent neurospheres (Doetsch et al., 2002). The selfrenewal capacity of NSCs declines with passaging in some species (e.g. rats), but remains
intact for hundreds of passages in mice (Steffenhagen et al., 2011). The ability of murine
SVZ NSCs to self-renew and to maintain multi-lineage potential has allowed researchers
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to study them in great detail. In addition, cultured SVZ NSCs can be grafted into the
lateral ventricle of a host and some behave normally, producing neuroblasts capable of
migrating down the rostral migratory stream and generating interneurons in the OB
(Aguirre and Gallo, 2004; Lledo et al., 2008; Shimada et al., 2012).
1.6.3. Cortical Development and the Adult Sub-Ventricular Zone (SVZ)
During formation of the cortical layers, radial glial cells that reside in the ventricular zone
extend single, radial processes out towards the embryonic pia mater. Radial glial cells
divide asymmetrically, forming neuroblasts that migrate along the radial processes and
that differentiate into neurons that compose the layers of the cerebral cortex. The layering
of cortical neurons proceeds in a coordinated manner that is timed and dictated by
mechanisms intrinsic and extrinsic to radial glial cells (Kazanis et al., 2008).
Gliogenesis, the formation of oligodendrocytes and astrocytes, begins around
E18.5 and continues into the post-natal period. A few days after birth, radial glial cells
give rise to glioblasts that populate the newly-formed cortex (Qian et al., 2000).
Subsequently, the apical processes of a few remaining radial glial cells retract; these cells
will reside in the SVZ as self-renewing, multipotent adult NSC (Merkle et al., 2004).
1.6.4. Endogenous Stem Cell Therapy for Ischemic injury from the SVZ
Since the discovery of the SVZ niche, researchers have attempted to harness it as a source
of stem cells for repair after brain injury (Temple and Alvarez-Buylla, 1999). For
cortical/striatal injury, including strokes, the SVZ has been the subject of intense study
because of its anatomical proximity to stroke injury. Migration of neuroblasts from the
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SVZ was reported for both adult rats and mice after they were subjected to ischemic
insult (Arvidsson et al., 2002; Gotts and Chesselet, 2005b, a; Yamashita et al., 2006).
Migration is a key aspect of injury repair by neuroblasts. Neuroblasts utilize the
architecture of the cerebral vasculature to migrate to sites of injury (Shen et al., 2008;
Kojima et al., 2010). New neurons derived from doublecortin (DCX+)-positive
neuroblasts tagged with thymidine-analogue 5-bromo-2'-deoxyuridine (BrdU) from the
time of injury have been observed in the murine striatum after transient intra-luminal
middle cerebral artery occlusion (tiMCAO) (Arvidsson et al., 2002; Yamashita et al.,
2006). It remains controversial whether or not functional recovery is enhanced by newly
born SVZ-derived neurons.
Using a focal injury model that damaged the cortex, corpus callosum and distal
striatum, Gotts and Chesselet (2005b) observed the migration of SVZ DCX+ neuroblasts
to the area of injury, but did not observe new neurons that derived from these cells. With
the use of a permanent distal Middle Cerebral Artery Occlusion (dMCAO) model our
group induced focal cortical ischemic injury that did not damage the striatum. Notably,
we observed that no DCX+ cells migrated from the SVZ to areas near the cortical infarct
or peri-infarct area (Shimada et al., 2010). From these studies, it appears that the SVZ is
stimulated by ischemic injury, but the severity and/or proximity of injury dictates the
number of neuroblasts that migrate from the niche to area of tissue damage.
1.6.5. Reactive Astrocyte-derived Neural Stem Cells
Lang et al. (2004) identified a population of nestin-expressing reactive astrocytes that
formed after hemi-transection of the rat spinal cord. In culture, these cells could form
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neurospheres under the same conditions as SVZ-derived NSCs. They also showed that
these cells were multipotent in culture (Lang et al., 2004). Lineage-tracing studies that
utilized inducible reporters under the control of astrocyte-specific promoters have
identified astrocytes as the source of NSCs derived from injured cortical tissue. Reactive
astrocyte-derived NSCs (Rad-NSCs) have been identified in brain stab injury (Buffo et
al., 2008), neonatal hypoxia injury (Bi et al., 2011) and stroke (Shimada et al., 2012).
Interestingly, not all brain injuries generate reactive astrocytes that are capable of
conversion to NSCs in culture. Sirko et al. (2013) examined the sphere-forming capacity
of reactive astrocytes in several mouse models of cortical injury. Certain injuries such as
cortical needle stab injury and ischemic stroke, respectively, affect reactive astrocytes in
a way that makes them competent for conversion to NSCs, in vivo. Insults and
pathologies such as murine models for Alzheimer’s (specifically the Swedish mutation:
AppS1) and neurotoxicity do activate astrocytes, but do not achieve the temporally brisk
activation or the reactive astrocyte proliferation that stroke and needle stab elicit.
1.6.6. Reactive Astrocyte Reprogramming, In Vivo
Reactive astrocytes share several characteristics with adult NSCs (i.e. Type B cells in the
SVZ). For example, both cell types express stem cell-associated transcription factors (e.g.
SOX2) and intermediate filaments (e.g. GFAP, nestin). The astrocyte-like stem cells in
the SVZ neurogenic niche divide undergo division, but are quiescent most of the time.
Similarly, cortical astrocytes are mitotically quiescent for long periods of time, then
undergo a period of rapid division during the response to injury after their conversion to
reactive astrocytes, and they become quiescent again. The new cells form during reactive
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astrocyte proliferation generate mature astrocytes and contribute to the glial scar (Wanner
et al., 2013). In contrast to adult NSC, adult reactive astrocytes are lineage-restricted in
vivo. This lineage restriction is controlled by both cell-extrinsic and intrinsic factors.
Futhermore, despite their multipotency in culture, Rad-NSCs grafted back to the
SVZ were not able to create neurons in the olfactory bulb (Shimada et al., 2012). Postnatal day 7 cortical NG2+ neural progenitor cells were unable to create neurons in the OB
after engraftment into the SVZ (Aguirre et al., 2005).
The addition of exogenous bFGF and EGF to injured CNS tissue is not sufficient
to spur neurogenesis from reactive astrocytes (Ohori et al., 2006). However, neurogenesis
in the peri-infarct area can be achieved to a limited degree by transfecting reactive
astrocytes with neurogenic transcription factors such as Nkx2.2 (Ohori et al., 2006) or
Pax6 (Heins et al., 2002). Niu et al. (2013) demonstrated that lentivirus-induced
expression of Sox2 under the control of the human GFAP promoter both necessary and
sufficient to induce astrocytes to become neuroblasts in the striatum of adult mice. Of
interest, they found that astrocytes first passed through a proliferative state—a feature of
reactive astrocytes—before becoming neuroblasts. Niu et al. (2013) were able to
terminally differentiate astrocyte-derived neuroblasts with Brain Derived Neurotrophic
Factor (BDNF) and Noggin treatment or Valproic Acid alone to produce mature,
functionally-integrated neurons. Thus, dividing reactive astrocytes that respond to injury
somewhat resemble NSCs and are amenable to viral induction by transcription factors
that break the multipotency barrier, allowing neurogenesis to occur. However, it remains
to be seen whether neurogenesis can be influenced in an orchestrated manner after injury
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in order to beneficially alter CNS tissue remodeling and restore function to damaged
neural tissue.
1.7. The Regulation of Reactive Astrocytes
1.7.1. Introduction
Understanding the signaling pathways that regulate proliferation and protective functions
of reactive astrocytes is essential for exploiting them therapeutically. Moreover,
manipulating reactive astrocytes to provide maximal therapeutic effect will require
knowledge of how they respond differently to particular types of CNS injury. For
example, Zamanian et al. (2012) found that reactive astrocytes formed during a model of
neuro-inflammation in the cortex expressed a markedly different set of genes compared
to reactive astrocytes responding to ischemic stroke.
1.7.2 Notch Signaling: a Brief Introduction
Notch signaling is a highly conserved cell-cell signaling system that is found in
multicellular animals (Hori et al., 2013). The gene and its significance in Metazoan
development were first described by Thomas Hunt Morgan in Drosophila melanogaster a
century ago (Imayoshi and Kageyama, 2014).
Components of the pathway
Mammalian express 4 genes with homology to the Notch gene in Drosophila: named
Notch 1 through 4. In terms of nomenclature, mammalian Notch ligands are separated
into two groups: the Delta-like or Delta group
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(DLL1-4) with homology to the

Drosophila Delta receptor and the Jagged group (Jagged1 and 2) with homology to the
Drosophila Serrate receptor. Notch receptors undergo extensive post-translational
modifications including O-linked glucosylation and fucosylation; these are important for
proper protein folding and intracellular trafficking of the receptors. Notch receptors
undergo a proteolytic cleavage before presentation to the cell surface (S1 cleavage) and
upon binding to its ligands (S2 and S3 cleavage) (Hori et al., 2013).
S3 cleavage is necessary for Notch signaling (Rozmahel et al., 2002) and
ismediated by a proteolytic intramembrane protein complex known as γ-secretase. In
mammalian systems γ-secretase is composed of four proteins: Nicastrin, Presenilin
Enhancer 2 (PEN2), Anterior PHarynx-defective 1 (APH1) and an aspartyl proteases
Presenilin1 or 2 (Kopan and Ilagan, 2004). Presenilins1 or 2 provides the catalytic site for
proteolysis, but do not have normal activity outside of the γ-secretase complex. Both
require Nicastrin for proteolytic activity (Chung and Struhl, 2001).
The γ-secretase complex has been proposed as the “proteasome of the membrane”
due to the wide array of membrane-bound receptors and proteins it cleaves and its
apparent role in receptor shedding (Kopan and Ilagan, 2004). It cleaves several other
type-1 transmembrane proteins, notably a protein linked to Alzheimer’s dementia called
Amyloid Precursor Protein. Several pharmacological inhibitors of γ-secretase activity
have been developed and are useful to inhibit the cleavage of Notch receptors and Notch
signaling. Most inhibit proteolysis by inhibiting the catalytic site of Presenilin1 and 2
(Wolfe and Haass, 2001).
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Signaling Mechanism
Canonical Notch signaling proceeds as follows: the Notch receptor binds to a Notch
ligand presented on the surface of an adjacent cell. The Notch-ligand interaction causes a
conformational change in the transmembrane domain of Notch that exposes a sequence of
peptides that is recognized and cleaved by γ-secretase. Cleavage releases the intracellular
domain of Notch (NICD) from the membrane. It then translocates to the nucleus and
interacts with the transcriptional repressor protein CSL (RBPJκ in mice). Upon
association, NICD/CSL recruits mastermind-like protein (MAML) and other coactivators to form a transcriptional activator complex that initiates gene expression of
downstream effector proteins such as transcription factors (Ables et al., 2011). Several of
the transcription factors that are activated by Notch, such as the Hairy/Enhancer of Split
(HES) family, are highly conserved across species and promote cell division and lineage
specification (Louvi and Artavanis-Tsakonas, 2006).
General Function in Animal Development
Notch signaling is necessary for the specification and differentiation of many cell and
tissue types during animal development, and is a large player in tissue patterning (Lai,
2004). In addition, Notch signaling can also induce proliferation or apoptosis (Hori et al.,
2013). During CNS development in vertebrates, Notch signaling is essential for
determining the number of neurons generated by regulating the size of the neural
progenitor pool and therefore affects brain morphogenesis (reviewed in Louvi and
Artavanis-Tsakonas, 2006).
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1.7.3. Jagged: a Ligand of Notch
The cDNA encoding Jagged, the mammalian homologue of the Serrate receptor in D.
melanogaster, was first cloned and described in rats (Lindsell et al., 1995). In this
seminal study, Jagged mRNA was shown to pattern the developing rat neural tube in a
distribution similar to that of Notch1, 2 and 3. Furthermore, Lindsell et al. (1995)
demonstrated that cloned Jagged cDNA expressed by L-cells could induce Notch1
signaling on adjacent myoblasts in culture. These observations suggested its activity as a
Notch1 ligand.
There are two mammalian Jagged genes: Jag1 and Jag2. The Jag1 gene encodes a
single-pass transmembrane domain receptor with a molecular weight of ~135 kDa
(Lindsell et al., 1995). Compared with Jagged proteins, members of the Delta family of
Notch ligands are smaller in molecular weight. Like the Notch receptors, Delta and
Jagged are processed by γ-secretase to release their respective intracellular domains,
although no signaling has been attributed to these fragments (LaVoie and Selkoe, 2003).
Both families of receptors contain a Delta-Serrate-LAG-2 (DSL) domain, which is highly
conserved across species and required for Notch receptor trans-activation and cisinhibition (Cordle et al., 2008). Notch receptors discriminate between Delta and Jagged
ligands depending on the context and conditions of the interaction (Yamamoto et al.,
2012).
The existence of two separate ligands of Notch in both D. melanogaster (Delta
and Serrate) and mammals (Delta 1-4 and Jagged 1,2) suggests functional importance in
metazoan biology. Differential expression of mRNA for Notch, Delta and Jagged
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isoforms in regions of the developing mammalian embryo, and particularly in the
developing brain, suggest specific roles for these receptors (Lindsell et al., 1996).
However, there does not appear to be a consensus of Notch signaling effects attributable
to Delta binding verses Jagged binding in mammalian systems. In early human
hematopoiesis, Jagged-2 signaling through Notch has an effect similar to that of Delta 14. It signals through Notch1 and induces T-cell lineage differentiation while inhibiting Bcell and myeloid cell development. In contrast, Jagged-1 prevents T-cell differentiation
and promotes the B-cell fate (Van de Walle et al., 2011). Elyaman et al. (2007)
demonstrated favorable outcomes after infusion of Jagged-1-FC in an experimental
model of autoimmune encephalomyelitis, whereas treatment with a Delta-1-FC or with a
neutralizing antibody to Jagged-1 was found to exacerbate the injury. These studies
provide evidence that Notch ligand isoforms differentially modulate Notch signaling to
influence development, cell fate determination, and response to injury.
Jagged in Neurodevelopment and Disease.
Little is known about how the Jagged family of Notch ligands participate in
neurodevelopment. Jagged-1 is essential for mammalian development as Jag1 null mice
do not survive embryogenesis and die in utero due to malformation of the cardiovascular
system and subsequent hemorrhaging (Xue et al., 1999). Jag1 mRNA is expressed in
different regions and at different times in the developing CNS and is independent of
Delta ligand patterning (Lindsell et al., 1996). In the developing optic nerve, Jagged-1 is
transiently-expressed on retina ganglion cells that interact with Notch1-expressing
oligodendrocyte precursors (OPC). Notch1 signaling in OPCs inhibits their maturation to
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oligodendrocytes. Though these cell-cell interactions, Jagged-1/Notch signaling controls
myelination of the optic nerve (Wang et al., 1998). Jagged-2 maintains multipotency and
proliferation of neural progenitors while inhibiting neuronal differentiation in the ventral
spinal cord of developing zebra fish (Yeo and Chitnis, 2007).
Mutations in the human gene encoding Jagged-1 causes Alagille syndrome, an
inherited developmental disorder that affects formation of the bile ducts in the liver and
the development of craniofacial bones. Alagille syndrome is also associated with
developmental delay and reduced cognitive function (Oda et al., 1997).
1.7.4 Notch Signaling in Astrogliogenesis
Development of the vertebrate cerebral cortex is a highly orchestrated event during
which neurogenesis is followed by gliogenesis. This process is discussed further in
section 1.6.3. Cortical Development and the Adult Sub-Ventricular Zone (SVZ).
Just before birth, radial glial cells in the developing cortex first populate the
cortical layers with neurons. At birth, radial glial cells switch to producing astrocytes in
an event known as the neurogenic-gliogenic switch (Okano and Temple, 2009). During
the early stages of neurogenesis, Notch signaling sustains symmetric divisions of radial
glial cells in order to maintain the pool of progenitors and to generate neurons (Yoon et
al., 2008; Dong et al., 2012). Notch1 overexpression in the neuroepithelium during early
forebrain development promotes the radial glial phenotype prematurely (Gaiano et al.,
2000).
At the neurogenic-gliogenic switch, glioblasts are the predominant cell type
created from the asymmetric divisions of radial glia (Temple and Alvarez-Buylla, 1999).
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Notch signaling drives this process through collaboration with BMP/SMAD signaling
and GP130/STAT3 signaling to promote the transcription of glial-specific genes like
GFAP. Notch1 signaling also promotes the expression of astroglial fate-specification
genes such as Nuclear Factor 1 (NF1a) and GLAST in spinal cord development (Deneen
et al., 2006; Miller and Gauthier, 2007). Notch suppresses the neurogenic program by
action of HES5. Direct protein-protein interactions with pro-neural basic helix-loop-helix
factors and HES5 prevent premature neurogenesis and maintain undifferentiated radial
glia during development (Imayoshi and Kageyama, 2014). In sum, Notch signaling
provides an important extrinsic signal that maintains the radial glial phenotype and selfrenewal in prenatal cortical development, and later drives astrogliogenesis at the
neurogenic-gliogenic switch.
1.7.5. Regulation of adult NSCs in the SVZ by Notch signaling
The SVZ of the adult mouse contains a germinal zone where NSCs give rise to
neuroblasts, oligodentrocyte precursors and astrocytes (Aguirre and Gallo, 2004).
Astrocyte-like type B cells (adult NSCs) depend on Notch1 signaling to maintain
properties of self-renewal (Aguirre et al., 2010a; Basak et al., 2012). Using a transgenic
mouse model to conditionally delete Notch1 in nestin-expressing NSCs, Basak et al.
(2012) saw a reduction of neurogenesis and depletion of the progenitor pool in the SVZ.
Using the anti-mitotic AraC to ablate proliferating Type C transit-amplifying cells in the
SVZ and then allowing for a period of recovery, they demonstrated a defect in the
symmetrical division of NSCs (Basak et al., 2012). In another study, upon recovery from
AraC treatment, the levels of NICD and RBPJκ (CSL) were increased in the SVZ. This
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was accompanied by a decrease in Numb, a protein that antagonizes Notch signaling
(Aguirre et al., 2010b).
Jagged-1 is expressed in the adult murine SVZ and SGZ (Stump et al., 2002). In
the SVZ, Jagged-1 expression was localized to GFAP-expressing astrocytes, whereas
Notch1 was expressed on DCX+ neuroblasts. Infusion of Jagged-1-FC into the lateral
ventricle increased the amount of DCX+ cells migrating out from the SVZ (Wang et al.,
2009).
1.7.6. Notch Signaling and Stroke: Helpful or Hurtful?
Following stroke, the outcome of Notch signaling is controversial. It has been reported to
be either detrimental or beneficial to tissue repair and neurological outcomes. Arumugam
et al. (2006) employed an occlusion/reperfusion model and found that, following stroke,
inhibition of Notch signaling with a γ-secretase inhibitor (GSI) or a Notch antisense RNA
decreased infarct volume and improved neurological function compared with control
levels. Conversely, Benner et al. (2013), using a photothrombosis-mediated MCA
permanent occlusion model, found that disruption of Notch signaling in nestin-expressing
reactive astrocytes worsen injury outcome. Arboleda-Velasquez et al. (2008) found that
deletion of Notch3 in vascular smooth muscle cells resulted in worse outcomes in a
transient cerebral ischemia model. Unfortunately, variations in stroke model, strategy for
disrupting Notch signaling, cell-type specificity for gene conditional knockouts and the
age differences make it difficult to compare the results from these three papers.
Jagged-1 mediated Notch signaling in reactive astrocytes has been also studied in
the context of demyelinating injury. In this case, recovery requires OPC migration,
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differentiation and remyelination of axons. Reactive astrocytes are also present in these
lesions. OPCs in the lesion area express Notch1 and contact reactive astrocytes that
express Jagged-1. Subsequent induction of Notch signaling in OPCs inhibits their
terminal differentiation into oligodendrocytes (Hammond et al., 2014; Wang et al., 1998).
In contrast, other groups have found no evidence of Jagged-1/Notch signaling causing
deficiencies of myelination of the CNS during development (Zhang et al., 2009) or after
demyelinating injury (Stidworthy et al., 2004).
1.7.7. Jagged-1/Notch Signaling in Reactive Astrocytes
Notch signaling in reactive astrogliosis has not received the kind of intense investigation
it has received for its roles in developmental processes. This is surprising considering the
clear importance of Notch1 in astrogliogenesis and in light of evidence suggesting that
Notch signaling supports gene and protein expression that promotes astrocyte identity
(Imayoshi and Kageyama, 2014). Our group has shown that Notch1 is required for
normal proliferation of reactive astrocytes after stoke (Shimada et al., 2011). The role of
Jagged-1/Notch signaling in reactive astrocyte functions remains undefined.
1.7.8. A Brief Introduction to Endothelin Signaling
The Endothelin signaling axis consists of three soluble peptides, Endothelin-1, -2, and 3,
that require proteolytic cleavage with Endothelin Converting Enzyme (ECE) in order to
be biologically active. Their cognate receptors, ETAR and ETBR, are G-protein coupled
receptors that increase intracellular Ca2+ through the action of phospholipases to effect
transcription early response genes. These receptors also crosstalk with many intracellular
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signaling pathways: MAPK, PI3K–AKT, NF‑κB, β‑catenin, HIF1α, RHO, PKA and PKC
(Rosano et al., 2013). ETAR has higher affinity for ET-1 and ET-2 than ET-3, whereas
ETBR has equal affinity for all three Endothelins. Endothelins, ECEs and ET receptors
are found in many organs systems and tissues. The Endothelin system is integral to the
vascular system, the kidneys, and the pulmonary tree, where it regulates blood pressure,
blood ion and acid-base balance, and bronchial tone, respectively (Masaki, 2004; Ge et
al., 2008; Uchida et al., 1988).
The Endothelin-1 was first discovered in the conditioned medium of endothelial
cells and was determined to be a potent vasoconstrictor (Yanagisawa et al., 1988). Under
normal physiological conditions, Endothelin 1 (ET-1) is secreted from endothelial cells
and controls tonic vasoconstriction by stimulating smooth muscle cell contraction.
Binding of ET-1 to ETAR on vascular smooth muscle cells causes signaling through the
phospholipase system that then increases intracellular calcium. This activates the
myosin/actin system and causes contraction of the smooth muscle cell. Endothelial cells
express ETBR, but not ETAR. Signaling through endothelial ETBR drives the production
of nitric oxide (NO), which causes relaxation of smooth muscle and vasodilatation. In
this way, ET-1 signaling maintains vascular tone. Perturbations of ET-1 signaling have
been implicated in the pathophysiology of many cardiovascular diseases including
hypertension-induced renal failure, arteriosclerosis, pulmonary fibrosis and hypertrophic
remodeling of the heart (reviewed in Kedzierski and Yanagisawa, 2001; Masaki, 2004).
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Special Focus: Endothelin Receptor B and Hischprung’s disease
ETBR regulates the development and migration of the neural crest, a specialized group of
multipotent cells that arise from the dorsal end of the neural tube during vertebrate
embryogenesis. Neural crest cells proliferate extensively and migrate to distal sites and
colonize the skin as melanocytes and the gut as enteric neurons. Mice with a spontaneous
deletion in the Ednrb gene, known as piebald-lethal (Ednrbs-l ) mice, have altered
melanocyte distribution, which gives them a patchy coat color, and die of toxic
megacolon, due to a lack of enteric neurons that mediate gastric motility in the colon
(Hosoda et al., 1994). By inducible transgenic Ednrb-rescue of Ednrbs-1 mice, Shin et al.
(1999) showed that ETBR was required for the proper migration of melanocyte precursor
and enteric neuron precursor cells.
Hischprung’s syndrome, an inherited human disease, is the result of a missense
mutation in the EDRNB gene, which encodes for human ETBR. Hischprung’s syndrome
is characterized by severely decreased gastric motility in the distal colon that can
progress to toxic megacolon—a fatal complication. Similar to Ednrbs-1 mice, patients with
Hischprung’s are missing enteric ganglia in the distal colon; this leads to reduced gastric
motility (Puffenberger et al., 1994).
1.7.9. Endothelin and Cerebral Ischemia
The Endothelin signaling axis plays a critical role in cerebral ischemia (reviewed in
Kaundal et al., 2012). Extracellular ET-1 levels increase in the brain acutely after focal
and global ischemia at 24 hours (Barone et al., 1995) and plasma levels increase in
humans following stroke (Ziv et al., 1992). ET-1 is produced at the site of injury and acts
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as an acute phase signaling peptide, producing a multitude of different effects on the
injury environment and acts on vascular smooth muscle cells, reactive astrocytes and
other cell types (discussed in detail later).
Researchers and drug developers have focused their efforts on understanding the
vascular effects of the Endothelin signaling axis after cerebral ischemia largely through
pharmacological manipulation of ETAR and ETBR using selective antagonists and
agonists, as well as pan-receptor antagonists. Antagonism of ETAR in reperfusion models
of stroke is associated with increased cerebral blood flow after ischemic insult, decreased
infarct volume, and improved neurological outcomes. A meta-analysis of animal studies
that treated transient cerebral ischemia with ETAR antagonists suggested that this
pharmacological strategy could be used to mitigate cerebral ischemia following
reperfusion in patients (Kaundal et al., 2012). Notably, most ischemic injuries in humans
are caused by permanent occlusions of large and/or small vessels.
Following focal cerebral ischemic injury, global ischemia from hypoperfusion and
subarachnoid hemorrhage (SAH), smooth muscle cells up-regulate ETBR and this causes
vasoconstriction, an effect opposed to its role in vasodilation in endothelial cells
(Stenman et al., 2002, Johansson et al., 2012). ETBR antagonists attenuate cerebral
vasospasm and subsequent ischemic damage of SAH in animal models (Zuccarello et al.,
1998). Mixed ET receptor antagonists have been used with the same effect in patients
with SAH (Macdonald et al., 2008). However, ETBR antagonists failed to increase
cerebral blood flow and improve outcomes in global ischemia (Patel and McCulloch,
1996). ETBR antagonists used in treatment studies in animal models of both transient and
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permanent focal ischemia decreased infarct volume when combined with ETAR
antagonists (Barone et al., 1995; Table 1-1). A study using both ETA and ETB receptor
antagonists had similar outcomes (Moldes et al., 2012; Table 1-1). Importantly, selectiveantagonism of ETBR exacerbates focal ischemia (Chuquet et al., 2002; Table 1-1).
Moreover, stimulation of ETBR signaling improves outcomes after focal ischemic injury
(Leonard et. al., 2011; Table 1-1). In summary, ETBA or pan ET receptor antagonism
seems to be beneficial for treating SAH-induced vasospasm and for increasing cerebral
blood flow following transient cerebral ischemia, but neither therapy improves focal
cerebral ischemia without reperfusion. Conversely, ETBR antagonists exacerbate cerebral
ischemia, while agonists of ETBR are beneficial in cerebral ischemia without reperfusion.
Pharmacologic
agent

Injury Model

Study Endpoints

Reference

Pre-treatment with Permanent MCAO in
SB 217242 (ETR spontaneously hypertensive
pan-antagonist)
rats.

30% reduction in infarct volume. No
change in edema.

(Barone et
al., 1995)

IRL-1620 (ETBR
agonist)

Permanent middle cerebral
artery occlusion in rats

85% reduction in infarct volume.
Reductions in reactive oxygen species.

(Leonard et.
al., 2011)

BQ-788 (ETBR
antagonist)

Rats were subjected to
178% increase in infarction volume
transient (60 minutes) focal
(MCAO). 26% decrease in CBF. No
cerebral ischemia (MCAO) or
effect on NMDA-induced lesions
cortical injection of NMDA.

Clazosentan
Clazosentan reduced edema.
Ischemia by transient
(ETRA antagonist)
Combination therapy further reduced
intraluminal MCAO (90 min)
& BQ-788 (ETBR
edema and infarct volume.
in rats.
antagonist)

(Chuquet et
al., 2002)
(Moldes et
al., 2012)

Table 1-1. Animal studies treating permanent or transient cerebral ischemia with
ETBR antagonists and agonists.

29

1.7.10. Endothelin and Reactive Astrocytes
One of the first and most comprehensive studies of the expression and distribution of
Endothelin receptor subtypes in the brain showed that ETBR was expressed by many
different cell types, including cortical astrocytes (Hori et al., 1992). Reactive astrocytes
up-regulate ET-1 in response to focal ischemia (Jiang et al., 1993), transient cerebral
ischemia (Yamashita et al., 1994), white matter lesions (Hammond et al., 2014), and
Alzheimer’s disease-related lesions (Jiang et al., 1993; Zhang et al., 1994). Cultured
primary astrocytes secrete ET-1 in response to thrombin, a component the clotting
cascade present in the CNS after injury (Ehrenreich et al., 1993). Similarly ETBR is
highly expressed in reactive astrocytes after many different CNS injuries (Baba, 1998;
Peters et al., 2003, Rogers et al., 2003).
ET-1 signaling through ETBR is capable of “activating” cultured astrocytes:
causing hypertrophy and proliferation (Baba, 1998). ET-1 produced by reactive
astrocytes signals through ETBR in an autocrine fashion (Ehrenreich et al., 1991;
Hasselblatt et al., 2001). Infusion of recombinant ET-1 increases proliferation of reactive
astrocytes in vivo (Koyama and Michinaga, 2012). Antagonism of ETBR, but not ETAR,
was shown to decrease the number of proliferating reactive astrocytes following chemical
demyelination of white matter through a JNK/ERK/c-Jun-dependent mechanism (Gadea
et al., 2008). In cultured astrocytes, exposure to ET-1 induced the expression of cyclin D1
and proliferation. ET-1 signaling through ETBR/JNK/ERK caused phosphorylation of the
transcription factor Sp1 and enhanced its binding to consensus sequences in the cyclin D1
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promoter (Michinaga et al., 2013). This body of research establishes that Endothelin
signaling through ETBR controls reactive astrocyte proliferation.
Koyama and Michinaga (2012) summarize an extensive body of literature
pertaining to ETBR signaling its affect(s) in reactive astrocytes. Beyond proliferation,
ETBR signaling induces gene expression for proteins that are important for the function of
reactive astrocytes (Table 1-2). To summarize, ETBR signaling promotes the expression
of neurotrophic factors, which provide trophic support for ischemic neurons and protect
against apoptosis. ETBR signaling increases the production and secretion of Tissue
Inhibitors of Matrix metalloproteinases (TIMPs); these proteins inhibit the disruption of
the blood brain barrier (BBB) by counteracting proteases such as MMP2 and MMP9 that
contribute to degradation of the BBB after injury. Yet, ETBR signaling has been shown
affect the increase of MMP2, and 9, and VEGF-A (Table 1-2). VEGF-A causes BBB leak
following injury. The disruption of the BBB can increase free water in brain tissue,
causing it to expand and leading to further damage. However, MMP2, and 9, and VEGFA are necessary for angiogenesis and the neovascularization of the injury area during
tissue repair (Zhang et al., 2000; Sood et al., 2008).
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Table 1-2. ETs regulate the production of various signaling molecules in cultured
astrocytes and the brain.
Adapted from Koyama and Michinaga (2012). IL: interleukin, TNF: tumor necrosis
factor, TIMP: tissue inhibitor of matrixmetalloproteinase, COX2: cyclooxygenase-2,
iNOS: inducible NO synthase.
1.7.11. Transcriptional Control of ETBR
The transcriptional regulation of ETBR in smooth muscle cells and reactive astrocytes of
the brain after ischemic injury is not well understood. However, transcriptional regulation
of the human EDNRB gene has been described in melanocytes, derivatives of the
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multipotent neural-crest lineage. Yokoyama and colleagues (2006) showed that Sry-box
10 (SOX10) transcription factor, in combination with the transcription factor Sp1, binds
to cis-acting elements in the EDNRB promoter thereby increasing ETBR expression.
Thus, similar transcriptional control of ETBR may occur in reactive astrocytes and
vascular smooth muscle cells.
Section 1.8. Summary and Introduction to the Dissertation
Reactive astrocytes are essential for the protection and repair of CNS tissue following
injury. Proliferating reactive astrocytes that border the infarct area are especially
important for containing the necrotic tissue and inflammatory cells and protect
surrounding neurons from secondary damage by creating a scar. The first step in
exploiting the protective features of reactive astrocytes to acquire a deep knowledge of
the cellular signaling pathways that regulate genes/proteins that physically interact with
the injury environment.
Given the importance of Notch signaling in astrogliogenesis during CNS
development and its role in maintaining the self-renewal of astrocyte-like adult NSCs in
the SVZ, it is likely that this conserved and ancient signaling pathway regulates the
identity, function and behavior of reactive astrocytes. For example, our group has shown
that Notch1 is required for normal proliferation of cortical reactive astrocytes following
stroke (Shimada et al., 2011).
Recent work has connected Jagged-1/Notch signaling to Endothelin signaling in
reactive astrocytes through ET-1-dependent up-regulation of Jagged-1 (Hammond et al.,
2014). But, it is not known if Notch modulates reactive astrocyte function directly or if it
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acts indirectly by supporting other cell signaling pathways that affect reactive astrocyte
function and proliferation. The experiments in this dissertation were designed to identify
new targets of Notch signaling in reactive astrocytes. The data from these experiments
provides evidence that Notch signaling has both direct and indirect transcriptional control
over the expression of proteins that perform protective functions in response to injury.
To investigate downstream effectors of Notch signaling, we developed an ex vivo
forward signaling screen with adult reactive astrocytes. By exposing cultured adult
astrocytes to immobilized Jagged-1, and comparing the transcriptome of these cells to
that of control cells, we were able to determine changes in gene expression mediated by
Jagged-1/Notch signaling. Genes for many proteins relevant to reactive astrocyte function
up-regulated. We used transgenic mouse models to conditionally delete Notch1 from
adult reactive astrocytes ex vivo and in vivo to explore the regulation of two target genes
identified in the screen: 1) Glutamate Aspartate Transporter (GLAST) and 2) Endothelin
Receptor B (ETBR). The data herein suggests Notch signaling acts directly on GLAST to
control its expression and indirectly on ETBR expression by enhancing the activity of a
direct effector of ETBR transcription: Signal Transducer and Activator of Transcription 3
(STAT3).
Reactive astrocytes protect healthy tissue and promote repair in the acute phase of
many types of injuries by taking up extracellular glutamate, secreting neurotrophic
factors, protecting the BBB and modulating the inflammatory response. The proliferation
of reactive astrocytes is essential for reactive astrocyte-mediated protection after severe
CNS injuries, like stroke. Therefore, enhancing reactive astrocyte proliferation after
34

stroke may provide greater protection and improve functional outcomes. The results of
experiments performed in this dissertation suggest that Notch signaling may directly
promote glutamate uptake and processing by reactive astrocytes. Additionally and
importantly, Notch signaling participates in a feed-forward loop with Endothelin
signaling to drive proliferation. Therefore, pharmacological stimulation of the Notch
signaling pathway may help mitigate CNS damage caused by ischemic stroke by
augmenting the protective function and number of reactive astrocytes.
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Summary
Reactive astrocytes have much promise as therapeutic targets in CNS injury. Promoting
their protective and reparative functions could improve outcomes after ischemic stroke, in
particular; this would require a broad knowledge of their regulation.
Notch1 signaling increases after injury in reactive astrocytes and is required for
the proliferation of peri-infarct reactive astrocytes after stroke. It may also enhance the
functions of reactive astrocytes such as extracellular ion homeostasis and glutamate
uptake and metabolism. Molecular effectors involved in astrocyte function and controlled
by Notch1 signaling were investigated by developing an ex vivo screen employing adult
reactive astrocyte-derived neural stem cells (Rad-NSCs) isolated from the peri-infarct
area of mice after stroke (permanent ligation model). Astrocytes re-differentiated from
Rad-NSCs (AstroRad-NSC) were then exposed to immobilized Jagged-1, a ligand of Notch.
Notch signaling supported the transcriptional effectors that promote astrocyte identity
while suppressing those of neural or oligodendrocyte lineages. Furthermore, in response
to Jagged1 signaling, many genes known to be involved in reactive astrocyte function and
tissue protection were up-regulated. We focused on genes involved in glutamate uptake
and metabolism that were increased by Jagged-1/Notch signaling. For one of these, glialspecific Glutamate-Aspartate Transporter (GLAST), we confirmed that loss of Notch1
decreased its transcript and protein levels in AstroRad-NSC. AstroRad-NSC take up glutamate
from the extracellular space and inhibition of Notch signaling decreased this function.
Furthermore, in vivo, after stroke, reactive astrocytes in which Notch1 was conditionally
deleted demonstrated decreased the level of GLAST protein. Our results suggest that, in
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addition to regulating reactive astrocyte proliferation, Jagged1/Notch1 signaling controls
critical aspects of reactive astrocyte function such as glutamate uptake. During or after
ischemic stroke, promotion of Notch signaling in reactive astrocytes may enhance
glutamate uptake and promote neuroprotection.
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Introduction
Within hours of cerebral ischemia, an infarct core forms that is composed predominantly
of necrotic tissue and immune cells. Coincident with these events, astrocytes proximal to
the site of infarction undergo hypertrophy and proliferate in response to signals from the
injury environment (Burda and Sofroniew, 2014). These “reactive astrocytes” provide
numerous critical functions after stroke and many other forms of CNS injury that include
neuroprotection, preservation and remodeling/repair of the blood brain barrier (BBB),
regulation of immune cell invasion and formation of a glial scar.
The Notch1 receptor is well known to control glial cell fate in CNS tissue. In
development, Notch signaling specifies radial glial cell identity (Gaiano et al, 2000) and
neural crest cell fate (Morrison et al., 2000). In adults, Notch regulates the self-renewal of
neural stem cells (Hitoshi et al., 2002). After CNS injury, the biology of other glial cell
types such as reactive astrocytes is also affected by Notch signaling. For example,
reactive astrocytes from the stroke peri-infarct area require Notch1 signaling to
proliferate (Shimada et al., 2011). The fundamental roles of Notch in glial cell identity,
self-renewal, and cell division raise the question of whether it controls also adult glial cell
function(s) in the healthy CNS and after injury.
Astrocytes are known to support neuronal activity in the brain, in part, by closely
regulating extracellular levels of L-glutamate (Glu), the main excitatory neurotransmitter.
Glu is removed from synapses and the surrounding extracellular space by astroglial
uptake and is converted into L-glutamine by a series of enzymatic reactions. Upon
conversion, the glutamine becomes “re-available” as a precursor molecule for amino acid
60

neurotransmitters (e.g. Glu and GABA) (Bak et al., 2006). During cerebral ischemia,
traumatic brain injury, or CNS disease, glutamate and ammonia levels can rise
dramatically, resulting in excitotoxicity and death of neurons, in part, by overstimulation
of neural receptors for N-ethyl-D-aspartic acid (NMDA) and kainic acid (KA) (Hazell et
al., 2003, 2010). Identification of molecular mechanisms or cell-cell signaling that
determines the level and/or activity of cellular glutamate transporters may lead to new
neuro-protective therapies for patients with stroke or other CNS injuries.
To control extracellular glutamate levels, astrocytes and endothelial cells use two
membrane-bound excitatory amino acid transporters: Glutamate transporter 1 (GLT-1,
EAAT-2,

SLC1A2)

(Rothstein

et

al.,

1994)

and

the

Glial

High

Affinity

Glutamate/Aspartate Transporter (GLAST, EAAT-1, SLC1A3). The importance of
glutamate transport in brain injury was demonstrated by increased infarct volumes after
stroke in animals that received glutamate uptake inhibitor (Yan et al., 1998) and by
increased brain edema and reduced motor function in GLAST-knockout mice following
cerebellar injury compared with controls (Watase et al., 1998). Of special interest,
GLAST is thought to perform the bulk of astroglial Glu transport in the cortical periinfarct area after stroke (Beschorner et al., 2007; Ketheeswaranathan et al., 2011).
Previously, we reported the multipotent differentiation capacity of Reactive
astrocyte-derived Neural Stem Cells (Rad-NSCs) isolated from the peri-infarct area after
stroke (Shimada et al., 2011; 2012). Adult astrocytes survive poorly in culture, however
Rad-NSCs can be maintained in culture for many passages and are useful to redifferentiate into large numbers of reactive astrocytes (AstroRad-NSC) for screening
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purposes. Here we use a Jagged1 forward signaling screen with AstroRad-NSC to identify
multiple genes that are putative targets of Jagged-1/Notch1 signaling and control
astroglial Glu. We demonstrate that Jagged1/Notch1 signaling induces GLAST levels
early after stroke. Our results indicate that Notch1 itself or downstream effectors of
Jagged1/Notch1 signaling may provide targets to modify Glu levels in patients with CNS
disease or brain injury.
Results
Jagged-1 forward signaling screen for Notch-induced gene expression in adult
astrocytes
Previous studies by our group show that Notch1 signaling is required for reactive
astrocyte proliferation after stroke (Shimada et al., 2011). In addition to controlling
proliferation, Notch1 may also regulate gene expression for proteins that contribute to the
protective functions of reactive astrocytes after CNS injury. To explore this hypothesis ex
vivo, developed a stem cell-based method for generating large amounts of cultured adult
reactive astrocytes. Reactive astrocyte-derived Neural Stem Cells (Rad-NSCs) were
isolated from the cortical peri-infarct area 3 d after distal middle cerebral artery occlusion
(dMCAO) (Shimada et al., 2012). Rad-NSC neurospheres (passage 2 to 4) were
dissociated and re-differentiated in medium containing 10% fetal bovine serum (see
Methods) to generate a population enriched for adult reactive astrocytes, called AstroRadNSC

(Figure 2-1).
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To induce Notch signaling, we exposed AstroRad-NSC to cell culture surfaces that
were previously coated with immobilized Jagged-1-FC/Protein-G/laminin or laminin only
(control). After 2 d of exposure, we isolated total RNA from experimental and control
AstroRad-NSC cultures for microarray assays of gene expression (Figure 2-1B). Two
independently-derived AstroRad-NSC cell lines isolated from separate experimental animals
responded to immobilized Jagged-1 by decreasing their expression of the basic helixloop-helix (bHLH) factors oligodendrocyte transcription factor (Olig2) and Achaete-scute
homolog 1 (Ascl1, a.k.a Mash1) transcription factors that direct neural stem cell fate
toward oligodendrocyte or neuron, respectively (Table 2-1). The expression and activity
of these bHLH factors are antagonized by Notch signaling effectors. In contrast, mRNA
for Hairy/enhancer-of-split related with YRPW motif protein 2 (HEY2) and
Hairy/enhancer-of-split 5 (HES5) were up-regulated by immobilized Jagged-1.
Expression of HEY2 and HES5 is induced by Notch intracellular domain (NICD), a
cleavage product after canonical Notch signaling (Table 2-1). During postnatal
astrogliogenesis, HES factors, along with Id factors, promote the differentiation of
astrocytes from neural precursor cells (Imayoshi and Kageyama, 2014).
The Glial Fibrillary Acidic Protein (GFAP) promoter is a direct target for NICDmediated transcriptional activation (Table 2-1) (Ge et al., 2002). In agreement with
canonical Jagged-1/Notch signaling, we observed that GFAP mRNA was increased in
cells of both clonal AstroRad-NSC lines after exposure to Jagged-1. Therefore, successful
stimulation of Jagged-1/Notch signaling in AstroRad-NSC was achieved based on the
pattern of gene expression of several well-known targets of Notch signaling.
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Jagged-1/Notch signaling reduced gene expression for DNA-binding proteins and
cell differentiation
We filtered our microarray data for genes that were either increased or decreased at least
1.2-fold in AstroRad-NSC after exposure to immobilized Jagged-1. Only genes that changed
in expression by this amount for both AstroRad-NSC clonal lines were further explored. By
this criteria, the expression of 278 genes decreased, whereas that of 449 genes increased
(Table 2-3 and Table 2-4, respectively). The two gene lists were submitted to the
Database for Annotation, Visualization and Integrated Discovery (DAVID). The DAVID
tool assesses enrichment of annotation terms in an experimental gene list, deriving a
statistical likelihood of such enrichment to occur in the background genome by chance.
DAVID also identifies functional clusters by grouping functionally-related annotation
terms (see Methods) (Huang da et al., 2009). Genes down-regulated by Jagged-1 were
most enriched for a cluster of annotations that related to bHLH DNA-binding motifs and
neurogenesis (Table 2-7). Of the specific annotations (Figure 2-1A), 28 of 278 genes had
the annotation for “DNA binding” (p = 1.70E-02. Table 2-7), whereas 45 had the
annotation “regulation of transcription” (p = 4.70E-04. Table 2-6), and 8 of 278 were
annotated “Helix-loop-helix dimerization region bHLH” (p = 5.40E-4, Table 2-8).
Amongst these genes were those for bHLH factors involved in neurogenesis: Ascl1 and
Single-minded homolog 1 (Sim1), and those involved in oligodendrogenesis: Olig1 and 2
(Table 2-8).
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Jagged-1/Notch signal induced gene expression for receptors with known functions
in reactive astrocytes
DAVID functional clustering analysis of the 449 genes up-regulated by Jagged-1
revealed significant enrichment for annotations related to proteins with extracellular
domains, particularly for those that have N-linked glycosylation (Table 2-9, annotation
group 1). A large fraction of the up-regulated genes (144 of 449 genes) were annotated
“transmembrane” (p = 3.10E-04), whereas 115 genes were annotated “glycosylation site:
N-linked” (p = 2.5E-07. Table 2-9), and 96 genes had the annotation “Signal peptide” (p
= 1.60E-05, Figure 2-2B). In addition to the enrichment of genes encoding for cell
surface receptors and membrane channels, genes for secreted factors were also enriched,
but to a lesser extent (44 of 449 genes, p = 0.013, Table 2-10, annotation group 1). In
addition, Jagged-1/Notch signaling up-regulated the expression of genes that enriched the
following functional clusters (Table 2-10): “Cellular and chemical homeostasis“
(annotation group 2, Figure 2-2C), “Vascular development and angiogenesis” (annotation
group 3), and “Inflammatory response to injury” (Figure 2-2C, annotation group 8).
Reactive astrocytes and meningeal fibroblasts commonly form a “scar” during the
resolution of CNS injury, e.g. after stroke or traumatic brain injury (Pekny and Nilsson,
2005). We found two functional groups associated with glial scar formation: “Cell and
biological adhesion” (Table 2-10, annotation group 5) and “Plexin/Semaphorin”-specific
group (Table 2-10, annotation group 6). Amongst gene members of the cell adhesion
group, the screen identified Neurocan and chondroitin sulfate proteoglycan 5
(Neuroglycan C). These proteins are both chondroitin sulfate proteoglycans and are
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extracellular components of the CNS scar (Sofroniew, 2009). Plexins and Semaphorins
constitute a transmembrane receptor/ligand system and Plexin signaling in neurons
causes axonal growth cone collapse and repulsion of the neurite. Semaphorin expression
has been localized to meningeal fibroblasts and Plexins to neurons (Sandvig et al., 2004).
Loss of Notch1 in AstroRad-NSC decreases GLAST mRNA and protein
We chose to focus on and verify expression of several genes up-regulated by Jagged1/Notch with functional significance to glutamate uptake and metabolism in astrocytes
(Hertz and Zielke, 2004). Although DAVID contained no specific functional clustering
related to glutamate metabolism and/or transport, our screen identified genes for 4
proteins known to function in astroglial handling of glutamate: Glutamate Dehydrogenase
1, Glutamate Ammonia Ligase (a.k.a. Glutamine Synthetase, Glul), glutamate receptor
metabotropic 5, and Solute Carrier Family 1 Member 3 (Slc1a3) (a.k.a. GLAST, Table 22).
By mapping the Glast promoter sequence, we identified a CBP-1/Suppressor of
Hairless/Lag-1 (CSL) DNA-binding sequence approximately 2.67 kb upstream of the
transcription start site (Figure 2-3A’); this sequence indicated direct regulation of Glast
transcription by Notch. To determine if Notch signaling regulated GLAST expression, we
treated AstroRad-NSC with Dibenzazepine (DBZ), a γ-secretase inhibitor (GSI). GSIs
inhibit proteolytic cleavage of Notch and its subsequent signaling by inhibiting the active
site of Presenilin, the proteolytic component of γ-secretase. We then assessed gene
expression by quantitative reverse transcriptase PCR (qRT-PCR). Glast and Notch1
expression was significantly reduced in DBZ-treated cells compared with vehicle
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(DMSO)-treated control cells (Glast: -1.54-fold ± 0.07, p ≤ 0.01. Notch1: -1.35-fold ±
0.09, p ≤ 0.01. Mean ± SEM, DMSO vs DBZ, n=3; Figure 2-3B).
GSIs can inhibit signaling through all four Notch receptors and any other
transmembrane receptor that requires γ-secretase cleavage for activity. To determine
whether Notch1 alone regulated GLAST mRNA and protein levels, we isolated RadNSCs from hGFAP-CreERTM;Notch1loxp/loxp animals (n=2 clonal cell lines, each from
different mice) and re-differentiated them into AstroRad-NSC (GNastroRad-NSC). To delete
Notch1, GNastroRad-NSC cells were incubated in 4-hydroxy-tamoxifen (OHTM), the
water-soluble form of tamoxifen (Figure 2-3C). Targeted deletion of Notch1 in
GNastroRad-NSC decreased Notch1, Gfap and Glast gene expression (Glast: -1.34-fold ±
0.06, p ≤ 0.01; Notch1: -1.52-fold ± 0.02, p ≤ 0.01; Gfap: -1.7-fold ± 0.16, p ≤ 0.01.
Mean ± SEM, DMSO vs DBZ, n=3; Figure 2-3B’) and also reduced the amount of
GLAST protein expressed by both clonal lines of GNastroRad-NSC (Figure 2-3D, 3F).
Glutamate Transporter 1 (GLT-1) is expressed by adult cortical astrocytes
(Rothstein et al., 1994) and together with GLAST controls astroglial glutamate uptake. In
cell lysates from GNastroRad-NSC, we observed that GLT-1 was expressed and was not
reduced by the loss of Notch1 (Figure 2-3E). Instead, GLT-1 levels appeared to increase
slightly after Notch1 knockdown, consistent with reports that tamoxifen induces GLT-1
gene expression (Karki et al., 2013). These data demonstrated that Notch1 controls Glast
expression in adult reactive astrocytes (AstroRad-NSC).
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Inhibition of Notch signaling decreases extracellular glutamate uptake by adult
astrocytes
Several groups have studied glutamate uptake in cultured astrocytes isolated from
postnatal rat or mouse cortex (Dallas et al., 2007; Boycott et al., 2008; Lehmann et al.,
2009; Raymond et al., 2011). However, postnatal astrocytes may differ from adult
astrocytes in glutamate uptake or metabolism. To examine the effects of Notch signaling
on GLAST-mediated glutamate uptake in adult astrocytes, we added a fix amount of
glutamate to AstroRad-NSC cultures and then measured the residual glutamate in the
medium after 15 minutes. To determine if AstroRad-NSC could take up glutamate through
both GLT-1 and Notch signaling-control GLAST, we blocked GLT-1 activity in with
dihydrokainic acid (DHK), a specific GLT-1 antagonist (Garlin et al., 1995) and treated
cells with a GSI. AstroRad-NSC that had been incubated for 2 days with a GSI (DAPT)
prior to addition of DHK significantly increased the level of residual glutamate relative to
levels in the medium of vehicle controls (Normalized residual glutamate, DHK+DAPT
vs. vehicle: 1.629 ± 0.163 vs. 1 ± 0.008, Mean ± SEM, n=3, p ≤ 0.01; Figure 2-4A).
We noted the decrease in GLAST protein and mRNA after Notch1 knockout in
two separate clonal lines of GNastroRad-NSC were highly consistent (Figure 2-3F vs. 3D).
However, AstroRad-NSC are differentiated from clonally-isolated neurospheres and could
therefore be subject to clonal variation of glutamate uptake capacity. To address this
possibility, we assayed AstroRad-NSC from three clonal lines of Rad-NSCs, each derived
from a separate animal. We found that incubation in DAPT for 2 d was sufficient to
increase residual extracellular glutamate for all three clones (Normalized residual
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glutamate, combined DAPT vs. combined Vehicle: 1.442 ± 0.045 VS 1 ± 0.053, mean ±
SEM, n=3 clones, p = 0.0014; Figure 2-4B). In addition to glutamate, GLAST takes up
extracellular aspartate. Of interest, our results agreed with attenuated aspartate uptake by
C6 glioma cells after treatment with DAPT reported by Angulo-Rojo et al. (2013).
Conditional Notch1 knockout decreases reactive astroglial GLAST levels after focal
ischemic injury in vivo
To determine if Notch1 regulated GLAST levels in reactive astrocytes in vivo, we
evaluated cortical tissue from injured and normal hGFAP-CreERTM;Notch1loxp/loxp mice
after injections of tamoxifen to delete Notch1 from reactive astrocytes. We used
magnetic-activated cell sorting (MACS) with antibodies to GLT-1 to directly isolate and
evaluate adult astrocytes or reactive astrocytes from disassociated cortex. We first
isolated astrocytes from the left and right cortices of normal (healthy) hGFAPCreERTM;Notch1loxp/loxp mice that received tamoxifen or vehicle control (corn oil) 30 d
prior. We found that GLAST was weakly-expressed by normal cortical astrocytes (Figure
2-5A), in agreement with GLAST levels previously reported by others (Rothstein et al.,
1994; Regan et al., 2007). In contrast, GFAP levels were significantly decreased by
deletion of Notch1 in astrocytes that had been acutely isolated by GLT-1 MACS from
normal cortex (Figure 2-5A). We hypothesized that CNS injury, such as cerebral
ischemia, GLAST levels increase in astrocytes that respond to injury through a Notch1dependent mechanism. To test this concept, we used hGFAP-CreERTM; Notch1loxp/loxp
mice and followed the same tamoxifen treatment regime as with normal (uninjured) mice.
At 30 d post-treatment, 3 mice per treatment group were subjected to dMCAO. After 3 d
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of recovery, we isolated the ipsilateral cortex from each mouse and disassociated it. To
obtain enough GLT-1-positive cells for immunoblotting, we pooled the cell suspensions
by treatment group prior to GLT-1 MACS. By immunoblot, pooled GLT-1-positive
MACS fractions were highly-enriched for both GLAST and GFAP (Figure 2-5B). GLT1-positive MACS cell fractions from pooled ipsilateral cortical tissues of vehicle control
animals had more GLAST and GFAP protein compared with isolates from tamoxifentreated animals (Figure 2-5). These data indicated that Notch1 signaling controls the level
of GLAST in reactive astrocytes in vivo after stroke.
Discussion
Here we report and validate a new model based on AstroRad-NSC for the study of signaling
in adult reactive astrocytes. In a Jagged1 forward signaling screen that used AstroRad-NSC
as a source of adult astrocytes, we generated a set of putative Jagged1/Notch-induced
gene targets. Among the gene targets we found multiple genes implicating Notch1 as
“master” regulator of glutamate uptake. We report that Notch1 controls the level of
GLAST both in cultured AstroRad-NSC and for reactive astrocytes in vivo, early after
stroke.
To date, the effects of Jagged1/Notch1-mediated signaling on reactive astrocyte
function(s) are poorly understood. Notch1 signaling is required for reactive astrocyte
proliferation after focal cortical ischemia (Shimada et al., 2011), and has been implicated
in the astrocyte-mediated inhibition of neurogenesis in the hippocampus (Wilhelmsson et
al., 2012) and oligodendrogenesis after white matter lesions (Hammond et al., 2014). By
increasing gene expression for a wide variety of astrocyte-associated receptors and
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transporters, and decreasing expression of transcription factors involved non-astroglial
cell specification, Jagged1/Notch signaling in AstroRad-NSC appeared to promote astrocyte
identity, in part by increasing expression of Hey2, HES5 and GFAP. From many gene
candidates identified by our screen, we elected to focus on Notch1-mediated control of
GLAST in reactive astrocytes. GLAST is expressed highly by neural progenitor cells and
radial glial cells during CNS development and by adult neural stem/progenitor cells in the
subventricular zone (Regan et al., 2007). In the cerebrum of adult mice, GLAST
expression is limited and thus unlikely to contribute measurably to uptake of glutamate in
normal cerebral cortex (i.e. uninjured and without pathology).
GLAST and GLT-1 have been extensively studied in the context of hypoxia and
ischemia ex vivo and in vivo (Rao et al., 2001; Dallas et al., 2007; Ketheeswaranathan et
al., 2011; Raymond et al., 2011). We found that GLAST was expressed weakly by GLT1-positive astrocytes in normal, healthy adult cortex, but its level increased markedly in
GLT-1-positive astrocytes from ipsilateral cortex 3 days following focal ischemia.
Furthermore, we showed that GLAST, along with the NICD1/CSL target GFAP, was
decreased in GLT-1-positive cells sorted from injured cortex in which Notch1 has been
conditionally deleted. Thus, Notch1 signaling may be critical for the rapid increase in
GLAST that occurs after CNS injury, whereas GLAST levels in astrocytes from normal
cortex may be less dependent on Notch1.
Current knowledge of signaling mechanisms that control the level and/or activity
of astroglial glutamate transporters in vivo is limited. In culture, the hormone estrogen
was shown to increase astroglial mRNA and protein for GLT-1 and GLAST (Pawlak et
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al., 2005). Similarly, Raloxifene (Rx), an estrogen receptor modulator, was reported to
increase astroglial levels of both GLT-1 and GLAST (Karki et al., 2014). Other
factors/receptor ligands shown to induce GLAST gene expression include EGF, TGF-α,
and PACAP (Unger et al., 2012). The extracellular matrix component Tenascin-R, was
also recently shown to increase GLAST expression (Okuda et al., 2014).
GLT-1 levels have been consistently shown to decrease in several models of cerebral
hypoxia/ischemia: transient focal ischemia (Rao et al., 2001; Ketheeswaranathan et al.,
2011), transient forebrain ischemia (Fujita et al., 1999; Gottlieb et al., 2000) and perinatal
hypoxia (Raymond et al., 2011). Deficits in the expression of GLAST have been lessconvincingly shown, as some studies report an increase after injury (Rao et al., 2001; Tao
et al., 2001). Raymond et al (2011) showed a decrease in GLAST and GLT-1 expression
commensurate with decreased GFAP expression in white matter astrocytes of mice
subjected to perinatal hypoxia. Unlike GLT-1 expression, GLAST expression was
sensitive to perturbations in JAK/STAT3 signaling in this model. JAK/STAT3 is known
to be critical for reactive astrocyte formation and function (Okada et al., 2006; Herrmann
et al., 2008; Nobuta et al., 2012; Wanner et al., 2013).
As a new model, re-differentiating cultured Rad-NSC into AstroRad-NSC provides
an efficient way to obtain large numbers of adult astrocytes for screening or other
purposes. But, how closely do the derived cells resemble bona fide cortical astrocytes or
reactive astrocytes in vivo? Lovett et al. (2008) evaluated the transcriptome of acutely
isolated protoplasmic astrocytes from adult mouse cortex using Fluorescent-Activated
Cell Sorting (FACS) for GLT-1 and GFAP-GFP. Notably, our list for genes up-regulated
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by Jagged1 exposure contained 8 of the 20 targets that Lovett et al. (2008) identified as
“enriched” (Supplemental table 9, see also Lovatt et al., 2007). Also relevant to our work,
gene expression profiling by Cahoy et al. (2008) demonstrated that gene-members of the
Notch signaling pathway were enriched in acutely-isolated astrocytes relative to those for
signaling by JAK/STAT, WNT/β-catenin, or TGF-β (Cahoy et al., 2008). Zamanian and
colleagues of the Barres group (2012) provided gene expression data for reactive
astrocytes 1 day after MCA occlusion. We found five genes up-regulated by Jagged1 in
AstroRad-NSC that were also included on Zamanian et al.’s list for “top 50 most-changed
genes” in reactive astrocytes (Supplement Table 10) (Zamanian et al., 2012).
Interestingly, a group of genes involved in p53 signaling and apoptosis that were
increased in reactive astrocytes in their study were decreased in Astrorad-NSC at 48 hours
after Jagged1 exposure (Supplemental Table 11).
Our work identified Jagged1/Notch1 signaling as a regulator of GLAST and
glutamate uptake in adult reactive astrocytes. Accordingly, modulation of the Notch
signaling pathway or it downstream effectors by pharmacologics or biologics during
and/or after ischemic stroke may provide a means to enhance glutamate uptake, promote
neuroprotection and improve patient outcomes.
Experimental procedures
Mice
All animal work was approved by the University of Vermont College of Medicine’s
Office of Animal Care in accordance with the American Association for Accreditation of
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Laboratory Animal Care and National Institutes of Health guidelines. Adult male
C57BL/6J mice (6–8 wks of age) were obtained from Taconic Farms. We obtained
GFAP-CreERTM mice from Dr. Suzanne Baker (St. Jude Children’s Research Hospital,
Memphis, TN) (Chow et al., 2008). Notch1tm2Rko/GridJ mice (Notch1-flox mice,
Cat#006951) from JAX.

Genotyping was performed with the REDExtract-N-Amp

Tissue PCR Kit (XNAT-1KT; Sigma). We used the following primers: Notch1, forward5’-TGCCCTTTCCTTAAAAGTGG-3’, reverse-5’-GCCTACTCCGACACCCAA TA-3’;
GFAP-CreERTM,

forward-5’-AGCGATCGCTGCCAGGAT-3’,

reverse-5’-

ACCAGCGTTTTCG TTCTGCC-3’.
dMCAO surgery
Mice were anesthetized with isoflurane (1–5%; Webster Veterinary) and body
temperature was maintained with a heated pad. Focal cerebral ischemia was produced by
permanently occluding the middle cerebral artery (MCA) (Shimada et al., 2010; Bakondi
et al., 2011; Shimada et al., 2012). Under low-power magnification, the left temporoparietal region of the head was shaved, and an incision was made between the left orbit
and the left ear in the shape of a “U.” An incision was made superiorly on the upper
margin of the temporal muscle forward. The MCA was observed through the semitranslucent skull. A small burr hole (1–2 mm) was drilled into the outer surface of the
skull just over the MCA. The inner layer of skull was removed with fine forceps. The
MCA was then encircled with 10–0 monofilament nylon suture (7V33; S & T), ligated,
and transected superior to the ligation point. The small flap of temporo-parietal skin
covering the skull was closed with Vetbond (3M Animal Care). For conditional knockout
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mouse studies, animals received 0.1 mg/g of tamoxifen (TM; T5648; Sigma) dissolved in
9:1 corn oil:absolute ethanol (vehicle) or vehicle alone by intraperitoneal injection for 3
consecutive days from d 0 to 3, followed by a 7 d or 20 d washout period, then subjected
to dMCAO. Mice were euthanized at various time points after dMCAO. Brain tissue was
then either processed for immunohistochemistry or cell isolation (see below).
Isolation and culture of Rad-NSCs
For isolation of Rad-NSCs, brains were removed 3 d after dMCAO, placed into a
polyacrylic brain block (Acrylic Matrices, RBMA-200C; World Precision Instruments),
and cut coronally into 1 mm sections. The sections were transferred into alpha-MEM
(Invitrogen) in 6-well plates. The cortical peri-infarct area was dissected under a light
microscope. Tissues from the anterior lateral ventricle, posterior lateral ventricle,
hippocampal arch, dentate gyrus, white matter, and third ventricle were carefully
excluded. The tissues containing the peri-infarct area were harvested, diced into ~1 mm3
pieces, and digested in enzyme digestion solution containing 200 U papain
(Worthington), 20 ug/ml DNase (Worthington), 1.5 mM EDTA (Fisher Scientific), 1.5
mM CaCl2 (Sigma), 2 mg L-cysteine (Sigma), and DMEM/F12 media (Lonza), at 37°C
for 20 min. Following enzymatic digestion, the tissues were triturated two times in
trituration solution: 5 ml DMEM/F12 medium containing 15 mg trypsin inhibitor
(Invitrogen) and 15 mg bovine serum albumin (BSA; Fisher Scientific). Cells were
resuspended in DMEM/F12 medium containing 0.9 M sucrose and centrifuged to remove
myelin (300 × g for 10 min). Cells were grown at a low density (10,000 cells/ml) in NSC
growth medium containing 10 ng/ml Epidermal Growth Factor (EGF; BD Biosciences),
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20 ng/ml basic Fibroblast Growth Factor (bFGF; recombinant human bFGF produced in
our laboratory), 1× B27 supplement (Invitrogen), 2 mM L-glutamine (Mediatech), and
100 U/ml penicillin/100 ug/ml streptomycin, in NeurobasalA (Invitrogen) in 12-well
plates (Nunc Thermo Fisher Scientific). To generate clonal spheres, individual small
spheres (10–100 cells) were pipetted under microscopy into separate 24-well plates 1 wk
after plating. Clonally-isolated neurospheres were expanded and passaged in NSC growth
medium for further studies.
Ex Vivo differentiation of astrocytes from Rad-NSCs
Rad-NSCs were expanded in NSC medium as neurospheres and dissociated with trypsinEDTA. Dissociated cells were plated in 10% CCM at a density of 5.5 × 105 cells/cm2 into
100 mm2 dishes (NUNC) previously coated with laminin/poly-D-lysine (5ug/ml each,
BD Biosciences). Under the above conditions, the plated cells differentiated for 7 d with
medium changes every 2 d.
Immobilized Jagged-1 treatment of AstroRad-NSC
To prepare culture surfaces with immobilized Jagged-1 we coated 100×20mm cell culture
plates (Nunc) with 50 µg/mL protein G (Sigma) + 5 µg/mL mouse laminin (BD sciences)
in PBS for 4 hours at normal culture conditions. We then rinsed plates with PBS ×2 with
minimal agitation before adding 5 µg/mL Recombinant Rat Jagged 1 Fc Chimera
(Cat#599-JG-100, R&D Systems) in PBS and incubated in normal culture conditions for
approximately 18 hours. The control surface was prepared by coating plates with 5
µg/mL mouse laminin for 18 hours under the same conditions. Both conditions were
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rinsed with PBS ×2 before AstroRad-NSC were plated in 10% CCM at a density of 3 × 105
cells per plate. Cells were allowed to incubate for 2 days before RNA extraction.
RNA purification, amplification, labeling, and hybridization
PureLink RNA Mini Kit (Cat#12183018A, Life Technologies) and protocol were used to
lyse and extract total RNA from cultured AstroRad-NSCs. The integrity and concentration of
the isolated total RNA was confirmed by an Agilent 2100 bioanalyzer (Agilent
Technologies). Twenty ng of total RNA from each sample was amplified and biotin
labeled using the Two-cycle Target Labeling kit (Affymetrix) then hybridized to a
GeneChip Mouse Gene 1.0 ST Array (Affymetrix). Samples were hybridized using a
GeneChip Hybridization Oven 640 (Affymetrix), processed using a GeneChip
FluidicsStation 450 (Affymetrix), and scanned using a 7G Genechip Scanner
(Affymetrix). All sample-handling aside from the RNA extraction and all Genechip
processing was preformed by the Microarray Core Facility at the University of Vermont.
Calculation of probe set statistics and normalization of array signals
The raw image data from each chip was summarized by Affymetrix GCOS software
using one probe intensity (in CEL files, one per chip). Probe-level intensities were
calculated using the Robust Multichip Average (RMA) algorithm, including backgroundcorrection, normalization (quantile), and summarization (median polish), for each probe
set and sample, as is implemented in Partek Genomic Suites®, version 6.6 (Copyright ©
2009, Partek Inc., St. Louis, MO, USA). Sample quality is assessed based on the 3’:5’
ratio (3’ arrays only), relative log expression (RLE), and normalized un-scaled standard
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error (NUSE). Principal Component Analysis (PCA) is also used to look for outlier
samples that would potentially introduce latent variation into the analysis of differential
expression across sample groups.
Compilation of gene lists and Functional Cluster Analysis
RLE for each gene from the control set was subtracted from the experimental set then
converted to fold-change for each clone. These list were filtered to include genes that
were ≥ 1.2 (up-regulated in experimental group) or ≤ -1.2 (down-regulated in
experimental group). Gene lists were analyzed for statistically enriched pathways and
functional groups using the Database for Annotation, Visualization and Integrated
Discovery (DAVID) http://david.abcc.ncifcrf.gov/tools.jsp (Huang da et al., 2009). Using
the official gene symbols, each list was submitted to the tool. Mus musculus was select as
the background genome. Functional clustering was preformed with the default variable
for classification stringency (medium), Kappa similarity (similarity term overlap: 3,
similarity threshold: 0.50), classification (initial group membership: 3, final group
membership: 3, multiple linkage threshold: 0.50). Functional groups with an EASE score
of > 1.3 were included in the analysis.
Experiments with AstroRad-NSC
For conditional knockout of Notch1 in reactive astrocytes that were re-differentiated from
Rad-NSCs of GFAP-CreERTM-Notch1-cKO mice, 10% CCM was removed and replaced
with 10% CCM containing 1 uM 4-OH-TM (Sigma) or ethanol (vehicle control). This
treatment was refreshed every 2 d for 5-8 days. For experiments with Gamma-secretase
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inhibitors (GSI), cells were treated with 10 µM N-[N-(3,5-Difluorophenacetyl)-L-alanyl]S-phenylglycine t-butyl ester (DAPT, D5942; Sigma), od dimethylsulfoxide (DMSO;
vehicle) for 2 d.
Glutamate uptake experiments
AstroRad-NSCs were differentiated in situ on 24-well plates (Nunc) at a density of 1×105
cells/well using the methods previously described. For GLT-1 transporter-blocking
experiments we added 200 µM Dihydrokainic acid (Sigma) diluted in growth medium 20
minutes prior to the glutamate uptake assay (Dallas et al., 2007). AstroRad-NSCs treated
with the GSI DAPT or DMSO control for 2 d prior to addition of DHK or glutamate
uptake assay. To assess the glutamate uptake capacity of AstroRad-NSCs, growth medium
was removed from the wells and these were rinsed ×2 with PBS. Phenol-free DMEM
containing 20 µM of glutamic acid was added to the wells. Experimental or control
groups were represented in triplicate wells. The cells were then cultured under normal
conditions for 10 to 15 minutes, depending on the experiment performed. The medium
contain residual glutamate was removed at that time and glutamate concentration was
assessed with the Amplex Red Glutamic Acid/Glutamate Oxidase Assay Kit (Cat#A12221, Life technologies) per protocol. The fluorescence of the product of the reaction
(dependent on the starting concentration of residue glutamate) was read at an excitation
of 530 nm and emission of 590 nm with an appropriately configured Synergy HT
Multimode Microplate reader (BioTek Instruments, Inc.; Winooski, VT).
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Immunobloting
Total protein was extracted from cells with a RIPA cell lysis buffer containing: 1.0%
Triton-X 100, 0.1% SDS, 0.5% Deoxycholate, 50 mM Tris HCL, 150 mM NaCl, 5 mM
EDTA, 1× Protease inhibitor Cocktail (Roche), and 1× phosphatase inhibitor Cocktail
(Sigma) when required. Protein concentrations were determined with a Bio-Rad DC
Protein Assay (Bio Rad). Protein preparations were separated by SDS-PAGE and
transferred to immobilon-P membrane (PVDF; Millipore). The membrane was blocked
with 5% w/v dry milk/0.1% Tween-20/1× PBS and then incubated with primary antibody
diluted in blocking buffer overnight at 4°C or at room temperature for anti-GAPDH.
Primary incubation with anti-GLAST was done in a blocking buffer of 5% w/v
BSA/0.1% Tween-20/1× PBS. After washes, the membrane was incubated with a
horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature. The
blot was visualized with Western Lightning Plus-ECL (NEL103001EA; Pierce), and
exposed to Kodak x-ray film. Equivalence of protein loading was verified by probing for
GAPDH. We used the following primary antibodies: GFAP (1:2000, Z0334; DAKO),
GFAP (1:1000, G3893; Sigma), GLAST (1:500,130-095-826, Miltenyi Biotech), cleaved
NICD1 (1:1000; AB8925; Abcam), GAPDH (1:2500, MAB374; Millipore), and GAPDH
(1:2500, G9545; Sigma). Films were scanned at 600 dpi for densitometry (ImageJ
software).
Real-time Quantitative Reverse-transcriptase Polymerase Chain Reaction
RNA was extracted from cells using a HighPure RNA Isolation kit (Roche, Cat:
11828665001). After first-strand cDNA synthesis with the SuperScript® III RT-PCR
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System (Life Technologies), relative quantification real-time PCR was performed as
described by Tharp et al., (2012) with minor modifications. Several TaqMan (Life
Technologies) gene expression kits and assays for mouse were employed: Notch1-FAM,
Mm00435249_m1; GFAP-FAM, Mm01253033_m1; Glast-FAM, Mm00600697_m1;
GAPDH-VIC, Mm99999915_g1). The cDNA input template was diluted 1:12 and
GAPDH-VIC probe was added to each well as an internal control. All samples were run
in triplicate. Real-time qRT-PCR was performed on an Applied Biosystems 7300 RealTime PCR System with standard settings (Applied Biosystems Inc, Foster City, CA).
Gene expression was normalized to internal GAPDH controls and fold change was
calculated using the 2(-Delta Delta C[T]) method (Livak and Schmittgen, 2001).
Statistical analysis
Statistical analyses were performed with GraphPad Prism software (version 6.0e).
Individual groups were compared by Student’s t-test (unpaired). Multiple comparisons
were made by analysis of variance (ANOVA) with Bonferroni post-hoc testing. P values
of less than 0.05 were considered significant.
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Figures and Tables
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Figure 2-1. Reactive astrocyte derived-neural stem cells (Rad-NSCs) differentiated
into astrocytes respond to immobilized Jagged-1.
A) Diagram of the distal middle cerebral artery occlusion (dMCAO) model and cell
isolation schema. Three days following ligation, reactive astrocytes surround an infarct
core composed of necrotic tissue and other cell types. Reactive astrocytes isolated from
the peri-infarct area (pink oval) form neural spheres after 14 days in neural stem cell
culture, so-called reactive astrocyte derived-stem cells (Rad-NSC). These spheres can
then be disassociated into single cells and cultured in serum-containing medium
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(astrocyte culture) to create a proponderance of astrocytes refered to as AstroRad-NSC. B)
Strategy for screening the transcriptome of AstroRad-NSC in response to immobilized
Jagged-1. AstroRad-NSC were plated on Jagged-1 or control surface and cultured for two
days. RNA was extracted and gene expression was then assayed with Affymetrix Gene
Chips. Expression data was normalized and converted to relative log expression (RLE).
R: rostral, C: caudal, D: dorsal, V: ventral, MCA: middle cerebral artery, GFAP: glial
fibilary acidic protein, d: days.

Gene Symbol

Gene Description

Δ Jagged-1 vs Laminin
(fold change)
Clone 1

Clone 2

Olig2

Oligodendrocyte fate specification, negatively
regulated by Notch

-2.3

-1.3

Ascl1

Neuronal fate specification, negatively regulated by
Notch

-3.1

-2.1

Hey2

Transcriptional effector of Notch Signaling

2.3

1.6

Hes5

Transcriptional effector of Notch Signaling

1.2

1.5

Gfap

Astrocyte intermediate filament. Transcriptionally
regulated by Notch signaling

1.4

1.8

Table 2-1. Notch-related Genes and Fold Change in Response to Immobilized
Jagged-1.
Shown are genes known to be affected by Notch signaling and their relative change in
AstroRad-NSC in response to Jagged-1 versus control. Two clonal AstroRad-NSC lines isolated
from two separate animals were assayed.
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dna-binding

GOTERM BP FAT:
regulation of transcription

8, 3%

45,
16%

28,
10%

Jagged1
decreased

INTERPRO: Basic helixloop-helix dimerization
region bHLH

246,
90%

233,
84%

p = 1.70E-02

p = 4.70E-04

270,
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In group
Out group

B

SP PIR KEYWORDS:
transmembrane

Jagged1
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p = 5.40E-4
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**
peptide

96,
21%

115,
26%

144,
32%

353,
79%

334,
74%

305,
68%

In group
Out group
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Figure 2-2. Jagged-1 up-regulates membrane-bound and secreted proteins and
down-regulates transcription factors and cell fate effectors.
A) Genes decreased more than or equal to 1.20-fold by Jagged-1 were enriched for
functional annotations for transcription and transcription factors. Pie charts show
percentage of genes in the down-regulated set that have a given annotation term (in
group). P values represent the probability that the experimenal list enriched for a given
annotation by chance compared with the background genome (see methods). B) Genes
with expression that was increased more than or equal to 1.2-fold by Jagged-1 enriched
for proteins with annotations related to membrane-bound proteins and proteins
glycosolated for secretion or presentation at the cell surface. C) DAVID output tabulating
for two functional clusters that were enriched in the Jagged-1 up-regulated list. (Top)
Cluster 2: Homeostasis cluster (partial table. See Table 2-10). (Bottom) Inflammatory
response cluster. D) DAVID-generated 2D plot of annotation terms (columns) vs gene
symbol (rows). A green square indicates gene membership in an annotation group. The
black arrow highlights Sla1A3 aka GLAST.

Gene Symbol

Δ Jagged-1 vs Laminin
(fold change)

Gene Description and Title

Clone 1

Clone 2

Glast

Glutamate uptake transporter. No known
transcriptional regulation by Notch.

1.4

1.5

Glul

Glutamine Synthetase. No known transcriptional
regulation by Notch.

2.4

1.6

Table 2-2. Astrocyte genes that process glutamate and fold change in response to
immobilized Jagged-1.
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Figure 2-3. GLAST gene and protein expression is decreased by GSI and specific
Notch1 deletion.
A’) A CSL sequence found ~2.67 KB upstream of the GLAST transcriptional start point
in Mus musculus. This suggests that it could be directly transcriptionally-activated by
Notch signaling. B) In AstroRad-NSC, GLAST and Notch1 gene expression decreased after 2
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d of incubation in DBZ. B’) 4-OH Tamoxifen (OHTM)-induced conditional deletion of
Notch1 from a clonal line of GNAstroRad-NSC significantly decreased GLAST gene
expression along with Gfap and Notch1 expression. See main text for statistics. Protein
levels of cleaved Notch1 (NICD1) (C) and GLAST (D), but not GLT-1 (E) were reduced
in GNAstroRad-NSC treated with OHTM. F) Another clonal GNAstroRad-NSC line
independent of that used for immunoblot (D) showed a time-dependent decrease in
GLAST protein: 5 > 8 days in OHTM. CSL: CBP-1/suppressor of hairless/LAG-1, GSI:
Gamma Secretase Inhibitor, EtOH: Ethanol.
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Figure 2-4. GSI DAPT inhibits AstroRad-NSC ability to take up extracellular
glutamate.
A) At 15 minutes following addition of glutamate to AstroRad-NSC culture medium,
residual extracellular glutamate was significantly higher in cultures treated with a GSI
(DAPT) and specific GLT-1 antagonizist (DHK) (*p < 0.01, Unpaired Student’s T-test,
n=3). All residual glutamate levels were normalized to vehicle (DMSO + water) control
culture levels. B) 2 d incubation in DAPT significantly decreased glutamate uptake
(increased residual glutamate) in all three AstroRAD-NSCs clones tested, with some
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variations between clones. “Combined” indicates the mean representation of the invidual
clonal uptake data displayed in the graph (*p < 0.01, unpaired Student’s t-test, n=3
clones).
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Figure 2-5. GLAST protein decreases reactive astrocytes from hGFAP-CreERTM;
Notch1loxp/loxp mice.
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A) GFAP was decreased in GLT-1-positive astrocytes sorted from uninjured cortex in
animals treated with tamoxifen (tm) compared with vehicle control (oil) (*p < 0.05, n=3
per group). GLAST protein levels were low or undetectable and not dependent on
treatment group. B) 3 days after dMCAO, GLT-1-positive astrocytes were isolated from
ispalateral cortex and pooled by treatment group. GLAST and GFAP protein levels
decreased in the pooled tm group compared with oil-treated control. GLT-1-negative
fraction contains no detectable GLAST or GFAP protein.
Gene assignment

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

NM_008553 // Ascl1 // achaete-scute complex homolog 1
(Drosophila) // 10 C1|10 // 17172
NM_024283 // 1500015O10Rik // RIKEN cDNA 1500015O10
gene // 1|1 C1 // 78896 /// ENSMUST
NM_016968 // Olig1 // oligodendrocyte transcription factor 1 //
16 C3.3|16 // 50914 ///
NM_001083342 // Ptchd2 // patched domain containing 2 // 4
E2|4 // 242748
NM_011817 // Gadd45g // growth arrest and DNA-damageinducible 45 gamma // 13|13 A5-B /
NM_016967 // Olig2 // oligodendrocyte transcription factor 2 //
16 C3.3|16 63.0 cM // 5
NM_001083342 // Ptchd2 // patched domain containing 2 // 4
E2|4 // 242748 /// ENSMUST00
NM_001103366 // Vmn2r87 // vomeronasal 2, receptor 87 // 10
D3|10 // 625131 /// ENSMUST
NM_001009819 // A3galt2 // alpha 1,3-galactosyltransferase 2
(isoglobotriaosylceramide
NM_207227 // Olfr1373 // olfactory receptor 1373 // 11 B1.3|11
// 211472 /// ENSMUST000
NM_007631 // Ccnd1 // cyclin D1 // 7 F5|7 72.3 cM // 12443 ///
ENSMUST00000093962 // Cc
NM_010849 // Myc // myelocytomatosis oncogene // 15 D2D3|15 32.0 cM // 17869 /// NM_00
NM_029646 // Il34 // interleukin 34 // 8 E1|8 // 76527 ///
ENSMUST00000150680 // Il34 /
NM_153778 // Atoh8 // atonal homolog 8 (Drosophila) // 6 C1|6
// 71093 /// ENSMUST00000
NM_016743 // Nell2 // NEL-like 2 (chicken) // 15 F1|15 // 54003
/// ENSMUST00000166170
NM_009129 // Scg2 // secretogranin II // 1 C4|1 43.6 cM //
20254 /// ENSMUST00000049972
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Clone1
(LamJag1)
3.39

Clone2
(LamJag1)
2.07

2.62

2.90

2.51

1.32

2.46

1.40

2.37

1.50

2.30

1.29

2.30

1.29

2.24

1.31

2.19

1.21

2.15

1.22

2.15

2.07

2.12

1.64

2.07

1.21

2.04

1.40

1.96

1.49

1.94

1.78

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

NM_032541 // Hamp // hepcidin antimicrobial peptide // 7 B1|7
11.0 cM // 84506 /// ENSM
NM_177367 // Gemin4 // gem (nuclear organelle) associated
protein 4 // 11 B5|11 // 2769
NM_001104542 // Vmn2r93 // vomeronasal 2, receptor 93 // 17
A3.2|17 // 627132 /// ENSMU
NM_008178 // Gsx1 // GS homeobox 1 // 5 G3|5 41.0 cM //
14842 /// ENSMUST00000065382 //
NR_003564 // Gm15698 // transcription elongation factor B
(SIII), polypeptide 2 pseudog
XM_891513 // Rpl31-ps21 // ribosomal protein L31,
pseudogene 21 // 5 A3|5 // 626903
NM_001037925 // BC147527 // cDNA sequence BC147527 // -- // 625360 /// ENSMUST00000081
ENSMUST00000139730 // Top2a // topoisomerase (DNA) II
alpha // 11 D|11 57.0 cM // 21973
NM_008665 // Myt1 // myelin transcription factor 1 // 2 H4|2
106.0 cM // 17932 /// ENSM
NM_007930 // Enc1 // ectodermal-neural cortex 1 // 13|13 D1 //
13803 /// ENSMUST0000004
NM_001025386 // Olfr243 // olfactory receptor 243 // 7 E3|7 //
436002 /// ENSMUST000000
NM_027426 // 2610109H07Rik // RIKEN cDNA 2610109H07
gene // 4|4 E1 // 70433 /// ENSMUST
NM_016901 // Oaz3 // ornithine decarboxylase antizyme 3 //
3|3 F2 // 53814 /// ENSMUST0
NM_001164594 // Pdzrn4 // PDZ domain containing RING
finger 4 // 15 E3|15 // 239618 ///
NM_013775 // Tcl1b2 // T cell leukemia/lymphoma 1B, 2 // 12
E|12 // 27381 /// ENSMUST00
NM_001164289 // Gm6907 // predicted gene 6907 // 14 C3|14
// 628705 /// ENSMUST00000166
NM_133198 // Pygl // liver glycogen phosphorylase // 12 C2|12
30.0 cM // 110095 /// ENS
NM_177407 // Camk2a // calcium/calmodulin-dependent
protein kinase II alpha // 18 E1|18
ENSMUST00000079601 // Etv5 // ets variant gene 5 // 16
B1|16 // 104156 /// NM_023794 //
NM_008709 // Mycn // v-myc myelocytomatosis viral related
oncogene, neuroblastoma deriv
NR_027759 // Dctd // dCMP deaminase // 8 B1.2|8 // 320685 ///
NM_178788 // Dctd // dCMP
AK144596 // G730007D18Rik // RIKEN cDNA G730007D18
gene // --- // 100038502
NR_030694 // 1110002L01Rik // RIKEN cDNA 1110002L01
gene // 12 A1.1|12 // 100043040
NM_178751 // Orai2 // ORAI calcium release-activated calcium
modulator 2 // 5 G2|5 // 2
NM_021719 // Cldn15 // claudin 15 // 5 G2|5 // 60363 ///
ENSMUST00000111093 // Cldn15 /
NM_001081310 // Tmem236 // transmembrane protein 236 // 2
A2|2 // 625286 /// ENSMUST000
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1.31

1.82
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1.82

1.43

1.81

2.03

1.81

1.49

1.74
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1.73
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1.29

1.65

1.27

1.64
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1.24

1.64

1.47

1.61

1.31

1.58

1.20

1.57

1.38
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1.31

1.55

1.29

1.54

1.54

1.53

1.24

1.52

1.39

1.51

1.37

1.51

1.24

1.51

1.21

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68

BC030401 // Gm4983 // predicted gene 4983 // 12 A1.2|12 //
245297 /// XR_105475 // Gm49
NM_178751 // Orai2 // ORAI calcium release-activated calcium
modulator 2 // 5 G2|5 // 2
NM_001077495 // Pik3r1 // phosphatidylinositol 3-kinase,
regulatory subunit, polypeptid
NM_146668 // Olfr739 // olfactory receptor 739 // 14 C3-D1|14
// 258663 /// ENSMUST0000
NM_177383 // Gpr21 // G protein-coupled receptor 21 // 2 B|2 //
338346 /// ENSMUST00000
NM_001001187 // Zfp738 // zinc finger protein 738 // 13 B3|13
// 408068 /// ENSMUST0000
NM_177793 // 9030224M15Rik // RIKEN cDNA 9030224M15
gene // 10 B1|10 // 327747 /// ENSM
XR_035401 // 4932431P20Rik // RIKEN cDNA 4932431P20
gene // 7 B1|7 // 114675
NM_001001187 // Zfp738 // zinc finger protein 738 // 13 B3|13
// 408068 /// ENSMUST0000
NM_011739 // Ywhaq // tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation pr
BC024822 // Vopp1 // vesicular, overexpressed in cancer,
prosurvival protein 1 // 6 B3|
NM_145635 // Adig // adipogenin // 2 H1|2 // 246747 ///
ENSMUST00000059889 // Adig // a
NM_020271 // Pdxp // pyridoxal (pyridoxine, vitamin B6)
phosphatase // 15 E1|15 // 5702
NM_001024846 // Zfp62 // zinc finger protein 62 // 11 B1.2|11
28.0 cM // 22720 /// ENSM
NM_007494 // Ass1 // argininosuccinate synthetase 1 // 2 B|2
20.0 cM // 11898 /// NR_00
NM_177773 // 4933408B17Rik // RIKEN cDNA 4933408B17
gene // 18 B1|18 // 271508 /// ENSM
NM_008342 // Igfbp2 // insulin-like growth factor binding protein
2 // 1 C3|1 36.1 cM /
NM_172746 // Hirip3 // HIRA interacting protein 3 // 7 F3|7 //
233876 /// ENSMUST000000
NM_178667 // Tfdp2 // transcription factor Dp 2 // 9 E3.3|9 //
211586 /// NM_001184706
NM_010415 // Hbegf // heparin-binding EGF-like growth factor
// 18 B2|18 15.0 cM // 152
NR_004410 // Snord87 // small nucleolar RNA, C/D box 87 // 1
A2|1 // 266793
NM_001104531 // Cyp2d11 // cytochrome P450, family 2,
subfamily d, polypeptide 11 // 15
NM_013738 // Plek2 // pleckstrin 2 // 12|12 D2 // 27260 ///
ENSMUST00000021544 // Plek2
NM_178020 // Hyal3 // hyaluronoglucosaminidase 3 // 9 F1F2|9 60.12 cM // 109685 /// EN
NR_004051 // Btnl5 // butyrophilin-like 5 // 17 B1|17 18.7 cM //
81497
NM_001163456 // Cox18 // COX18 cytochrome c oxidase
assembly homolog (S. cerevisiae) //
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NR_033304 // Lypd6 // LY6/PLAUR domain containing 6 // 2
C1.1|2 // 320343 /// ENSMUST00
AK139984 // Gm10616 // predicted gene 10616 // --- //
100038478 /// XR_105123 // Gm1061
NM_001011733 // Olfr288 // olfactory receptor 288 // 15 F1|15
// 545140 /// ENSMUST0000
NM_010755 // Maff // v-maf musculoaponeurotic fibrosarcoma
oncogene family, protein F (
ENSMUST00000032402 // Bcat1 // branched chain
aminotransferase 1, cytosolic // 6 G3|6 7
ENSMUST00000019861 // Zfp451 // zinc finger protein 451 // 1
B|1 18.5 cM // 98403 /// N
NM_007494 // Ass1 // argininosuccinate synthetase 1 // 2 B|2
20.0 cM // 11898 /// ENSMU
NM_145401 // Prkag2 // protein kinase, AMP-activated, gamma
2 non-catalytic subunit //
NM_011915 // Wif1 // Wnt inhibitory factor 1 // 10 D2|10 //
24117 /// ENSMUST0000002043
NR_029736 // Mir18 // microRNA 18 // 14|14 // 387135

1.41

1.33

1.41

1.50

1.41

1.25

1.40

1.40

1.40

1.78

1.40

1.26

1.40

1.99

1.40

1.21

1.40

1.31

1.40

1.66

NR_002870 // Dnm3os // dynamin 3, opposite strand // 1
H2.1|1 // 474332
NM_001014974 // Ttll4 // tubulin tyrosine ligase-like family,
member 4 // 1 C3|1 // 675
NM_183263 // Rnmtl1 // RNA methyltransferase like 1 // 11
B5|11 // 67390 /// ENSMUST000
NM_026214 // Kctd4 // potassium channel tetramerisation
domain containing 4 // 14|14 D2
NR_003368 // Pvt1 // plasmacytoma variant translocation 1 //
15 D2-D3|15 32.0 cM // 192
NM_019731 // Nme4 // NME/NM23 nucleoside diphosphate
kinase 4 // 17|17 B1 // 56520 ///
NM_172539 // Astl // astacin-like metalloendopeptidase (M12
family) // 2|2 F // 215095
NM_147017 // Olfr1045 // olfactory receptor 1045 // 2 E1|2 //
259019 /// ENSMUST0000009
NM_025564 // Magohb // mago-nashi homolog B (Drosophila)
// 6 C7|6 // 66441 /// ENSMUST
NM_001001332 // BC117090 // cDNA sequence BC1179090 //
16 B3|16 // 100038854 /// ENSMUS
ENSMUST00000098278 // B3gnt6 // UDP-GlcNAc:betaGal
beta-1,3-N-acetylglucosaminyltransfe
NM_173789 // Helt // helt bHLH transcription factor // 8 B1.1|8
27.0 cM // 234219 /// E
NM_024413 // Plekhf1 // pleckstrin homology domain
containing, family F (with FYVE doma
NM_027976 // Acsl5 // acyl-CoA synthetase long-chain family
member 5 // 19 D2|19 // 433
ENSMUST00000021822 // Ogn // osteoglycin // 13 A5|13 //
18295
NM_001164598 // Irf2bp2 // interferon regulatory factor 2
binding protein 2 // 8 E2|8 /
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NM_134240 // Vmn1r222 // vomeronasal 1 receptor 222 // 13
A3.1|13 // 171274 /// ENSMUST
NM_170778 // Dpyd // dihydropyrimidine dehydrogenase // 3
G1|3 // 99586 /// ENSMUST0000
NM_001081235 // Mn1 // meningioma 1 // 5 F|5 59.0 cM //
433938 /// ENSMUST00000094463 /
NM_010330 // Emb // embigin // 13 D2.3|13 // 13723 ///
ENSMUST00000022242 // Emb // emb
NM_020044 // Lat2 // linker for activation of T cells family,
member 2 // 5 G2|5 // 567
NM_008536 // Tm4sf1 // transmembrane 4 superfamily
member 1 // 3 D|3 // 17112 /// ENSMU
NM_001081417 // Chd7 // chromodomain helicase DNA
binding protein 7 // 4 A1|4 1.0 cM //
NM_145482 // Setd4 // SET domain containing 4 // 16 C4|16 //
224440 /// ENSMUST00000023
NM_021352 // Crybb3 // crystallin, beta B3 // 5 F|5 60.0 cM //
12962 /// ENSMUST0000007
NR_045766 // Gm10509 // zinc finger protein 51 pseudogene //
17 A3.2 // 100310809 /// N
NM_009944 // Cox7a1 // cytochrome c oxidase, subunit VIIa 1
// 7 B1|7 8.0 cM // 12865 /
NM_001083927 // Tle3 // transducin-like enhancer of split 3,
homolog of Drosophila E(sp
NM_029863 // 9230110F15Rik // RIKEN cDNA 9230110F15
gene // 9 A4|9 // 77080 /// ENSMUST
NM_146664 // Olfr734 // olfactory receptor 734 // 14 C3-D1|14
// 258658 /// ENSMUST0000
NM_011397 // Slc23a1 // solute carrier family 23 (nucleobase
transporters), member 1 //
NM_008928 // Map2k3 // mitogen-activated protein kinase
kinase 3 // 11 B2|11 // 26397 /
NM_025403 // Nop10 // NOP10 ribonucleoprotein homolog
(yeast) // 2|2 E4 // 66181 /// EN
NM_134195 // Vmn1r227 // vomeronasal 1 receptor 227 // 17
A3.2|17 // 171229
NM_011808 // Ets1 // E26 avian leukemia oncogene 1, 5'
domain // 9 A4|9 15.0 cM // 2387
NM_025863 // Trim59 // tripartite motif-containing 59 // 3|3 E2 //
66949 /// ENSMUST000
NM_172125 // Adam1b // a disintegrin and metallopeptidase
domain 1b // 5 F|5 // 280667
NM_009731 // Akr1b7 // aldo-keto reductase family 1, member
B7 // 6 B1|6 14.0 cM // 119
NM_145852 // Ropn1l // ropporin 1-like // 15 B2|15 // 252967 ///
ENSMUST00000110408 //
NM_001114385 // Chrdl1 // chordin-like 1 // X F3|X // 83453 ///
ENSMUST00000112878 // C
NM_008327 // Ifi202b // interferon activated gene 202B // 1
H3|1 // 26388 /// NM_011940
NM_146786 // Olfr914 // olfactory receptor 914 // 9 A5|9 //
258782 /// ENSMUST000000577
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NM_027261 // Taf1d // TATA box binding protein (Tbp)associated factor, RNA polymerase
NM_011560 // Tcte3 // t-complex-associated testis expressed 3
// 17 A2|17 8.16 cM // 21
NM_009214 // Sms // spermine synthase // X F4|X 65.45 cM //
20603 /// AF031486 // Sms /
ENSMUST00000129632 // Tcp1 // t-complex protein 1 // 17 A3B|17 7.5 cM // 21454
NM_001085549 // Gm12824 // predicted gene 12824 // 4 D1|4
// 666048 /// ENSMUST00000094
AK033210 // 8030451A03Rik // RIKEN cDNA 8030451A03
gene // 4 C1|4 // 100504061 /// XR_1
NM_019643 // Fam60a // family with sequence similarity 60,
member A // 6 G3|6 // 56306
NM_172482 // Zfp719 // zinc finger protein 719 // 7 B4|7 //
210105 /// ENSMUST000001638
NM_138757 // 4933424B01Rik // RIKEN cDNA 4933424B01
gene // 6 G3|6 // 71177 /// ENSMUST
NM_008274 // Hoxd12 // homeobox D12 // 2 C3|2 45.0 cM //
15432 /// ENSMUST00000001878 /
NM_146666 // Olfr736 // olfactory receptor 736 // 14 C3-D1|14
// 258660 /// ENSMUST0000
NM_011560 // Tcte3 // t-complex-associated testis expressed 3
// 17 A2|17 8.16 cM // 21
NM_010053 // Dlx1 // distal-less homeobox 1 // 2 C2|2 44.0 cM
// 13390 /// ENSMUST00000
NM_177175 // Tmem215 // transmembrane protein 215 // 4
A5|4 // 320500 /// ENSMUST000000
NM_148413 // Myo3a // myosin IIIA // 2 A3|2 // 667663 ///
ENSMUST00000044749 // Myo3a /
ENSMUST00000025764 // Cst6 // cystatin E/M // 19 A|19 4.0
cM // 73720 /// BC061036 // C
NM_013598 // Kitl // kit ligand // 10 D1|10 57.0 cM // 17311 ///
ENSMUST00000105283 //
NM_009967 // Crygs // crystallin, gamma S // 16 B1|16 16.1 cM
// 12970 /// ENSMUST00000
NM_021362 // Pappa // pregnancy-associated plasma protein
A // 4 C1|4 32.2 cM // 18491
NR_030764 // 2700097O09Rik // RIKEN cDNA 2700097O09
gene // 12 C1|12 // 72658 /// NM_02
NM_146319 // Olfr727 // olfactory receptor 727 // 14 C1|14 //
258316 /// ENSMUST0000007
NM_019643 // Fam60a // family with sequence similarity 60,
member A // 6 G3|6 // 56306
NR_033613 // 1700001J11Rik // ring finger protein 19A
pseudogene // 9 A5.1|9 // 72224
NM_172514 // Tmem71 // transmembrane protein 71 // 15
D2|15 // 213068 /// ENSMUST000000
NM_026150 // 4921536K21Rik // RIKEN cDNA 4921536K21
gene // 11 A1|11 // 67430 /// ENSMU
NM_007986 // Fap // fibroblast activation protein // 2 C1.3|2
36.0 cM // 14089 /// ENSM
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NM_009464 // Ucp3 // uncoupling protein 3 (mitochondrial,
proton carrier) // 7 E3|7 50.
ENSMUST00000027422 // Slc16a14 // solute carrier family 16
(monocarboxylic acid transpo
ENSMUST00000137376 // Gm11362 // predicted gene 11362
// 13 A3.1|13 // 626683 /// ENSMU
NM_025414 // Myo19 // myosin XIX // 11|11 B5 // 66196 ///
ENSMUST00000093969 // Myo19 /
AK164247 // Nfxl1 // nuclear transcription factor, X-box bindinglike 1 // 5|5 D // 100
NM_029271 // Mrpl32 // mitochondrial ribosomal protein L32 //
13|13 A2 // 75398 /// ENS
NM_023816 // Ankrd36 // ankyrin repeat domain 36 // 11 A1|11
// 76389 /// ENSMUST000001
NM_008066 // Gabra2 // gamma-aminobutyric acid (GABA) A
receptor, subunit alpha 2 // 5
NM_008933 // Prm2 // protamine 2 // 16 A1|16 3.4 cM // 19119
/// ENSMUST00000037996 //
AK038227 // Gm9734 // predicted gene 9734 // 11 E2|11 //
76377 /// XR_035387 // Gm9734
NM_023794 // Etv5 // ets variant gene 5 // 16 B1|16 // 104156
/// ENSMUST00000079601 //
NM_172308 // Mthfd1l // methylenetetrahydrofolate
dehydrogenase (NADP+ dependent) 1-lik
NM_001013816 // Gm5622 // predicted gene 5622 // 14 C2|14
// 434459 /// ENSMUST00000096
NM_201411 // Flrt1 // fibronectin leucine rich transmembrane
protein 1 // 19 A|19 // 39
NM_001081417 // Chd7 // chromodomain helicase DNA
binding protein 7 // 4 A1|4 1.0 cM //
NM_025844 // Chordc1 // cysteine and histidine-rich domain
(CHORD)-containing, zinc-bin
NM_054058 // Psg20 // pregnancy-specific glycoprotein 20 // 7
A3|7 // 434540 /// ENSMUS
NM_177367 // Gemin4 // gem (nuclear organelle) associated
protein 4 // 11 B5|11 // 2769
NM_207153 // Olfr325 // olfactory receptor 325 // 11 B1.3|11 //
258261 /// ENSMUST00000
NM_023653 // Wnt2 // wingless-related MMTV integration site
2 // 6 A2-A3.1|6 4.2 cM //
NM_198011 // E430018J23Rik // RIKEN cDNA E430018J23
gene // 7 F3|7 // 101604 /// ENSMUS
NM_146875 // Olfr895 // olfactory receptor 895 // 9 A5|9 //
258875 /// ENSMUST000000938
NM_001167983 // Sipa1l1 // signal-induced proliferationassociated 1 like 1 // 12 D1|12
XM_001002269 // Gm8290 // predicted gene 8290 // 10 C1|10
// 666790 /// ENSMUST00000079
BC117944 // Slco5a1 // solute carrier organic anion transporter
family, member 5A1 // 1
NM_177092 // Msrb3 // methionine sulfoxide reductase B3 // 10
D2|10 // 320183 /// ENSMU

103

1.30

1.26

1.30

1.33

1.29

1.31

1.29

1.26

1.29

1.24

1.29

1.28

1.29

1.42

1.29

1.27

1.29

1.23

1.29

1.30

1.29

1.46

1.29

1.30

1.29

1.29

1.29

1.21

1.29

1.37

1.28

1.41

1.28

1.29

1.28

1.23

1.28

1.28

1.28

1.25

1.28

1.21

1.28

1.29

1.28

1.44

1.28

1.21

1.28

1.20

1.28

1.31

173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198

ENSMUST00000020849 // Tom1l1 // target of myb1-like 1
(chicken) // 11 D|11 53.0 cM // 7
AK048707 // C230012O17Rik // RIKEN cDNA C230012O17
gene // 4 A3|4 // 319564
NM_181406 // Rars2 // arginyl-tRNA synthetase 2,
mitochondrial // 4 A5|4 // 109093 ///
NM_008961 // Pter // phosphotriesterase related // 2 A1|2 //
19212 /// ENSMUST000001347
NM_001146180 // Mtss1 // metastasis suppressor 1 // 15 D1|15
// 211401 /// ENSMUST00000
NM_010244 // Fv1 // Friend virus susceptibility 1 // 4 E2|4 76.5
cM // 14349 /// ENSMUS
NM_024187 // U2af1 // U2 small nuclear ribonucleoprotein
auxiliary factor (U2AF) 1 // 1
AK145303 // Gm10747 // predicted gene 10747 // --- //
100038610 /// XR_105386 // Gm1074
NM_001166024 // Arfgap2 // ADP-ribosylation factor GTPase
activating protein 2 // 2 E1|
NM_025520 // Lsm5 // LSM5 homolog, U6 small nuclear RNA
associated (S. cerevisiae) // 6
AK155938 // Gm10388 // predicted gene 10388 // --- //
100038707 /// XR_140411 // Gm1038
NM_146451 // Olfr164 // olfactory receptor 164 // 16 B1|16 //
258443 /// ENSMUST0000005
NR_033261 // Gm14492 // predicted gene 14492 // 7 F5|7 //
677289
NM_198026 // Iqcc // IQ motif containing C // 4 D2.2|4 //
230767 /// ENSMUST00000046675
NM_001013813 // Maml2 // mastermind like 2 (Drosophila) // 9
A1|9 // 270118 /// ENSMUST
NM_013496 // Crabp1 // cellular retinoic acid binding protein I //
9 A5.3|9 31.0 cM //
NM_029755 // Calcoco2 // calcium binding and coiled-coil
domain 2 // 11 C|11 55.8 cM //
NM_011505 // Stxbp4 // syntaxin binding protein 4 // 11|11 C //
20913 /// ENSMUST000001
NM_024187 // U2af1 // U2 small nuclear ribonucleoprotein
auxiliary factor (U2AF) 1 // 1
NM_026348 // Itgb3bp // integrin beta 3 binding protein (beta3endonexin) // 4 C6|4 //
NM_153459 // Dusp7 // dual specificity phosphatase 7 // 9 F1|9
// 235584 /// ENSMUST000
NM_001161845 // Sgk1 // serum/glucocorticoid regulated
kinase 1 // 10 A3|10 // 20393 //
NM_011382 // Six4 // sine oculis-related homeobox 4 homolog
(Drosophila) // 12 C3|12 //
NM_026257 // Ubxn11 // UBX domain protein 11 // 4 D3|4 65.7
cM // 67586 /// ENSMUST0000
NM_001099688 // Fbxo39 // F-box protein 39 // 11 B4|11 //
628100 /// ENSMUST00000108504
ENSMUST00000126435 // Mri1 // methylthioribose-1phosphate isomerase homolog (S. cerevi
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NM_023142 // Arpc1b // actin related protein 2/3 complex,
subunit 1B // 5 G2|5 // 11867
NM_001134461 // Prickle2 // prickle homolog 2 (Drosophila) //
6 D1|6 // 243548 /// ENSM
NR_028359 // 5830417I10Rik // gon-4-like pseudogene // 3
F1|3 // 100302730
NM_010584 // Itln1 // intelectin 1 (galactofuranose binding) //
1|1 H2 // 16429 /// AY1
NM_001146007 // Trim12c // tripartite motif-containing 12C // 7
E3|7 // 319236 /// NM_1
NM_001029876 // Urb2 // URB2 ribosome biogenesis 2
homolog (S. cerevisiae) // 8 E2|8 //
NM_011463 // Spink4 // serine peptidase inhibitor, Kazal type 4
// 4|4 A // 20731 /// E
NM_001033348 // Ralgapa2 // Ral GTPase activating protein,
alpha subunit 2 (catalytic)
NR_027619 // Mug-ps1 // murinoglobulin, pseudogene 1 // 6
F1|6 // 17835 /// NM_008646 /
BC030179 // Fam173b // family with sequence similarity 173,
member B // 15 B2|15 // 680
NM_015759 // Fgd3 // FYVE, RhoGEF and PH domain
containing 3 // 13 A5|13 31.0 cM // 309
NM_017399 // Fabp1 // fatty acid binding protein 1, liver // 6
C1|6 30.0 cM // 14080 //
NM_001161548 // Tmem184a // transmembrane protein 184a
// 5 G2|5 // 231832 /// ENSMUST0
NM_001042592 // Arrdc4 // arrestin domain containing 4 // 7
D1|7 // 66412 /// ENSMUST00
NM_011946 // Map3k2 // mitogen-activated protein kinase
kinase kinase 2 // 18 B3|18 //
NR_015491 // A630089N07Rik // RIKEN cDNA A630089N07
gene // 16 C4|16 // 320586
ENSMUST00000032192 // Itpr1 // inositol 1,4,5-trisphosphate
receptor 1 // 6 E1-E2|6 48.
NM_025356 // Ube2d3 // ubiquitin-conjugating enzyme E2D 3 //
3 G3|3 // 66105 /// ENSMUS
ENSMUST00000100403 // Tmem106a // transmembrane
protein 106A // 11 D|11 // 217203 /// N
NM_026656 // Mcoln2 // mucolipin 2 // 3 H2|3 // 68279 ///
NM_001005846 // Mcoln2 // muc
ENSMUST00000078508 // Sp7 // Sp7 transcription factor 7 //
15 F3|15 // 170574 /// AF184
NM_007981 // Acsl1 // acyl-CoA synthetase long-chain family
member 1 // 8|8 B2 // 14081
NM_029427 // Pnpla5 // patatin-like phospholipase domain
containing 5 // 15|15 E3 // 75
NM_009707 // Arhgap6 // Rho GTPase activating protein 6 // X
F5|X // 11856 /// ENSMUST0
NM_134067 // AW209491 // expressed sequence AW209491 //
13 A1|13 // 105351 /// ENSMUST0
NM_009238 // Sox4 // SRY-box containing gene 4 // 13 A3A5|13 20.0 cM // 20677 /// ENSM
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NM_009979 // Cst9 // cystatin 9 // 2|2 H1 // 13013 ///
ENSMUST00000028935 // Cst9 // cy
NM_145434 // Nr1d1 // nuclear receptor subfamily 1, group D,
member 1 // 11 D|11 // 217
NM_029733 // 2010005H15Rik // RIKEN cDNA 2010005H15
gene // 16 B3|16 // 76770 /// BC125
NM_009214 // Sms // spermine synthase // X F4|X 65.45 cM //
20603 /// BC058688 // Sms /
NM_001048168 // Nfyc // nuclear transcription factor-Y gamma
// 4 D2.2|4 55.0 cM // 180
NM_009601 // Chrnb1 // cholinergic receptor, nicotinic, beta
polypeptide 1 (muscle) //
NM_011376 // Sim1 // single-minded homolog 1 (Drosophila) //
10 B3|10 26.5 cM // 20464
NM_026866 // Disp1 // dispatched homolog 1 (Drosophila) //
1|1 101.2 cM // 68897 /// EN
NM_009189 // Six1 // sine oculis-related homeobox 1 homolog
(Drosophila) // 12 C3|12 31
NM_025430 // Mrpl35 // mitochondrial ribosomal protein L35 //
6|6 C3 // 66223 /// ENSMU
NM_009687 // Apex1 // apurinic/apyrimidinic endonuclease 1 //
14 C3|14 18.5 cM // 11792
NM_176933 // Dusp4 // dual specificity phosphatase 4 // 8 A4|8
// 319520 /// ENSMUST000
NM_001034902 // Gm5878 // predicted gene 5878 // 6 C3|6 //
545861 /// ENSMUST0000011380
NM_001146002 // Txndc2 // thioredoxin domain containing 2
(spermatozoa) // 17|17 E1.2-E
NM_026352 // Ppid // peptidylprolyl isomerase D (cyclophilin D)
// 3|3 F1 // 67738 ///
NM_013813 // Epb4.1l3 // erythrocyte protein band 4.1-like 3 //
17 E1.3|17 42.5 cM // 1
NM_146005 // Ank3 // ankyrin 3, epithelial // 10 B5.3|10 38.0
cM // 11735 /// NM_170688
NR_027885 // Vaultrc5 // vault RNA component 5 // --- //
378472
NM_030743 // Rnf114 // ring finger protein 114 // 2 H3|2 //
81018 /// ENSMUST0000010921
NM_013722 // Syn3 // synapsin III // 10|10 C2 // 27204 ///
ENSMUST00000120638 // Syn3 /
NM_025274 // Dppa5a // developmental pluripotency
associated 5A // 9 E1|9 // 434423 ///
NM_001025561 // Pus1 // pseudouridine synthase 1 // 5 F|5 //
56361 /// ENSMUST000000866
NM_001113180 // Gria4 // glutamate receptor, ionotropic,
AMPA4 (alpha 4) // 9 A1|9 8.0
NM_001024385 // Crls1 // cardiolipin synthase 1 // 2|2 F3 //
66586 /// NM_025646 // Crl
NM_001081417 // Chd7 // chromodomain helicase DNA
binding protein 7 // 4 A1|4 1.0 cM //
NM_009384 // Tiam1 // T cell lymphoma invasion and
metastasis 1 // 16 C3-4|16 61.8 cM /
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ENSMUST00000078623 // Cryba1 // crystallin, beta A1 // 11 BC1|11 44.71 cM // 12957 ///
NM_001002927 // Penk // preproenkephalin // 4 A1|4 0.8 cM //
18619 /// ENSMUST000000703
NM_026371 // Loh12cr1 // loss of heterozygosity, 12,
chromosomal region 1 homolog (huma
NM_007710 // Ckm // creatine kinase, muscle // 7 A3|7 4.5 cM
// 12715 /// ENSMUST000000
NM_001011822 // Olfr787 // olfactory receptor 787 // 10 D3|10
// 258069 /// ENSMUST0000
ENSMUST00000002708 // Shh // sonic hedgehog // 5 B1|5
16.0 cM // 20423 /// NM_009170 //
NM_010504 // Ifna4 // interferon alpha 4 // 4 C4|4 42.6 cM //
15967 /// ENSMUST00000094
NM_029370 // Spata25 // spermatogenesis associated 25 // 2
H3|2 // 75642 /// ENSMUST000
NM_172818 // Ttll8 // tubulin tyrosine ligase-like family,
member 8 // 15 E3|15 // 2395
NM_001033306 // Shb // src homology 2 domain-containing
transforming protein B // 4 B1|
ENSMUST00000087521 // Nif3l1 // Ngg1 interacting factor 3like 1 (S. pombe) // 1|1 C //
NM_008888 // Phox2b // paired-like homeobox 2b // 5 C3.1|5
40.0 cM // 18935 /// ENSMUST
NM_027926 // Cpa4 // carboxypeptidase A4 // 6 A3.3|6 //
71791 /// ENSMUST00000049251 //
ENSMUST00000022656 // 6720463M24Rik // RIKEN cDNA
6720463M24 gene // 14 E2.2|14 // 7774
NR_037995 // 0610009B14Rik // RIKEN cDNA 0610009B14
gene // 12 C3|12 // 68354
NM_146323 // Olfr1232 // olfactory receptor 1232 // 2 E1|2 //
258320 /// ENSMUST0000009
NM_001042653 // Oip5 // Opa interacting protein 5 // 2 E5|2 //
70645 /// ENSMUST0000012
NM_026878 // Rasl11b // RAS-like, family 11, member B // 5|5
D // 68939 /// ENSMUST0000
NM_025738 // Cypt1 // cysteine-rich perinuclear theca 1 // X
A1.2|X // 66742 /// BC0610
NM_001004194 // Nlrp4e // NLR family, pyrin domain
containing 4E // 7 A3|7 // 446099 //
NM_010664 // Krt18 // keratin 18 // 15 F3|15 58.86 cM // 16668
/// ENSMUST00000023803 /
ENSMUST00000120432 // Mlkl // mixed lineage kinase
domain-like // 8|8 D3 // 74568 /// N
NM_025481 // Smurf2 // SMAD specific E3 ubiquitin protein
ligase 2 // 11 E1|11 // 66313
NM_019764 // Amotl2 // angiomotin-like 2 // 9 F1|9 // 56332 ///
ENSMUST00000035121 // A
BC016246 // 1810029B16Rik // RIKEN cDNA 1810029B16
gene // 8|8 B3.3 // 66282 /// ENSMUS
NM_029122 // Iqca // IQ motif containing with AAA domain // 1
D|1 // 74918 /// ENSMUST0
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1.21
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1.64
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NR_030153 // Mir470 // microRNA 470 // X|X // 723873

1.21

1.33

NM_177681 // Zfp12 // zinc finger protein 12 // 5 G2|5 //
231866 /// ENSMUST00000077485
NM_026479 // Zcchc10 // zinc finger, CCHC domain containing
10 // 11 B1.3|11 28.5 cM //
NM_001005788 // Zfp69 // zinc finger protein 69 // 4 D2.2|4
54.0 cM // 381549 /// ENSMU
NM_009087 // Polr1d // polymerase (RNA) I polypeptide D // 5
G3|5 // 20018 /// ENSMUST0
NM_001253847 // Cbll1 // Casitas B-lineage lymphoma-like 1 //
12 A3|12 // 104836 /// NM
BC063063 // 2410018L13Rik // RIKEN cDNA 2410018L13
gene // 12 A1.3|12 // 69732
NM_172908 // Ovch2 // ovochymase 2 // 7 E3|7 // 244199 ///
ENSMUST00000106755 // Ovch2
NM_026235 // Larp6 // La ribonucleoprotein domain family,
member 6 // 9 B|9 // 67557 //
AK082708 // Gm16487 // predicted gene 16487 // --- // 791285

1.21

1.24

1.21

1.70

1.21

1.29

1.21

1.60

1.21

1.38

1.21

1.40

1.21

1.25

1.21

1.29

1.21

1.21

NM_001033039 // Klhdc9 // kelch domain containing 9 // 1 H3|1
93.3 cM // 68874 /// ENSM
ENSMUST00000050833 // Ino80e // INO80 complex subunit E
// 7 F3|7 // 233875 /// NM_1535
NM_001013369 // Pfdn4 // prefoldin 4 // 2 H3|2 99.0 cM //
109054 /// ENSMUST00000075087
NM_026821 // D4Bwg0951e // DNA segment, Chr 4, Brigham
& Women's Genetics 0951 expresse
NM_147000 // Olfr173 // olfactory receptor 173 // 16 C2|16 //
259002 /// ENSMUST0000004
NR_045618 // Gm9958 // predicted gene 9958 // 5|5 // 791294

1.21

1.25

1.21

1.24

1.20

1.82

1.20

1.49

1.20

1.28

1.20

1.52

NM_023680 // Tnfrsf22 // tumor necrosis factor receptor
superfamily, member 22 // 7 F5|
NM_146641 // Olfr1164 // olfactory receptor 1164 // 2 E1|2 //
258634 /// ENSMUST0000009
NM_011836 // Lamc3 // laminin gamma 3 // 2 B|2 // 23928 ///
ENSMUST00000028187 // Lamc3
NM_001141965 // Naa20 // N(alpha)-acetyltransferase 20,
NatB catalytic subunit // 2 H1|
NM_001161855 // 4933416C03Rik // RIKEN cDNA
4933416C03 gene // 10 D2|10 // 619332 /// E
NR_029731 // Mirlet7f-1 // microRNA let7f-1 // 13|13 // 387252

1.20

1.29

1.20

1.32

1.20

1.27

1.20

1.21

1.20

1.29

1.20

1.29

Table 2-3. Supplementary Table 1: Gene Expression decreased ≥ 1.2-fold by
Immobilized Jagged-1.
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Gene assignment

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

NM_025980 // Nrarp // Notch-regulated ankyrin repeat protein // 2
A3|2 // 67122 /// ENS
NM_008407 // Itih3 // inter-alpha trypsin inhibitor, heavy chain 3 //
14|14 A2-C1 // 16
ENSMUST00000037048 // Mmd2 // monocyte to macrophage
differentiation-associated 2 // 5
NM_001014395 // Fbxw22 // F-box and WD-40 domain protein 22
// 9 F2|9 // 382156 /// ENS
ENSMUST00000167204 // Dclk1 // doublecortin-like kinase 1 //
3|3 D // 13175
NM_001011750 // Olfr294 // olfactory receptor 294 // 7 D3|7 //
257904 /// ENSMUST000000
NM_026376 // Plxnd1 // plexin D1 // 6 E3|6 // 67784
ENSMUST00000041042 // Tbc1d10a // TBC1 domain family,
member 10a // 11 A1|11 // 103724
BC051076 // BC051076 // cDNA sequence BC051076 // 5 E1|5 //
243090
ENSMUST00000162664 // Nckap5 // NCK-associated protein 5 //
1 E3|1 // 210356 /// ENSMUS
NM_001013770 // Lipo1 // lipase, member O1 // 19 C1|19 //
381236 /// ENSMUST00000112508
NM_172290 // Ntm // neurotrimin // 9 A4|9 // 235106 ///
ENSMUST00000075069 // Ntm // ne
NM_181395 // Pxdn // peroxidasin homolog (Drosophila) // 12
A2|12 // 69675 /// ENSMUST0
NM_008624 // Mras // muscle and microspikes RAS // 9 E3.3|9 //
17532 /// ENSMUST0000003
NM_018760 // Slc4a4 // solute carrier family 4 (anion exchanger),
member 4 // 5|5 E2 //
NM_177364 // Sh3pxd2b // SH3 and PX domains 2B // 11 A4|11 //
268396 /// ENSMUST0000003
NM_009381 // Thrsp // thyroid hormone responsive SPOT14
homolog (Rattus) // 7|7 E3 // 2
NM_008362 // Il1r1 // interleukin 1 receptor, type I // 1 B|1 19.5 cM
// 16177 /// ENSM
NM_010497 // Idh1 // isocitrate dehydrogenase 1 (NADP+),
soluble // 1 C2|1 29.8 cM // 1
NM_011436 // Sorl1 // sortilin-related receptor, LDLR class A
repeats-containing // 9 B
NM_009115 // S100b // S100 protein, beta polypeptide, neural //
10 C1|10 41.0 cM // 202
NM_025524 // Krtap3-3 // keratin associated protein 3-3 // 11 D|11
// 66380 /// ENSMUST
ENSMUST00000081265 // Ebf1 // early B cell factor 1 // 11
B1.1|11 20.0 cM // 13591 ///
BC112909 // 5930403N24Rik // RIKEN cDNA 5930403N24 gene
// 10 B1|10 // 320504
NM_011371 // St6galnac1 // ST6 (alpha-N-acetyl-neuraminyl-2,3beta-galactosyl-1,3)-N-ac
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Ac(Jag
1-lam)
fold

Ca(Jag1
-lam)
fold

1.40

4.44

1.71

3.47

1.25

2.83

1.33

1.96

1.39

1.95

1.30

1.84

1.74

2.23

1.33

1.82

1.21

1.70

1.34

1.82

1.38

1.84

1.48

1.94

1.71

2.15

1.30

1.74

1.33

1.72

1.31

1.70

1.44

1.82

1.54

1.91

1.22

1.58

1.21

1.57

1.21

1.56

1.31

1.66

1.35

1.69

1.21

1.55

1.20

1.53

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

ENSMUST00000105363 // Gamt // guanidinoacetate
methyltransferase // 10 C1|10 43.0 cM //
NM_024441 // Hspb2 // heat shock protein 2 // 9 A5.3|9 29.0 cM //
69253 /// ENSMUST0000
NR_033496 // Lrp8 // low density lipoprotein receptor-related
protein 8, apolipoprotein
NM_007709 // Cited1 // Cbp/p300-interacting transactivator with
Glu/Asp-rich carboxy-te
ENSMUST00000001027 // Aox1 // aldehyde oxidase 1 // 1 C1C2|1 23.2 cM // 11761
NM_008606 // Mmp11 // matrix metallopeptidase 11 // 10 C1|10
40.9 cM // 17385 /// ENSMU
NM_138685 // Wfdc15b // WAP four-disulfide core domain 15B //
2 H3|2 // 192201 /// ENSM
NM_007428 // Agt // angiotensinogen (serpin peptidase inhibitor,
clade A, member 8) //
NM_026523 // Nmb // neuromedin B // 7 D3|7 // 68039 ///
ENSMUST00000026817 // Nmb // ne
NM_011658 // Twist1 // twist homolog 1 (Drosophila) // 12 B-C1|12
16.0 cM // 22160 ///
NM_022417 // Itm2c // integral membrane protein 2C // 1 C5|1 //
64294 /// ENSMUST000000
NM_026840 // Pdgfrl // platelet-derived growth factor receptor-like
// 8 A4|8 // 68797
NM_001256259 // 4930524N10Rik // RIKEN cDNA 4930524N10
gene // X F3|X // 75071 /// ENSM
NM_010304 // Gna15 // guanine nucleotide binding protein, alpha
15 // 10 C1|10 43.0 cM
NM_001170847 // Rbm20 // RNA binding motif protein 20 // 19
D2|19 // 73713 /// ENSMUST0
NM_198170 // Szt2 // seizure threshold 2 // 4 D2.1|4 // 230676 ///
ENSMUST00000075406 /
NM_172473 // Hace1 // HECT domain and ankyrin repeat
containing, E3 ubiquitin protein l
NM_009142 // Cx3cl1 // chemokine (C-X3-C motif) ligand 1 // 8
C5|8 46.0 cM // 20312 ///
NR_015566 // A330023F24Rik // RIKEN cDNA A330023F24 gene
// 1|1 // 320977
BC100510 // Gm2511 // predicted gene 2511 // 7 B4|7 //
100039946
NM_013661 // Sema5b // sema domain, seven thrombospondin
repeats (type 1 and type 1-lik
XM_621234 // Olfr766 // olfactory receptor 766 // 10 D3|10 //
546487
BC035950 // BC043934 // cDNA sequence BC043934 // 9 E3.3|9
// 270185
NM_001005510 // Syne2 // synaptic nuclear envelope 2 // 12
C3|12 33.0 cM // 319565 ///
NM_001162884 // Igsf10 // immunoglobulin superfamily, member
10 // 3 D|3 // 242050 ///
NM_010419 // Hes5 // hairy and enhancer of split 5 (Drosophila) //
4 E2|4 81.5 cM // 15
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1.47

1.28

1.49

1.32

1.54

1.25

1.46
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67
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71
72
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NR_033548 // D030047H15Rik // RIKEN cDNA D030047H15
gene // --- // 100037396
NR_033568 // 9430041J12Rik // RIKEN cDNA 9430041J12 gene
// 7|7 // 77323
ENSMUST00000117160 // Cdh13 // cadherin 13 // 8 E1|8 64.0 cM
// 12554 /// NM_019707 //
NM_009404 // Tnfsf9 // tumor necrosis factor (ligand) superfamily,
member 9 // 17 D|17
NM_001114174 // Fam189a2 // family with sequence similarity
189, member A2 // 19 B|19 /
NM_001011779 // Olfr286 // olfactory receptor 286 // 15 F1|15 //
629524 /// ENSMUST0000
NM_001164763 // Rarres1 // retinoic acid receptor responder
(tazarotene induced) 1 // 3
NM_013584 // Lifr // leukemia inhibitory factor receptor // 15 A1|15
4.6 cM // 16880 //
NM_177872 // Adamts3 // a disintegrin-like and metallopeptidase
(reprolysin type) with
BC052447 // 4930402H24Rik // RIKEN cDNA 4930402H24 gene
// 2 F3|2 // 228602 /// ENSMUST
NM_021452 // Kcnmb4 // potassium large conductance calciumactivated channel, subfamily
NM_015790 // Icosl // icos ligand // 10 C1|10 // 50723 ///
ENSMUST00000105393 // Icosl
NM_001166721 // Vmn1r176 // vomeronasal 1 receptor 176 // 7
A3|7 // 546943 /// ENSMUST0
NM_177167 // Ppm1e // protein phosphatase 1E (PP2C domain
containing) // 11 C|11 // 320
NM_008716 // Notch3 // notch 3 // 17 B1|17 20.0 cM // 18131 ///
ENSMUST00000087723 // N
NM_008827 // Pgf // placental growth factor // 12 D|12 39.0 cM //
18654 /// ENSMUST0000
NM_008800 // Pde1b // phosphodiesterase 1B, Ca2+-calmodulin
dependent // 15 F3|15 // 18
NM_033145 // Lcn8 // lipocalin 8 // 2 A3|2 // 78076 ///
ENSMUST00000038482 // Lcn8 // l
NM_001080814 // Fat3 // FAT tumor suppressor homolog 3
(Drosophila) // 9 A2|9 // 270120
NM_011448 // Sox9 // SRY-box containing gene 9 // 11 E2|11
69.5 cM // 20682 /// ENSMUST
NM_026677 // Rab13 // RAB13, member RAS oncogene family //
3 F1|3 45.0 cM // 68328 ///
NM_009730 // Atrn // // 2 F1|2 73.9 cM // 11990 ///
ENSMUST00000028781 // Atr
NM_199146 // Trim30d // tripartite motif-containing 30D // 7 E3|7 //
209387 /// ENSMUST
NM_007703 // Elovl3 // elongation of very long chain fatty acids
(FEN1/Elo2, SUR4/Elo3,
NM_023707 // 1810009J06Rik // RIKEN cDNA 1810009J06 gene
// 6 B1|6 // 73626 /// ENSMUST
NM_001145452 // Arhgef33 // Rho guanine nucleotide exchange
factor (GEF) 33 // 17 E3|17
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NM_008762 // Olfr15 // olfactory receptor 15 // 16 A1|16 // 18312
/// ENSMUST0000008091
NM_001085477 // Olfr765 // olfactory receptor 765 // 10 D3|10 //
544748 /// ENSMUST0000
NM_008360 // Il18 // interleukin 18 // 9 A5.3|9 29.0 cM // 16173 ///
ENSMUST00000059081
NM_011469 // Sprr2b // small proline-rich protein 2B // 3 F1|3 45.2
cM // 20756 /// ENS
NM_146726 // Olfr514 // olfactory receptor 514 // 7 E3|7 // 258721
/// ENSMUST000000847
NM_009917 // Ccr5 // chemokine (C-C motif) receptor 5 // 9 F|9
72.0 cM // 12774 /// ENS
NM_009917 // Ccr5 // chemokine (C-C motif) receptor 5 // 9 F|9
72.0 cM // 12774 /// ENS
NM_001137547 // Usp51 // ubiquitin specific protease 51 // X F3|X
// 635253 /// ENSMUST
NM_025979 // Mastl // microtubule associated serine/threonine
kinase-like // 2 A3|2 //
NM_146470 // Olfr1392 // olfactory receptor 1392 // 11 B1|11 //
258462 /// ENSMUST00000
NM_178405 // Atp1a2 // ATPase, Na+/K+ transporting, alpha 2
polypeptide // 1 H3|1 94.2
NM_183166 // Gm4884 // predicted gene 4884 // 7 B3|7 // 233164
/// ENSMUST00000164422 /
NM_011977 // Slc27a1 // solute carrier family 27 (fatty acid
transporter), member 1 //
NM_027298 // Ccdc89 // coiled-coil domain containing 89 // 7|7 E1
// 70054 /// ENSMUST0
NM_010738 // Ly6a // lymphocyte antigen 6 complex, locus A // 15
D3|15 42.7 cM // 11045
ENSMUST00000056129 // Npas4 // neuronal PAS domain protein
4 // 19 A|19 // 225872 /// A
NM_025359 // Tspan13 // tetraspanin 13 // 12|12 B2 // 66109 ///
ENSMUST00000020896 // T
NM_001105187 // Vmn2r74 // vomeronasal 2, receptor 74 // 7
D3|7 // 546980 /// ENSMUST00
NM_016695 // Mpp2 // membrane protein, palmitoylated 2
(MAGUK p55 subfamily member 2) /
NM_025877 // Slc25a23 // solute carrier family 25 (mitochondrial
carrier; phosphate car
NM_007395 // Acvr1b // activin A receptor, type 1B // 15 F2|15
60.4 cM // 11479 /// ENS
AK080381 // 9330175E14Rik // RIKEN cDNA 9330175E14 gene //
8 C5|8 // 320377
ENSMUST00000070518 // Nkg7 // natural killer cell group 7
sequence // 7|7 B2 // 72310 /
NM_173394 // Ticam2 // toll-like receptor adaptor molecule 2 // 18
C|18 // 225471 /// E
NM_008813 // Enpp1 // ectonucleotide
pyrophosphatase/phosphodiesterase 1 // 10 A4|10 19
NM_027808 // Alpk1 // alpha-kinase 1 // 3|3 H1 // 71481 ///
ENSMUST00000029662 // Alpk1
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NM_146334 // Olfr1330 // olfactory receptor 1330 // 4 D2|4 //
258331 /// ENSMUST0000009
ENSMUST00000044217 // Syne2 // synaptic nuclear envelope 2 //
12 C3|12 33.0 cM // 31956
NM_198111 // Akap6 // A kinase (PRKA) anchor protein 6 // 12
C1|12 // 238161 /// ENSMUS
ENSMUST00000087321 // Ppp1r3c // protein phosphatase 1,
regulatory (inhibitor) subunit
NM_001166251 // Mgll // monoglyceride lipase // 6 D1|6 // 23945
/// ENSMUST00000163271
NR_046014 // A530006G24Rik // RIKEN cDNA A530006G24
gene // 2 G2|2 // 381384
NM_053108 // Glrx // glutaredoxin // 13 C1|13 44.0 cM // 93692 ///
ENSMUST00000022082 /
NM_026189 // Eepd1 // endonuclease/exonuclease/phosphatase
family domain containing 1 /
NM_008402 // Itgav // integrin alpha V // 2 D|2 46.0 cM // 16410 ///
ENSMUST00000028499
NM_147088 // Olfr569 // olfactory receptor 569 // 7 E3|7 // 259092
/// ENSMUST000000781
NM_009557 // Zfp46 // zinc finger protein 46 // 4 D3|4 65.9 cM //
22704 /// ENSMUST0000
NM_183389 // Duxbl // double homeobox B-like // 14 A3|14 //
278672 /// NM_001177538 //
NM_183389 // Duxbl // double homeobox B-like // 14 A3|14 //
278672 /// NM_001177538 //
NR_033550 // Gm10248 // predicted gene 10248 // --- // 791307
NM_172809 // Sacs // sacsin // 14 D1|14 26.75 cM // 50720 ///
ENSMUST00000089394 // Sac
ENSMUST00000012426 // Wnt8a // wingless-related MMTV
integration site 8A // 18|18 B3 //
NM_008020 // Fkbp2 // FK506 binding protein 2 // 19 A|19 //
14227 /// NM_001166368 // F
NM_009528 // Wnt7b // wingless-related MMTV integration site 7B
// 15 E2|15 46.9 cM //
ENSMUST00000031901 // Trpv5 // transient receptor potential
cation channel, subfamily V
ENSMUST00000028389 // Frzb // frizzled-related protein // 2 C3|2
49.75 cM // 20378 ///
NM_145942 // Hmgcs1 // 3-hydroxy-3-methylglutaryl-Coenzyme A
synthase 1 // 13 66.0 cM|1
NM_153776 // Tmem121 // transmembrane protein 121 // 12
F1|12 // 69195 /// ENSMUST00000
BC005613 // Lpp // LIM domain containing preferred translocation
partner in lipoma // 1
NM_009367 // Tgfb2 // transforming growth factor, beta 2 // 1 H5|1
101.5 cM // 21808 //
ENSMUST00000170808 // Vmn2r22 // vomeronasal 2, receptor
22 // 6 F2|6 // 546913
NM_146094 // Fads1 // fatty acid desaturase 1 // 19 A|19 // 76267
/// ENSMUST0000001080
NM_001014397 // Gm13154 // predicted gene 13154 // 4 E1|4 //
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NM_008997 // Rab11b // RAB11B, member RAS oncogene family
// 17 B1|17 18.3 cM // 19326
NM_146831 // Olfr133 // olfactory receptor 133 // 17 B1|17 //
258828 /// ENSMUST0000011
NM_147114 // Olfr575 // olfactory receptor 575 // 7 E3|7 // 259118
/// ENSMUST000000848
NR_030262 // Mir539 // microRNA 539 // 12|12 // 723917
NM_033144 // Sept8 // septin 8 // 11 B1.3|11 28.75 cM // 20362 ///
NM_001252332 // Sept
NM_019696 // Cpxm1 // carboxypeptidase X 1 (M14 family) // 2
F1|2 // 56264 /// ENSMUST0
NM_029061 // Ccdc7 // coiled-coil domain containing 7 // 8 E2|8 //
74703 /// ENSMUST000
NM_172890 // Slc6a11 // solute carrier family 6 (neurotransmitter
transporter, GABA), m
ENSMUST00000022921 // Angpt1 // angiopoietin 1 // 15 B3.1|15
14.3 cM // 11600 /// NM_00
NM_134437 // Il17rd // interleukin 17 receptor D // 14 A3|14 //
171463 /// ENSMUST00000
NM_011545 // Tcf21 // transcription factor 21 // 10 A3|10 16.0 cM
// 21412 /// ENSMUST0
NM_011158 // Prkar2b // protein kinase, cAMP dependent
regulatory, type II beta // 12|1
ENSMUST00000040227 // Cldnd2 // claudin domain containing 2
// 7|7 B2 // 74276 /// NM_0
NM_001048196 // Krtap4-1 // keratin associated protein 4-1 // 11
D|11 // 665891 /// ENS
NM_175174 // Klhl5 // kelch-like 5 (Drosophila) // 5 C3.1|5 // 71778
/// ENSMUST0000010
NR_027881 // 6530411M01Rik // RIKEN cDNA 6530411M01
gene // 17|17 // 67791
NM_008624 // Mras // muscle and microspikes RAS // 9 E3.3|9 //
17532 /// ENSMUST0000003
NR_045177 // 2900055J20Rik // RIKEN cDNA 2900055J20 gene
// 18 B3|18 // 73001
ENSMUST00000026613 // Gusb // glucuronidase, beta // 5 G1.3|5
72.0 cM // 110006 /// NM_
NM_018826 // Irx5 // Iroquois related homeobox 5 (Drosophila) //
8 C5|8 43.3 cM // 5435
ENSMUST00000028807 // Ivd // isovaleryl coenzyme A
dehydrogenase // 2 E4-E5|2 // 56357
NM_177819 // Fam135b // family with sequence similarity 135,
member B // 15 D3|15 // 70
NM_175406 // Atp6v0d2 // ATPase, H+ transporting, lysosomal V0
subunit D2 // 4 A3|4 //
NM_001159535 // Cacna1c // calcium channel, voltagedependent, L type, alpha 1C subunit
NR_003185 // Sprr2j-ps // small proline-rich protein 2J,
pseudogene // 3 F1|3 45.2 cM /
NM_198663 // C87499 // expressed sequence C87499 // 4 C4|4 //
381590 /// ENSMUST0000005
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NR_003517 // Pisd-ps1 // phosphatidylserine decarboxylase,
pseudogene 1 // 11 A1|11 //
ENSMUST00000052500 // 4930412D23Rik // RIKEN cDNA
4930412D23 gene // X E3|X // 73934
NM_001081428 // Fam184a // family with sequence similarity 184,
member A // 10 B3|10 //
NM_146995 // Olfr202 // olfactory receptor 202 // 16 C2|16 //
258997 /// ENSMUST0000004
NM_001076791 // Zfp874b // zinc finger protein 874b // 13 B3|13 //
408067
DQ284430 // 1700003O11Rik // RIKEN cDNA 1700003O11 gene
// 18|18 // 75632
NM_144854 // ORF63 // open reading frame 63 // 16 C3.3|16 //
224419 /// ENSMUST00000026
NM_001024617 // Inpp4b // inositol polyphosphate-4phosphatase, type II // 8 C2|8 38.0
NM_020578 // Ehd3 // EH-domain containing 3 // 17 E2|17 43.25
cM // 57440 /// ENSMUST00
NR_045335 // Gm13582 // predicted gene 13582 // 2 C1.2|2 //
100038493
NM_009223 // Snn // stannin // 16|16 A2 // 20621 ///
ENSMUST00000089011 // Snn // stann
NM_009480 // Usf1 // upstream transcription factor 1 // 1 H|1 93.3
cM // 22278 /// ENSM
ENSMUST00000171664 // 4930433I11Rik // RIKEN cDNA
4930433I11 gene // 7 B3|7 // 243944
NM_001011834 // Olfr1152 // olfactory receptor 1152 // 2 D|2 //
258103 /// ENSMUST00000
NM_010424 // Hfe // hemochromatosis // 13 A2-A4|13 15.0 cM //
15216 /// ENSMUST00000091
NM_023210 // Anp32e // acidic (leucine-rich) nuclear
phosphoprotein 32 family, member E
NM_001110300 // Ap1m2 // adaptor protein complex AP-1, mu 2
subunit // 9 A3|9 9.0 cM //
NM_146119 // Fam129b // family with sequence similarity 129,
member B // 2 B|2 // 22773
NM_010143 // Ephb3 // Eph receptor B3 // 16|16 B1-B4 // 13845
/// ENSMUST00000006112 //
NM_146408 // Olfr1065 // olfactory receptor 1065 // 2 D|2 //
258403 /// ENSMUST00000099
NR_027838 // Atp2a2 // ATPase, Ca++ transporting, cardiac
muscle, slow twitch 2 // 5 F|
NM_008100 // Gcg // glucagon // 2 C1.3|2 36.0 cM // 14526 ///
ENSMUST00000102733 // Gcg
NM_032006 // Mmp1a // matrix metallopeptidase 1a (interstitial
collagenase) // 9|9 A1-A
NM_001039238 // Dcpp2 // demilune cell and parotid protein 2 //
17 A3.3|17 // 630537 //
NM_080465 // Kcnn2 // potassium intermediate/small
conductance calcium-activated channe
ENSMUST00000167042 // U2af1l4 // U2 small nuclear RNA
auxiliary factor 1-like 4 // 7 B1
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NM_029048 // Spdyb // speedy homolog B (Xenopus laevis) // 5
G2|5 // 74673 /// ENSMUST0
ENSMUST00000078842 // Mucl1 // mucin-like 1 // 15 F3|15 58.1
cM // 20771
NM_001012269 // Olfr1513 // olfactory receptor 1513 // 14 C2|14 //
258008 /// ENSMUST00
NM_001030305 // Pmp2 // peripheral myelin protein 2 // 3 A1|3
3.9 cM // 18857 /// ENSMU
NM_008552 // Mas1 // MAS1 oncogene // 17 A1|17 7.45 cM //
17171 /// ENSMUST00000089015
NM_025758 // Asb17 // ankyrin repeat and SOCS box-containing
17 // 3 H3|3 // 66772 ///
ENSMUST00000073109 // Ctdspl // CTD (carboxy-terminal
domain, RNA polymerase II, polype
BC080695 // BC080695 // cDNA sequence BC080695 // 4 E1|4 //
329986 /// ENSMUST000001057
NM_009553 // Zscan2 // zinc finger and SCAN domain containing
2 // 7 D3|7 42.0 cM // 22
NM_001099323 // Zkscan16 // zinc finger with KRAB and SCAN
domains 16 // 4 B3|4 // 1000
NM_001081175 // Itpkb // inositol 1,4,5-trisphosphate 3-kinase B //
1 H5|1 100.0 cM //
NM_001042719 // Ddhd1 // DDHD domain containing 1 // 14
C1|14 // 114874 /// NM_176845 /
NM_175347 // Srl // sarcalumenin // 16 A1|16 // 106393 ///
ENSMUST00000023161 // Srl //
NM_022325 // Ctsz // cathepsin Z // 2 H4|2 103.5 cM // 64138 ///
ENSMUST00000016400 //
NM_007472 // Aqp1 // aquaporin 1 // 6 B3|6 27.0 cM // 11826 ///
ENSMUST00000004774 // A
NM_030721 // Acox3 // acyl-Coenzyme A oxidase 3, pristanoyl // 5
B1|5 // 80911 /// ENSM
NM_011942 // Lypla2 // lysophospholipase 2 // 4 D3|4 // 26394 ///
ENSMUST00000067567 //
NM_177872 // Adamts3 // a disintegrin-like and metallopeptidase
(reprolysin type) with
NM_001081143 // Gnat3 // guanine nucleotide binding protein,
alpha transducing 3 // 5 A
NM_025797 // Cyb5 // cytochrome b-5 // 18 E4|18 55.0 cM //
109672 /// ENSMUST0000016018
NM_013544 // H2-M10.1 // histocompatibility 2, M region locus
10.1 // 17 B1|17 19.84 cM
NM_029726 // Trdn // triadin // 10 A4|10 // 76757 ///
ENSMUST00000095762 // Trdn // tri
NM_029629 // Fahd2a // fumarylacetoacetate hydrolase domain
containing 2A // 2|2 F3 //
NM_008720 // Npc1 // Niemann Pick type C1 // 18 A1|18 4.0 cM //
18145 /// ENSMUST000000
AK135004 // Gm10561 // predicted gene 10561 // 1 C1.2|1 //
628004
NM_177857 // Dennd2c // DENN/MADD domain containing 2C // 3
F2.2|3 // 329727 /// ENSMUS
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NM_029662 // Mfsd2a // major facilitator superfamily domain
containing 2A // 4|4 D1 //
NM_001161817 // Myo1b // myosin IB // 1 C1.1|1 24.8 cM // 17912
/// ENSMUST00000018561
NM_146754 // Olfr556 // olfactory receptor 556 // 7 E3|7 // 258749
/// ENSMUST000000982
NM_008669 // Naga // N-acetyl galactosaminidase, alpha // 15
E|15 46.0 cM // 17939 ///
NM_010640 // Klk1b11 // kallikrein 1-related peptidase b11 // 7
B4|7 23.16 cM // 16613
NM_177571 // Gm13103 // predicted gene 13103 // 4 E1|4 //
194225 /// ENSMUST00000094522
NM_009150 // Selenbp1 // selenium binding protein 1 // 3 F2.1|3
43.25 cM // 20341 /// E
NM_013808 // Csrp3 // cysteine and glycine-rich protein 3 // 7
B4|7 // 13009 /// ENSMUS
NM_001005510 // Syne2 // synaptic nuclear envelope 2 // 12
C3|12 33.0 cM // 319565 ///
NM_001002896 // Bfsp2 // beaded filament structural protein 2,
phakinin // 9 F1|9 // 10
XR_141235 // D830044D21Rik // RIKEN cDNA D830044D21
gene // 14 B|14 // 320621
AK137946 // Gm10673 // predicted gene 10673 // --- // 100038559
NM_029357 // Pcdh1 // protocadherin 1 // 18 B3|18 18.0 cM //
75599 /// ENSMUST000000571
NM_009128 // Scd2 // stearoyl-Coenzyme A desaturase 2 // 19
C3|19 43.0 cM // 20250 ///
ENSMUST00000078239 // Akr1c20 // aldo-keto reductase family
1, member C20 // 13 A1|13 /
NM_148925 // Fyco1 // FYVE and coiled-coil domain containing 1
// 9 F|9 71.3 cM // 1728
ENSMUST00000069800 // Fut2 // fucosyltransferase 2 // 7 B4|7
23.2 cM // 14344 /// NM_01
NM_026988 // Ptms // parathymosin // 6 F2|6 // 69202 ///
ENSMUST00000032216 // Ptms //
NM_008483 // Lamb2 // laminin, beta 2 // 9 F1|9 60.0 cM // 16779
/// ENSMUST00000065014
ENSMUST00000099946 // Net1 // neuroepithelial cell
transforming gene 1 // 13 A1|13 // 5
NM_010117 // Rhbdf1 // rhomboid family 1 (Drosophila) // 11
A4|11 16.0 cM // 13650 ///
NM_146513 // Olfr95 // olfactory receptor 95 // 17 B1|17 // 258506
/// ENSMUST000000607
NM_001162884 // Igsf10 // immunoglobulin superfamily, member
10 // 3 D|3 // 242050 ///
NM_146845 // Olfr1098 // olfactory receptor 1098 // 2 E1|2 //
258842 /// ENSMUST0000009
NM_026840 // Pdgfrl // platelet-derived growth factor receptor-like
// 8 A4|8 // 68797
NM_173023 // Catsperb // cation channel, sperm-associated, beta
// 12 E|12 // 271036 //
NM_008579 // Meig1 // meiosis expressed gene 1 // 2 A1|2 //
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NM_001190444 // Aamp // angio-associated migratory protein // 1
C3|1 41.0 cM // 227290
NM_001081407 // Plb1 // phospholipase B1 // 5 B1|5 // 665270 ///
ENSMUST00000101376 //
NM_001163141 // Krtap24-1 // keratin associated protein 24-1 //
16 C3.3|16 // 239932 //
NM_019975 // Hacl1 // 2-hydroxyacyl-CoA lyase 1 // 14 B|14 //
56794 /// ENSMUST00000022
XM_985917 // Gm626 // predicted gene 626 // 14 B|14 // 268729
/// XM_001481294 // Gm626
NM_178736 // Elmod2 // ELMO domain containing 2 // 8 C2|8 //
244548 /// NM_001170691 //
NM_146145 // Jak1 // Janus kinase 1 // 4 C6|4 46.3 cM // 16451 ///
ENSMUST00000102781 /
NM_178681 // Dgkb // diacylglycerol kinase, beta // 12 A3|12 //
217480 /// ENSMUST00000
NM_001166273 // Cspg5 // chondroitin sulfate proteoglycan 5 // 9
F2|9 // 29873 /// ENSM
ENSMUST00000113476 // Rasgrp2 // RAS, guanyl releasing
protein 2 // 19 A|19 // 19395 //
NM_011079 // Phkg1 // phosphorylase kinase gamma 1 // 5
G1.3|5 72.0 cM // 18682 /// ENS
NM_010593 // Jup // junction plakoglobin // 11 D|11 60.0 cM //
16480 /// ENSMUST0000000
NR_033139 // AI427809 // expressed sequence AI427809 // 4
B2|4 // 381524 /// NR_033140
ENSMUST00000053252 // Ctxn1 // cortexin 1 // 8 A1.1|8 13.0 cM
// 330695 /// BC028881 //
ENSMUST00000039775 // Lgi4 // leucine-rich repeat LGI family,
member 4 // 7 B1|7 15.2 c
NM_015737 // Galnt4 // UDP-N-acetyl-alpha-Dgalactosamine:polypeptide N-acetylgalactosa
NM_145853 // Tpcn1 // two pore channel 1 // 5 F|5 // 252972 ///
ENSMUST00000046426 // T
AK009122 // 2310003L06Rik // RIKEN cDNA 2310003L06 gene //
5 E1|5 // 74248 /// XM_14440
NM_145584 // Spon1 // spondin 1, (f-spondin) extracellular matrix
protein // 7 F1|7 //
NM_172782 // Nxt2 // nuclear transport factor 2-like export factor 2
// X F2|X // 23708
NM_177872 // Adamts3 // a disintegrin-like and metallopeptidase
(reprolysin type) with
NM_172701 // Oscp1 // organic solute carrier partner 1 // 4 D2.2|4
// 230751 /// AB2869
AJ311773 // Art3 // ADP-ribosyltransferase 3 // 5 E2|5 52.0 cM //
109979 /// ENSMUST000
NM_007528 // Bcl6b // B cell CLL/lymphoma 6, member B // 11|11
B4 // 12029 /// ENSMUST0
NM_008861 // Pkd2 // polycystic kidney disease 2 // 5 E5|5 55.0
cM // 18764 /// ENSMUST
NM_175114 // Trak1 // trafficking protein, kinesin binding 1 // 9
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NM_145473 // Csdc2 // cold shock domain containing C2, RNA
binding // 15 E1|15 // 10585
NM_178214 // Hist2h2be // histone cluster 2, H2be // 3 F1-F2|3 //
319190 /// ENSMUST000
NM_053268 // Rasa2 // RAS p21 protein activator 2 // 9|9 E4 //
114713 /// ENSMUST000000
NM_133974 // Cdcp1 // CUB domain containing protein 1 // 9 F4|9
// 109332 /// ENSMUST00
NM_001204983 // Gm9766 // predicted gene 9766 // 10|10 //
100038725
NM_019395 // Fbp1 // fructose bisphosphatase 1 // 13|13 B3-C1 //
14121 /// ENSMUST00000
NM_018732 // Scn3a // sodium channel, voltage-gated, type III,
alpha // 2 C1.3|2 36.0 c
NM_001005227 // Olfr1200 // olfactory receptor 1200 // 2 E1|2 //
257887 /// ENSMUST0000
NM_010008 // Cyp2j6 // cytochrome P450, family 2, subfamily j,
polypeptide 6 // 4 C5|4
NM_021345 // Ptplad1 // protein tyrosine phosphatase-like A
domain containing 1 // 9|9
NM_001081171 // Lama5 // laminin, alpha 5 // 2 H4|2 106.0 cM //
16776 /// ENSMUST000000
NM_001102455 // Aplp2 // amyloid beta (A4) precursor-like
protein 2 // 9 A2-B|9 13.0 cM
NM_027975 // Fam83d // family with sequence similarity 83,
member D // 2 H1|2 // 71878
NM_001081977 // Rnf144a // ring finger protein 144A // 12|12 A3
// 108089 /// ENSMUST00
NM_001159544 // Frk // fyn-related kinase // 10 B1|10 // 14302 ///
ENSMUST00000170771 /
NM_025817 // Tril // TLR4 interactor with leucine-rich repeats // 6
B3|6 // 66873 /// E
NM_009117 // Saa1 // serum amyloid A 1 // 7 B4|7 23.5 cM //
20208 /// ENSMUST0000012808
NM_029758 // Fam49a // family with sequence similarity 49,
member A // 12 A1.1|12 2.5 c
NM_029706 // Cpb1 // carboxypeptidase B1 (tissue) // 3 A2|3 13.0
cM // 76703 /// ENSMUS
NM_153526 // Insig1 // insulin induced gene 1 // 5 B1|5 // 231070
/// ENSMUST0000005915
NM_007988 // Fasn // fatty acid synthase // 11 E2|11 72.0 cM //
14104 /// ENSMUST000000
NM_001144992 // 2810459M11Rik // RIKEN cDNA 2810459M11
gene // 1 C5|1 // 72792 /// NM_0
NM_007535 // Bcl2a1c // B cell leukemia/lymphoma 2 related
protein A1c // 9 F3|9 // 120
NM_172442 // Dtx4 // deltex 4 homolog (Drosophila) // 19 A|19 //
207521 /// ENSMUST0000
NM_016721 // Iqgap1 // IQ motif containing GTPase activating
protein 1 // 7 D3|7 39.0 c
NR_015543 // 2810055G20Rik // RIKEN cDNA 2810055G20 gene
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NM_010234 // Fos // FBJ osteosarcoma oncogene // 12 D2|12
40.0 cM // 14281 /// ENSMUST0
NM_001206335 // Itfg3 // integrin alpha FG-GAP repeat containing
3 // 17 A3.3|17 // 106
NM_172484 // Nckap5 // NCK-associated protein 5 // 1 E3|1 //
210356 /// ENSMUST00000161
NM_009892 // Chi3l3 // chitinase 3-like 3 // 3 F2.2|3 50.5 cM //
12655 /// ENSMUST00000
NM_175328 // Slc6a15 // solute carrier family 6 (neurotransmitter
transporter), member
NR_046286 // H2-T10 // histocompatibility 2, T region locus 10 //
17 B1|17 19.96 cM //
NM_177089 // Tacc1 // transforming, acidic coiled-coil containing
protein 1 // 8 A2|8 /
BC025646 // Fam81a // family with sequence similarity 81,
member A // 9 D|9 // 76886 //
ENSMUST00000068880 // Paqr8 // progestin and adipoQ
receptor family member VIII // 1|1
NM_027784 // 5530400C23Rik // RIKEN cDNA 5530400C23 gene
// 6 G1|6 // 232426 /// ENSMUS
ENSMUST00000035129 // Ephb1 // Eph receptor B1 // 9 F1|9 //
270190 /// ENSMUST000000851
NM_027154 // Tmbim1 // transmembrane BAX inhibitor motif
containing 1 // 1 C3|1 // 6966
NM_201529 // Lmo7 // LIM domain only 7 // 14 E2.3|14 48.5 cM //
380928 /// ENSMUST00000
NM_025654 // Rdm1 // RAD52 motif 1 // 11 D|11 // 66599 ///
ENSMUST00000010506 // Rdm1 /
NM_144520 // Sec14l2 // SEC14-like 2 (S. cerevisiae) // 11 A1|11
// 67815 /// ENSMUST00
NM_001025576 // Ccdc141 // coiled-coil domain containing 141 //
2 C3|2 // 545428 /// EN
NM_178796 // A530064D06Rik // RIKEN cDNA A530064D06
gene // 17 C|17 // 328830 /// ENSMU
NM_201406 // Pigs // phosphatidylinositol glycan anchor
biosynthesis, class S // 11 B5|
ENSMUST00000026225 // Sema4g // sema domain,
immunoglobulin domain (Ig), transmembrane
NM_001163314 // Pgap1 // post-GPI attachment to proteins 1 // 1
C1.1|1 // 241062
NM_009982 // Ctsc // cathepsin C // 7|7 D3-E1.1 // 13032 ///
ENSMUST00000032779 // Ctsc
NM_026369 // Arpc5 // actin related protein 2/3 complex, subunit 5
// 1|1 A3 // 67771 /
AF318068 // Defb5 // defensin beta 5 // 8 A1.3|8 // 81007
NM_022030 // Sv2a // synaptic vesicle glycoprotein 2 a // 3|3 F2 //
64051 /// ENSMUST00
NM_023612 // Esm1 // endothelial cell-specific molecule 1 // 13
D2.2|13 // 71690 /// EN
AK032909 // Atp6v0a2 // ATPase, H+ transporting, lysosomal V0
subunit A2 // 5 F|5 // 21
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NM_198651 // 4430402I18Rik // RIKEN cDNA 4430402I18 gene //
19 C1|19 // 381218 /// ENSM
NM_008822 // Pex7 // peroxisomal biogenesis factor 7 // 10 A3|10
// 18634 /// ENSMUST00
ENSMUST00000025078 // Map3k8 // mitogen-activated protein
kinase kinase kinase 8 // 18
ENSMUST00000022099 // Lpcat1 // lysophosphatidylcholine
acyltransferase 1 // 13 C1|13 /
NM_010332 // Ednra // endothelin receptor type A // 8 C2|8 //
13617 /// ENSMUST00000034
NM_009912 // Ccr1 // chemokine (C-C motif) receptor 1 // 9 F|9
71.6 cM // 12768 /// ENS
NM_001081279 // Mfhas1 // malignant fibrous histiocytoma
amplified sequence 1 // 8 A4|8
NM_053272 // Dhcr24 // 24-dehydrocholesterol reductase // 4
C7|4 // 74754 /// ENSMUST00
NM_024281 // Rrbp1 // ribosome binding protein 1 // 2 G1|2 //
81910 /// ENSMUST00000016
AY512912 // Gm12511 // predicted gene 12511 // 4 B3|4 //
791419
NM_001172160 // Flrt3 // fibronectin leucine rich transmembrane
protein 3 // 2 F3|2 //
BC158045 // Synpo2 // synaptopodin 2 // 3|3 G3 // 118449 ///
ENSMUST00000051443 // Synp
NM_007644 // Scarb2 // scavenger receptor class B, member 2 //
5|5 E3 // 12492 /// ENSM
NM_172893 // Parp12 // poly (ADP-ribose) polymerase family,
member 12 // 6 B1|6 // 2437
NM_008381 // Inhbb // inhibin beta-B // 1 E2.3|1 64.1 cM // 16324
/// ENSMUST0000003876
ENSMUST00000162269 // Plch1 // phospholipase C, eta 1 // 3
E1|3 // 269437 /// ENSMUST00
NM_026062 // Fam69a // family with sequence similarity 69,
member A // 5 E5|5 // 67266
NM_177872 // Adamts3 // a disintegrin-like and metallopeptidase
(reprolysin type) with
NM_001024606 // Pdp2 // pyruvate dehyrogenase phosphatase
catalytic subunit 2 // 8 D3|8
BC132286 // 4933433C11Rik // RIKEN cDNA 4933433C11 gene
// 2 A3|2 // 74472 /// ENSMUST0
NM_029999 // Lbh // limb-bud and heart // 17 E2|17 // 77889 ///
ENSMUST00000024857 // L
NM_021274 // Cxcl10 // chemokine (C-X-C motif) ligand 10 // 5
E2|5 53.0 cM // 15945 ///
NM_133821 // Phlpp1 // PH domain and leucine rich repeat
protein phosphatase 1 // 1 E2.
AK084042 // D130079A08Rik // RIKEN cDNA D130079A08 gene
// 14 E2.3|14 // 320671 /// XR_
ENSMUST00000068233 // Kcnmb4 // potassium large
conductance calcium-activated channel,
NM_031874 // Rab3d // RAB3D, member RAS oncogene family //
9|9 A2-A3 // 19340 /// ENSMU
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NM_001081009 // Parp8 // poly (ADP-ribose) polymerase family,
member 8 // 13 D2.3|13 71
NR_029728 // Mirlet7c-1 // microRNA let7c-1 // 16|16 // 387246
ENSMUST00000154208 // Dhrs3 // dehydrogenase/reductase
(SDR family) member 3 // 4 E1|4
NM_009808 // Casp12 // caspase 12 // 9 A1|9 1.11 cM // 12364 ///
BC028979 // Casp12 //
NM_138752 // Plekhg2 // pleckstrin homology domain containing,
family G (with RhoGef do
ENSMUST00000105574 // Agrn // agrin // 4 E2|4 80.0 cM // 11603
/// NM_021604 // Agrn //
NM_001025576 // Ccdc141 // coiled-coil domain containing 141 //
2 C3|2 // 545428 /// EN
NM_178589 // Tnfrsf21 // tumor necrosis factor receptor
superfamily, member 21 // 17|17
NM_001204915 // Reep3 // receptor accessory protein 3 // 10
B5.1|10 30.0 cM // 28193 //
NM_030127 // Htra3 // HtrA serine peptidase 3 // 5|5 B1 // 78558
/// ENSMUST00000087629
NM_172476 // Tmc7 // transmembrane channel-like gene family 7
// 7 F2|7 // 209760 /// E
NM_008509 // Lpl // lipoprotein lipase // 8 B3.3|8 33.0 cM // 16956
/// ENSMUST00000015
NM_173775 // Ccdc37 // coiled-coil domain containing 37 // 6 D1|6
// 243538 /// ENSMUST
NM_009835 // Ccr6 // chemokine (C-C motif) receptor 6 // 17
A1|17 // 12458 /// ENSMUST0
AK136967 // Gm10808 // predicted gene 10808 // --- // 100038470
/// XR_141286 // Gm1080
NM_022434 // Cyp4f14 // cytochrome P450, family 4, subfamily f,
polypeptide 14 // 17 B1
NM_001113474 // Lair1 // leukocyte-associated Ig-like receptor 1
// 7 A1|7 4.5 cM // 52
ENSMUST00000032175 // Aldh1l1 // aldehyde dehydrogenase 1
family, member L1 // 6 D1|6 /
ENSMUST00000029935 // Gbp3 // guanylate binding protein 3 // 3
H1|3 // 55932 /// NM_018
NM_001105183 // Vmn2r70 // vomeronasal 2, receptor 70 // 7
D3|7 // 670940 /// ENSMUST00
NM_021426 // Nkain4 // Na+/K+ transporting ATPase interacting 4
// 2 H4|2 // 58237 ///
NM_001199151 // Sncaip // synuclein, alpha interacting protein
(synphilin) // 18 D1|18
NM_177784 // Klhl23 // kelch-like 23 (Drosophila) // 2 C2|2 //
277396 /// ENSMUST000000
NM_001171010 // Slc14a1 // solute carrier family 14 (urea
transporter), member 1 // 18
NM_011633 // Traf5 // TNF receptor-associated factor 5 // 1 H6|1
105.0 cM // 22033 ///
NM_027868 // Slc41a3 // solute carrier family 41, member 3 // 6|6
D2 // 71699 /// ENSMU
NM_197988 // 1190005I06Rik // RIKEN cDNA 1190005I06 gene //
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AK138039 // Gm10757 // predicted gene 10757 // --- // 100038551
/// XR_141985 // Gm1075
ENSMUST00000096084 // Ccdc136 // coiled-coil domain
containing 136 // 6 A3.3|6 // 23266
NM_001081206 // Dgki // diacylglycerol kinase, iota // 6 B1|6 //
320127
NM_153151 // Acat3 // acetyl-Coenzyme A acetyltransferase 3 //
17 A1|17 7.55 cM // 2245
NM_011122 // Plod1 // procollagen-lysine, 2-oxoglutarate 5dioxygenase 1 // 4 E2|4 76.5
XM_143371 // Dchs2 // dachsous 2 (Drosophila) // 3 E3|3 //
229459
NM_175437 // Pion // pigeon homolog (Drosophila) // 5 A3|5 //
212167 /// ENSMUST0000003
NM_008706 // Nqo1 // NAD(P)H dehydrogenase, quinone 1 // 8
D3|8 53.3 cM // 18104 /// EN
NM_008255 // Hmgcr // 3-hydroxy-3-methylglutaryl-Coenzyme A
reductase // 13 D1|13 49.0
NM_009525 // Wnt5b // wingless-related MMTV integration site 5B
// 6 F1|6 56.2 cM // 22
NM_001143834 // Grm5 // glutamate receptor, metabotropic 5 // 7
E1|7 // 108071 /// ENSM
NM_144938 // C1s // complement component 1, s subcomponent
// 6 F2|6 // 50908 /// ENSMU
NM_153807 // Acsf2 // acyl-CoA synthetase family member 2 // 11
D|11 // 264895 /// ENSM
NM_008131 // Glul // glutamate-ammonia ligase (glutamine
synthetase) // 1 G2|1 // 14645
NM_153560 // Fam102a // family with sequence similarity 102,
member A // 2 B|2 // 98952
ENSMUST00000103164 // Acsf2 // acyl-CoA synthetase family
member 2 // 11 D|11 // 264895
NM_177872 // Adamts3 // a disintegrin-like and metallopeptidase
(reprolysin type) with
NM_001011852 // Olfr1029 // olfactory receptor 1029 // 2 D|2 //
258154 /// ENSMUST00000
NM_011693 // Vcam1 // vascular cell adhesion molecule 1 // 3
G1|3 50.8 cM // 22329 ///
ENSMUST00000127587 // Tlcd1 // TLC domain containing 1 // 11
B5|11 // 68385 /// NM_0267
NM_008398 // Itga7 // integrin alpha 7 // 10 D3|10 72.0 cM //
16404 /// ENSMUST00000099
NM_011173 // Pros1 // protein S (alpha) // 16 C1.3|16 // 19128 ///
ENSMUST00000023629 /
BC150846 // 1700084C01Rik // RIKEN cDNA 1700084C01 gene
// 1 H3|1 // 78465 /// BC172001
ENSMUST00000108271 // Mecom // MDS1 and EVI1 complex
locus // 3 A3|3 14.4 cM // 14013 /
NM_001081401 // Adamts3 // a disintegrin-like and
metallopeptidase (reprolysin type) wi
NM_145360 // Idi1 // isopentenyl-diphosphate delta isomerase //
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NM_012006 // Acot1 // acyl-CoA thioesterase 1 // 12 D1|12 33.0
cM // 26897 /// ENSMUST0
NM_010218 // Fjx1 // four jointed box 1 (Drosophila) // 2 E2|2 //
14221 /// ENSMUST0000
ENSMUST00000169107 // Fat3 // FAT tumor suppressor homolog
3 (Drosophila) // 9 A2|9 //
NM_175236 // Adhfe1 // alcohol dehydrogenase, iron containing, 1
// 1 A2|1 // 76187 ///
NM_021432 // Nap1l5 // nucleosome assembly protein 1-like 5 //
6|6 C1 // 58243 /// ENSM
NM_017469 // Gucy1b3 // guanylate cyclase 1, soluble, beta 3 // 3
E3|3 // 54195 /// NM_
NM_010473 // Hrc // histidine rich calcium binding protein // 7 B4|7
20.4 cM // 15464 /
NM_177872 // Adamts3 // a disintegrin-like and metallopeptidase
(reprolysin type) with
NM_013904 // Hey2 // hairy/enhancer-of-split related with YRPW
motif 2 // 10 A4|10 // 1
NM_153145 // Abca8a // ATP-binding cassette, sub-family A
(ABC1), member 8a // 11 E1|11
NM_178725 // Lrrc4c // leucine rich repeat containing 4C // 2 E1|2
// 241568 /// ENSMUS
NM_009780 // C4b // complement component 4B (Chido blood
group) // 17 B1|17 18.8 cM //
NM_001081278 // Tbc1d4 // TBC1 domain family, member 4 // 14
E2.3|14 // 210789 /// ENSM
NM_009252 // Serpina3n // serine (or cysteine) peptidase
inhibitor, clade A, member 3N
NM_021324 // Ttyh1 // tweety homolog 1 (Drosophila) // 7 A1|7 //
57776 /// ENSMUST00000
NM_134022 // 6330403K07Rik // RIKEN cDNA 6330403K07 gene
// 11 B4|11 // 103712 /// BC06
NM_009696 // Apoe // apolipoprotein E // 7 A3|7 4.0 cM // 11816
/// ENSMUST00000174064
NM_144847 // Nrbp2 // nuclear receptor binding protein 2 // 15
D3|15 // 223649 /// ENSM
NM_172775 // Plxnb1 // plexin B1 // 9 F2|9 // 235611 ///
ENSMUST00000072093 // Plxnb1 /
NM_175260 // Myh10 // myosin, heavy polypeptide 10, nonmuscle // 11 B3|11 40.0 cM // 7
NM_010277 // Gfap // glial fibrillary acidic protein // 11 D|11 62.0
cM // 14580 /// EN
NM_009911 // Cxcr4 // chemokine (C-X-C motif) receptor 4 // 1
E4|1 67.4 cM // 12767 ///
NM_172961 // Abat // 4-aminobutyrate aminotransferase // 16|16
A3 // 268860 /// ENSMUST
NM_009657 // Aldoc // aldolase C, fructose-bisphosphate // 11
B5|11 44.98 cM // 11676 /
NM_019699 // Fads2 // fatty acid desaturase 2 // 19|19 B // 56473
/// ENSMUST0000002556
NM_007407 // Adcyap1r1 // adenylate cyclase activating
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NM_001199186 // Slc44a2 // solute carrier family 44, member 2 //
9 A3|9 // 68682 /// NM
NM_013515 // Stom // stomatin // 2 B-C1|2 24.0 cM // 13830 ///
ENSMUST00000028241 // St
ENSMUST00000005493 // Slc1a3 // solute carrier family 1 (glial
high affinity glutamate
NM_001205181 // Abhd4 // abhydrolase domain containing 4 // 14
C2|14 // 105501 /// NM_1
NM_013864 // Ndrg2 // N-myc downstream regulated gene 2 // 14
C2|14 // 29811 /// ENSMUS
NM_199241 // Sema6d // sema domain, transmembrane domain
(TM), and cytoplasmic domain,
NM_015740 // Bloc1s1 // biogenesis of lysosome-related
organelles complex-1, subunit 1
NM_013415 // Atp1b2 // ATPase, Na+/K+ transporting, beta 2
polypeptide // 11 B3|11 40.0
NM_009976 // Cst3 // cystatin C // 2 G3|2 84.0 cM // 13010 ///
ENSMUST00000028938 // Cs
NM_008817 // Peg3 // paternally expressed 3 // 7 A2-B1|7 6.5 cM
// 18616 /// ENSMUST000
ENSMUST00000159021 // Arhgef4 // Rho guanine nucleotide
exchange factor (GEF) 4 // 1 B|
NM_026819 // Dhrs1 // dehydrogenase/reductase (SDR family)
member 1 // 14 C3|14 22.5 cM
NM_024461 // 1810037I17Rik // RIKEN cDNA 1810037I17 gene //
3 G1|3 // 67704 /// BC08691
ENSMUST00000086868 // Gpam // glycerol-3-phosphate
acyltransferase, mitochondrial // 19
NM_008377 // Lrig1 // leucine-rich repeats and immunoglobulinlike domains 1 // 6 D2|6
NM_011857 // Odz3 // odd Oz/ten-m homolog 3 (Drosophila) // 8|8
B2 // 23965 /// ENSMUST
NM_007657 // Cd9 // CD9 antigen // 6 F3|6 58.0 cM // 12527 ///
ENSMUST00000032492 // Cd
NM_025821 // Carhsp1 // calcium regulated heat stable protein 1
// 16 A1|16 1.7 cM // 5
NM_010329 // Pdpn // podoplanin // 4 E1|4 // 14726 ///
ENSMUST00000030317 // Pdpn // po
NM_008548 // Man1a // mannosidase 1, alpha // 10 B3|10 //
17155 /// ENSMUST00000003843
NM_001146120 // Psap // prosaposin // 10 B4|10 35.0 cM // 19156
/// NM_011179 // Psap /
NM_026037 // Mboat2 // membrane bound O-acyltransferase
domain containing 2 // 12 A1.3|
NM_008133 // Glud1 // glutamate dehydrogenase 1 // 14 B|14
15.5 cM // 14661 /// ENSMUST
NR_029535 // Mir99a // microRNA 99a // 16|16 // 387229
NM_028392 // Ppp2r2b // protein phosphatase 2 (formerly 2A),
regulatory subunit B (PR 5
NM_027008 // Kctd5 // potassium channel tetramerisation domain
containing 5 // 17 A3.3|
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NM_019880 // Mtch1 // mitochondrial carrier homolog 1 (C.
elegans) // 17 A3.3|17 // 564
NM_008410 // Itm2b // integral membrane protein 2B // 14 D3|14
32.5 cM // 16432 /// ENS
NM_207237 // Man1c1 // mannosidase, alpha, class 1C, member
1 // 4 D3|4 // 230815 /// E
NM_177740 // Rgma // RGM domain family, member A // 7 D1|7 //
244058 /// ENSMUST0000009
NM_013872 // Pmm1 // phosphomannomutase 1 // 15 E1|15 //
29858 /// ENSMUST00000023112 /
NM_018804 // Syt11 // synaptotagmin XI // 3 F1|3 42.0 cM //
229521 /// ENSMUST000001075
NM_010926 // Cox4nb // COX4 neighbor // 8 E1|8 64.0 cM //
18117 /// ENSMUST00000034277
NM_001008231 // Daam2 // dishevelled associated activator of
morphogenesis 2 // 17 C|17
NM_007514 // Slc7a2 // solute carrier family 7 (cationic amino acid
transporter, y+ sys
NM_001171026 // Os9 // amplifyied in osteosarcoma // 10 D3|10 //
216440 /// ENSMUST00000
NM_021356 // Gab1 // growth factor receptor bound protein 2associated protein 1 // 8 C
NM_001098171 // Pcdh10 // protocadherin 10 // 3|3 C // 18526 ///
NM_011043 // Pcdh10 //
NM_010847 // Mxi1 // Max interacting protein 1 // 19 D|19 49.5 cM
// 17859 /// NM_00100
ENSMUST00000034630 // Fez1 // fasciculation and elongation
protein zeta 1 (zygin I) //
NM_153781 // Pygb // brain glycogen phosphorylase // 2 G3|2
84.0 cM // 110078 /// ENSMU
NM_007789 // Ncan // neurocan // 8 B3.3|8 33.5 cM // 13004 ///
ENSMUST00000002412 // Nc
NM_001168304 // Cdk19 // cyclin-dependent kinase 19 // 10
B1|10 // 78334 /// ENSMUST000
NM_008885 // Pmp22 // peripheral myelin protein 22 // 11 B3|11
34.45 cM // 18858 /// EN
NM_025610 // Asrgl1 // asparaginase like 1 // 19 A|19 // 66514 ///
ENSMUST00000049948 /
NM_021391 // Ppp1r1a // protein phosphatase 1, regulatory
(inhibitor) subunit 1A // 15|
NM_010288 // Gja1 // gap junction protein, alpha 1 // 10 B4|10
29.0 cM // 14609 /// ENS
ENSMUST00000169713 // Plce1 // phospholipase C, epsilon 1 //
19 D1|19 // 74055
ENSMUST00000111230 // Tagln2 // transgelin 2 // 1 H3|1 94.2 cM
// 21346 /// NM_178598 /
NM_007901 // S1pr1 // sphingosine-1-phosphate receptor 1 // 3
G1|3 // 13609 /// ENSMUST
NM_007904 // Ednrb // endothelin receptor type B // 14 E2.3|14
51.0 cM // 13618 /// ENS
NM_134006 // Rdh5 // retinol dehydrogenase 5 // 10 D3|10 72.0
cM // 19682 /// ENSMUST00
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NM_153098 // Cd109 // CD109 antigen // 9 E1|9 // 235505 ///
ENSMUST00000093812 // Cd109
NM_007705 // Cirbp // cold inducible RNA binding protein // 10
C1|10 44.0 cM // 12696 /
NM_008131 // Glul // glutamate-ammonia ligase (glutamine
synthetase) // 1 G2|1 // 14645
NM_011271 // Rnase1 // ribonuclease, RNase A family, 1
(pancreatic) // 14 B-C1|14 18.5
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Table 2-4. Supplementary Table 2: Gene Expression increased ≥ 1.2-fold by
Immobilized Jagged-1.

Annotation Cluster 1
UP SEQ FEATURE
INTERPRO
SMART
UP SEQ FEATURE
INTERPRO
SP PIR KEYWORDS

Enrichment Score: 2.93
domain:Helix-loop-helix motif
Basic helix-loop-helix dimerisation
region bHLH
HLH
DNA-binding region:Basic motif
Helix-loop-helix DNA-binding
neurogenesis

Count

P_Value

8

4.3E-4

8

5.4E-4

8
9
7
6

6.2E-4
7.1E-4
7.5E-4
3.5E-2

Table 2-5. Supplementary Table 3: Functional Annotation Cluster 1 Enriched in the
Annotation of Genes Decreased by Immobilzed Jagged-1.
GENE
GENE NAME
SYMBOL
Ets1
E26 avian leukemia oncogene 1, 5' domain
Gsx1
GS homeobox 1
Helt
Hey-like transcription factor (zebrafish)
2410018L13Rik RIKEN cDNA 2410018L13 gene
Zfp738
RIKEN cDNA 3830402I07 gene
A630089N07Ri
RIKEN cDNA A630089N07 gene
k
E430018J23Rik RIKEN cDNA E430018J23 gene; RIKEN cDNA 9130019O22 gene
Sox4
SRY-box containing gene 19; SRY-box containing gene 4
Sp7
Sp7 transcription factor 7
TATA box binding protein (Tbp)-associated factor, RNA polymerase I, D;
Taf1d
predicted gene 13487
Ascl1
achaete-scute complex homolog 1 (Drosophila)
Atoh8
atonal homolog 8 (Drosophila)
Chd7
chromodomain helicase DNA binding protein 7
Dlx1
distal-less homeobox 1
Etv5
ets variant gene 5
Vopp1
expressed sequence AW146242
Hoxd12
homeo box D12
Irf2bp2
interferon regulatory factor 2 binding protein 2
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Myt1
Myc
Nr1d1
Nfxl1
Nfyc
Olig1
Olig2
Phox2b
Itgb3bp
Gm4983
Gm6907
Pus1
Maml2
Six1
Six4
Sim1
Shh
Top2a
Tfdp2
Tle3
Maff
Mycn
Zfp12
Zfp451
Zfp62
Zfp69
Zfp719

myelin transcription factor 1
myelocytomatosis oncogene
nuclear receptor subfamily 1, group D, member 1
nuclear transcription factor, X-box binding-like 1
nuclear transcription factor-Y gamma
oligodendrocyte transcription factor 1
oligodendrocyte transcription factor 2
paired-like homeobox 2b
predicted gene 3507; integrin beta 3 binding protein (beta3-endonexin); similar
to integrin beta 3 binding protein
predicted gene 4983
predicted gene 6907; predicted gene 6904; predicted gene 4902; DNA segment,
Chr 14, ERATO Doi 668, expressed; PHD finger protein 11
pseudouridine synthase 1
similar to Maml2 protein; mastermind like 2 (Drosophila)
sine oculis-related homeobox 1 homolog (Drosophila)
sine oculis-related homeobox 4 homolog (Drosophila)
single-minded homolog 1 (Drosophila)
sonic hedgehog
topoisomerase (DNA) II alpha
transcription factor Dp 2
transducin-like enhancer of split 3, homolog of Drosophila E(spl)
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian)
v-myc myelocytomatosis related oncogene, neuroblastoma derived (avian)
zinc finger protein 12
zinc finger protein 451
zinc finger protein 62
zinc finger protein 69
zinc finger protein 719

Table 2-6. Supplementary Table 4: GOTERM_BP_FAT regulation of transcription.
GENE
SYMBOL
Ets1
Gsx1
Helt
Sox4
Sp7
Taf1d
Ascl1
Atoh8
Chd7
Dlx1
Etv5
Hoxd12
Myt1
Myc
Nr1d1
Nfyc
Olig1

GENE NAME
E26 avian leukemia oncogene 1, 5' domain
GS homeobox 1
Hey-like transcription factor (zebrafish)
SRY-box containing gene 19; SRY-box containing gene 4
Sp7 transcription factor 7
TATA box binding protein (Tbp)-associated factor, RNA polymerase I, D;
predicted gene 13487
achaete-scute complex homolog 1 (Drosophila)
atonal homolog 8 (Drosophila)
chromodomain helicase DNA binding protein 7
distal-less homeobox 1
ets variant gene 5
homeo box D12
myelin transcription factor 1
myelocytomatosis oncogene
nuclear receptor subfamily 1, group D, member 1
nuclear transcription factor-Y gamma
oligodendrocyte transcription factor 1
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Olig2
Phox2b
Prm2
Six1
Six4
Sim1
Top2a
Tfdp2
Maff
Mycn
Zfp451

oligodendrocyte transcription factor 2
paired-like homeobox 2b
protamine 2
sine oculis-related homeobox 1 homolog (Drosophila)
sine oculis-related homeobox 4 homolog (Drosophila)
single-minded homolog 1 (Drosophila)
topoisomerase (DNA) II alpha
transcription factor Dp 2
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F (avian)
v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)
zinc finger protein 451

Table 2-7. Supplementary Table 5: SP PIR KEYWORDS: dna-binding.

GENE
SYMBOL
Helt
Ascl1
Atoh8
Myc
Olig1
Olig2
Sim1
Mycn

GENE NAME
Hey-like transcription factor (zebrafish)
achaete-scute complex homolog 1 (Drosophila)
atonal homolog 8 (Drosophila)
myelocytomatosis oncogene
oligodendrocyte transcription factor 1
oligodendrocyte transcription factor 2
single-minded homolog 1 (Drosophila)
v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)

Table 2-8. Supplementary Table 6: INTERPRO: Basic helix-loop-helix dimerization
region bHLH.
OFFICIAL
GENE
SYMBOL
Hmgcr
Abca8a
Atp1b2
Cd109
Cd9
Cdcp1
Ephb1
Ephb3
Fat3
Naga
Npc1
Notch3
Rgma
Galnt4
Acvr1b
Adcyap1r1

GENE NAME
3-hydroxy-3-methylglutaryl-Coenzyme A reductase
ATP-binding cassette, sub-family A (ABC1), member 8a
ATPase, Na+/K+ transporting, beta 2 polypeptide
CD109 antigen
CD9 antigen
CUB domain containing protein 1
Eph receptor B1
Eph receptor B3
FAT tumor suppressor homolog 3 (Drosophila)
N-acetyl galactosaminidase, alpha
Niemann Pick type C1
Notch gene homolog 3 (Drosophila)
RGM domain family, member A
UDP-N-acetyl-alpha-D-galactosamine:polypeptide Nacetylgalactosaminyltransferase 4
activin A receptor, type 1B
adenylate cyclase activating polypeptide 1 receptor 1
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Agrn
Os9
Aplp2
Angpt1
Agt
Aqp1
Atrn
Cdh13
Cacna1c
Cpxm1
Ctsc
Ctsz
Catsperb
Ccr6
Cxcr4
Cspg5
Enpp1
Elovl3
Ednra
Ednrb
Fjx1
Frzb
Fut2
Gusb
Grm5
Hfe
Icosl
Igsf10
Inhbb
Itm2b
Itm2c
Itga7
Itfg3
Itgav
Itih3
Il1r1
Il17rd
Klk1b11
Lama5
Lamb2
Lgi4
Lrig1
Lifr
Lair1
Lcn8
Lpl
Lrp8
Man1a
Mmp1a
Ncan
Ntm
Odz3
Olfr15

agrin
amplified in osteosarcoma
amyloid beta (A4) precursor-like protein 2
angiopoietin 1
angiotensinogen (serpin peptidase inhibitor, clade A, member 8)
aquaporin 1
attractin
cadherin 13
calcium channel, voltage-dependent, L type, alpha 1C subunit
carboxypeptidase X 1 (M14 family)
cathepsin C
cathepsin Z
cation channel, sperm-associated, beta
chemokine (C-C motif) receptor 6
chemokine (C-X-C motif) receptor 4
chondroitin sulfate proteoglycan 5
ectonucleotide pyrophosphatase/phosphodiesterase 1
elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3
endothelin receptor type A
endothelin receptor type B
four jointed box 1 (Drosophila)
frizzled-related protein
fucosyltransferase 2
glucuronidase, beta
glutamate receptor, metabotropic 5
hemochromatosis
icos ligand
immunoglobulin superfamily, member 10
inhibin beta-B
integral membrane protein 2B
integral membrane protein 2C
integrin alpha 7
integrin alpha FG-GAP repeat containing 3
integrin alpha V
inter-alpha trypsin inhibitor, heavy chain 3
interleukin 1 receptor, type I
interleukin 17 receptor D
kallikrein 1-related peptidase b11
laminin, alpha 5
laminin, beta 2
leucine-rich repeat LGI family, member 4
leucine-rich repeats and immunoglobulin-like domains 1
leukemia inhibitory factor receptor
leukocyte-associated Ig-like receptor 1
lipocalin 8
lipoprotein lipase; similar to Lipoprotein lipase precursor (LPL)
low density lipoprotein receptor-related protein 8, apolipoprotein e receptor
mannosidase 1, alpha
matrix metallopeptidase 1a (interstitial collagenase)
neurocan; similar to Neurocan
neurotrimin
odd Oz/ten-m homolog 3 (Drosophila)
olfactory receptor 15
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Pmp22
Pxdn
Pigs
Plb1
Pgf
Pdgfrl
Plxnb1
Pdpn
Pkd2
Pgap1

peripheral myelin protein 22
peroxidasin homolog (Drosophila)
phosphatidylinositol glycan anchor biosynthesis, class S
phospholipase B1
placental growth factor
platelet-derived growth factor receptor-like
plexin B1
podoplanin
polycystic kidney disease 2
post-GPI attachment to proteins 1
potassium large conductance calcium-activated channel, subfamily M, beta
Kcnmb4
member 4
Plod1
procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1
Psap
prosaposin
Pros1
protein S (alpha)
Rhbdf1
rhomboid family 1 (Drosophila)
Srl
sarcalumenin
Scarb2
scavenger receptor class B, member 2
sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and
Sema4g
short cytoplasmic domain, (semaphorin) 4G
sema domain, seven thrombospondin repeats (type 1 and type 1-like),
Sema5b
transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B
sema domain, transmembrane domain (TM), and cytoplasmic domain,
Sema6d
(semaphorin) 6D
Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N
similar to Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 (GalNAc
alpha-2,6-sialyltransferase I) (ST6GalNAc I) (Sialyltransferase 7A); predicted
St6galnac1
gene 11735; ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-Nacetylgalactosaminide alpha-2,6-sialyltransferase 1
similar to Complement C4 precursor; complement component 4A (Rodgers blood
C4b
group); similar to complement C4; complement component 4B (Childo blood
group)
similar to Complement component 1, s subcomponent; complement component
C1s
1, s subcomponent
Mas1
similar to MAS1 oncogene; MAS1 oncogene
similar to sortilin-related receptor, LDLR class A repeats-containing; sortilinSorl1
related receptor, LDLR class A repeats-containing
Slc1a3
solute carrier family 1 (glial high affinity glutamate transporter), member 3
Slc14a1
solute carrier family 14 (urea transporter), member 1
Slc4a4
solute carrier family 4 (anion exchanger), member 4
Slc44a2
solute carrier family 44, member 2
Slc6a15
solute carrier family 6 (neurotransmitter transporter), member 15
Slc6a11
solute carrier family 6 (neurotransmitter transporter, GABA), member 11
Slc7a2
solute carrier family 7 (cationic amino acid transporter, y+ system), member 2
S1pr1
sphingosine-1-phosphate receptor 1
Spon1
spondin 1, (f-spondin) extracellular matrix protein
Sv2a
synaptic vesicle glycoprotein 2 a
Tspan13 tetraspanin 13
Tgfb2
transforming growth factor, beta 2
Tmc7
transmembrane channel-like gene family 7; similar to Tmc7 protein
Tnfsf9
tumor necrosis factor (ligand) superfamily, member 9
Tnfrsf21
tumor necrosis factor receptor superfamily, member 21
Ttyh1
tweety homolog 1 (Drosophila)
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Vcam1
Wnt5b
Wnt7b
Wnt8a

vascular cell adhesion molecule 1
wingless-related MMTV integration site 5B
wingless-related MMTV integration site 7B
wingless-related MMTV integration site 8A

Table 2-9. Supplementary Table 7: UP_SEQ_FEATURE: glycosylation site:Nlinked (GlcNAc...).
Annotation Cluster 1
UP_SEQ_FEATURE
SP_PIR_KEYWORDS
UP_SEQ_FEATURE
SP_PIR_KEYWORDS
SP_PIR_KEYWORDS
UP_SEQ_FEATURE
SP_PIR_KEYWORDS
GOTERM_CC_FAT
Annotation Cluster 2
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
Annotation Cluster 3
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
Annotation Cluster 4
SP_PIR_KEYWORDS
UP_SEQ_FEATURE
UP_SEQ_FEATURE
SP_PIR_KEYWORDS
UP_SEQ_FEATURE
GOTERM_CC_FAT

Enrichment Score: 3.99
glycosylation site:N-linked (GlcNAc...)
glycoprotein
signal peptide
signal
disulfide bond
disulfide bond
Secreted
extracellular region
Enrichment Score: 3.88
calcium ion homeostasis
ion homeostasis
cation homeostasis
di-, tri-valent inorganic cation
homeostasis
chemical homeostasis
metal ion homeostasis
cellular calcium ion homeostasis
cellular metal ion homeostasis
cellular di-, tri-valent inorganic cation
homeostasis
cellular ion homeostasis
cellular chemical homeostasis
cellular cation homeostasis
homeostatic process
cellular homeostasis
cytosolic calcium ion homeostasis
Enrichment Score: 3.4
vasculature development
blood vessel morphogenesis
blood vessel development
angiogenesis
Enrichment Score: 3.01
membrane
topological domain:Cytoplasmic
transmembrane region
transmembrane
topological domain:Extracellular
intrinsic to membrane
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12
21
16

P_Valu
e
2.5E-7
3.0E-7
1.6E-5
1.9E-5
8.7E-4
1.9E-3
1.3E-2
2.3E-2
P_Valu
e
8.4E-6
9.4E-6
1.6E-5

14

2.3E-5

23
12
11
11

2.4E-5
2.4E-5
3.4E-5
7.7E-5

12

2.0E-4

17
17
12
26
18
4

2.6E-4
3.5E-4
6.0E-4
1.4E-3
1.8E-3
5.2E-2
P_Valu
e
4.6E-5
1.4E-4
3.8E-4
9.9E-3
P_Valu
e
6.1E-5
1.7E-4
1.7E-4
3.1E-4
3.0E-3
1.7E-2

Count
115
119
96
96
76
72
44
53
Count

Count
18
15
16
9
Count
154
87
119
144
66
159

GOTERM_CC_FAT
Annotation Cluster 5
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
SP_PIR_KEYWORDS
Annotation Cluster 6
INTERPRO
SMART
INTERPRO
SMART
INTERPRO
UP_SEQ_FEATURE
KEGG_PATHWAY
INTERPRO
Annotation Cluster 7
GOTERM_BP_FAT
SP_PIR_KEYWORDS
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
GOTERM_BP_FAT
SP_PIR_KEYWORDS
GOTERM_BP_FAT
SP_PIR_KEYWORDS
GOTERM_BP_FAT
SP_PIR_KEYWORDS
KEGG_PATHWAY
GOTERM_BP_FAT
GOTERM_BP_FAT
Annotation Cluster 8
GOTERM_BP_FAT
GOTERM_BP_FAT

integral to membrane
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Enrichment Score: 2.79
cell adhesion
biological adhesion
cell-cell adhesion
cell adhesion

Count
27
27
13
17

Enrichment Score: 2.11
Plexin
PSI
Plexin/semaphorin/integrin
Sema
Semaphorin/CD100 antigen
domain:Sema
Axon guidance
WD40/YVTN repeat-like
Enrichment Score: 2.03
cholesterol metabolic process
lipid synthesis
cholesterol biosynthetic process
sterol metabolic process
lipid biosynthetic process
sterol biosynthetic process
Cholesterol biosynthesis
steroid metabolic process
sterol biosynthesis
steroid biosynthetic process
Steroid biosynthesis
Terpenoid backbone biosynthesis
isoprenoid biosynthetic process
isoprenoid metabolic process
Enrichment Score: 1.96
response to wounding
inflammatory response

Count
6
6
6
5
5
4
8
10
Count
8
9
5
8
16
5
4
10
4
6
4
3
3
3
Count
19
12

3.1E-2
P_Valu
e
3.5E-4
3.6E-4
6.8E-3
7.9E-3
P_Valu
e
3.7E-4
2.7E-3
2.7E-3
3.8E-3
3.9E-3
2.1E-2
7.4E-2
2.0E-1
P_Valu
e
9.2E-4
1.3E-3
1.5E-3
1.6E-3
1.9E-3
4.2E-3
6.2E-3
1.0E-2
1.4E-2
2.1E-2
5.3E-2
5.7E-2
8.5E-2
3.0E-1
P_Valu
e
8.0E-4
1.2E-2

Table 2-10. Supplementary Table: Functional Annotation Clusters Enriched in the
Annotation of Genes Increased by Immobilized Jagged-1.
Gene Symbol
Gja1
S100b

Gene Title
Gap junction membrane channel protein α1(Connexin 30)
S100 protein, β polypeptide, neural

Ppp1r3c

Protein phosphatase 1, regulatory subunit 3C(PTG)

Slc14a1

Solute carrier family 14 (urea transporter), member 1

Slc6a11

Solute carrier family 6 (GABA transporter), member 11 (GAT4)

Ednrb

Endothelin receptor type B
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Hes5

Hairy and enhancer of split 5

Sox9

SRY-box containing gene 9

Table 2-11. Supplementary Table 9: Genes Increased by Immobilized Jagged-1 in
AstroRad-NSC also enriched in protoplasmic astrocytes in vivo according to Lovett et.
al. (2008). Listed genes are enriched in protoplasmic astrocytes and up-regulated in
AstroRad-NSC in response to Jagged-1.
Gene Symbol

Gene Title

In the top 50 changes in MCAO reactive astrocytes AND up-regulated by Jagged-1 in Astro
Gfap
Serpina3n

Rad-NSCs

glial fibrillary acidic protein
serine (or cysteine) peptidase inhibitor, clade A, member 3N

Ifi202b

interferon activated gene 202B

Cxcl10

chemokine (C-X-C motif) ligand 10

Cd109

CD109 antigen

Other genes up-regulated in MCAO reactive astrocytes and by Jagged-1 in Astro
C1s

complement component 1, s subcomponent

Il1r1

interleukin 1 receptor, type I

Rad-NSCs

2+

Pde1b

phosphodiesterase 1B, Ca -calmodulin dependent

Plce1

phospholipase C, epsilon 1

Tagln2

transgelin 2

Table 2-12. Supplementary Table 10: Genes Increased by Immobilized Jagged-1 in
AstroRad-NSC also increase in MCAO reactive astrocytes in vivo according to
Zamanian et. al. (2012). Listed are genes up-regulated in reactive astrocytes 1 day after
MCAO and up-regulated in AstroRad-NSC in response to Jagged-1.
Gene Symbol
Top2a
Gadd45g
Ccnd1
Myc

Gene Title
Topoisomerase (DNA) II alpha
Growth arrest and DNA-damage-inducible 45 gamma
Cyclin D1
Myelocytomatosis oncogene
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Table 2-13. Supplementary Table 11: Genes Decreased by Immobilized Jagged-1 in
AstroRad-NSC also increase in reactive astrocytes in vivo according to Zamanian et. al.
(2012). Listed are genes up-regulated in astrocytes 1 day after MCAO but downregulated in AstroRad-NSC in response to Jagged-1.
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CHAPTER 3. NOTCH1-STAT3-ETBR SIGNALING CONTROLS REACTIVE
ASTROCYTE PROLIFERATION AFTER BRAIN INJURY.
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Summary
Defining the signaling network that controls reactive astrogliosis may provide novel
treatment targets for patients with diverse CNS injuries and pathologies. We report that
the radial glial cell antigen RC2 identifies the majority of proliferating reactive astrocytes
after stroke. These cells highly expressed endothelin receptor type B (ETBR) and the
Notch1 ligand, Jagged-1. To study signaling in adult reactive astrocytes, we developed a
new model based on Reactive astrocyte-derived Neural Stem Cells (Rad-NSCs) isolated
from GFAP-CreERTM-Notch1 conditional knockout (cKO) mice. By loss- and gain-offunction studies and promoter activity assays, we found that Jagged-1/Notch1 signaling
increased ETBR expression indirectly by raising the level of phosphorylated STAT3, a
previously unidentified EDNRB transcriptional activator. Similar to inducible transgenic
GFAP-CreERTM-Notch1-cKO mice, GFAP-CreERTM-ETBR-cKO mice exhibited a defect
in reactive astrocyte proliferation after cerebral ischemia. Our results indicate that the
Notch1-STAT3-ETBR axis connects a signaling network that promotes reactive astrocyte
proliferation after brain injury.
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Introduction
Reactive astrogliosis occurs after most forms of CNS injury, including cerebral ischemia
and trauma, but the signaling network that regulates reactive astrocyte proliferation and
function(s) in vivo is complex and remains poorly understood. Early after CNS injury,
reactive astrocytes perform a variety of beneficial roles, many of which relate to the
supportive functions of mature astrocytes during the maintenance of normal tissue
homeostasis. These activities include regulation of extracellular ion and fluid levels, pH,
and the blood brain barrier (BBB). Responding to CNS injury, reactive astrocytes reduce
immune cell infiltration into parenchymal tissue and provide neuroprotection through
uptake of the main excitatory neurotransmitter, glutamate, and by secreting numerous
growth factors, neurotrophins, cytokines, and hormones (Sofroniew, 2009; Voskuhl et al.,
2009; Shimada et al., 2011). Late after CNS injury, newly proliferated reactive astrocytes
contribute to formation of the glial scar. The glial scar is often viewed as a negative
consequence of CNS injury due to its ability to impede axonal re-growth. However, it
also serves a positive, protective function and its structure and cellular composition are
important determinants of CNS remodeling and repair. Given the fundamental roles of
reactive astrocytes both early and late after CNS injury, delineation of the
paracrine/autocrine signaling network that controls reactive astrogliosis in vivo may lead
to therapeutic strategies that maintain or repair the BBB, control immune cell infiltration,
provide neuroprotection and/or reduce or modify glial scarring.
Astrocytes undergo dramatic changes in gene expression, morphology
(hypertrophy), and proliferation based on the size and duration of CNS injury. The pool
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of proliferating reactive astrocytes performs key activities that impact tissue preservation,
repair/remodeling and functional outcome. For example, specific deletion of proliferating
reactive astrocytes after brain injury leads to increased immune cell infiltration and
neuronal degeneration and inability to repair the BBB. Similarly, specific astroglial
deletion after spinal cord injury results in increased immune cell infiltration, neuronal
death, demyelination, and motor deficit (Faulkner et al. 2004).
In relation to their distance from cell/tissue damage, subpopulations of reactive
astrocytes typically exhibit increased expression of several different intermediate
filament proteins that include Glial Fibrillary Acidic Protein (GFAP) and nestin, and an
intermediate filament-associated protein that is bound by the RC2 monoclonal antibody.
The RC2 antigen (hereafter called RC2) is reported to be a post-translational modification
of nestin. In cortical development, RC2 is expressed by proliferating radial glial cells,
specialized neural stem/progenitor cells that provide scaffolding for migrating
neuroblasts. Radial glial cell identity and function are regulated by Notch signaling. We
have shown that Notch1 signaling regulates reactive astrocyte proliferation after cortical
stroke (Shimada et al., 2011).
In addition to Notch1, Signal Transducer and Activator of Transcription 3
(STAT3) is activated during CNS injury and phosphorylated STAT3 (p-STAT3)
transduces signals for multiple molecules secreted or released from damaged cells such as
EGF and factors that bind the gp130 receptor (e.g. IL-6, LIF, CNTF). STAT3 is required
for gliogenesis during CNS development and studies with Cre-loxP-based conditional
knockout (cKO) mouse models have shown that STAT3 is also a key signaling
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component for reactive astrogliosis. Using a non-inducible nestin-Cre-STAT3-cKO
model, Okada et al. (2006) reported that mice with spinal cord injury had increased
immune cell infiltration, demyelination, and severe motor deficit. GFAP-Cre-STAT3cKO mice with spinal cord injury had reactive astrocytes with reduced expression of
GFAP and hypertrophy; this correlated with disrupted glial scar formation and attenuated
motor recovery.
Proliferation of reactive astrocytes is stimulated by many peptides and proteins
released during CNS injury that include endothelin (ET-1), epidermal growth factor
(EGF), and fibroblast growth factor (FGF). Notably, some factors such as ET-1, EGF,
and IL-6 are released by reactive astrocytes themselves into the injury environment and
act in an autocrine as well as paracrine manner. ET-1 signaling through endothelin
receptor type B (ETBR) is reported to have mitogenic effects on both cultured primary
astrocytes and glioblastoma cell lines. In addition, pharmacological inhibition of ETBR
was reported to reduce reactive astrocyte proliferation in vivo after brain stab injury and
lysolecithin-induced focal demyelination. Other factors known to trigger reactive
astrogliosis include (but are not limited to): IL-1, IL-10, LIF, CNTF, BMP, TGF-β, TNFα, INF-γ, lipopolysaccharide, glutamate, adenosine triphosphate, nitric oxide, and
reactive oxygen species.
Although RC2 is rarely expressed in cortical tissue of healthy adults, it is reexpressed by a subpopulation of proliferative reactive astrocytes early after brain injury.
Here we show that RC2+ reactive astrocytes represent the majority of proliferating
reactive astrocytes after stroke and report a sorting scheme for prospective isolation of
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RC2+ reactive astrocytes directly from injured CNS tissue based on cell surface Jagged-1
(Notch1 ligand). In addition to expressing Jagged-1 and Notch1, RC2-positive reactive
astrocytes expressed high levels of ETBR. Investigating whether Notch1 signaling
interacted with ETBR, we found that Jagged-1 increased ETBR levels in an indirect
manner, through STAT3. Experiments with transgenic inducible GFAP-CreERTM-ETBRcKO mice demonstrated that ETBR was necessary for reactive astrocyte proliferation
after stroke and the deficit observed in GFAP-CreERTM-ETBR-cKO mice closely
resembled that of GFAP-CreERTM-Notch1-cKO mice. Our results identify ETBR as a
transcriptional target of STAT3 and demonstrate a Notch1-STAT3-ETBR axis that
promotes reactive astrogliosis after brain injury.
Results
RC2+/ETBR+ cells represent the majority of proliferating reactive astrocytes early
after cerebral ischemia
To better understand astroglial signaling and receptors that control reactive astrogliosis,
we focused on the subpopulation of RC2+ reactive astrocytes that form immediately
adjacent to the infarct core early after cerebral ischemia (Shimada et al., 2010). Studying
the timing of reactive astrogliosis, we observed GFAP+/RC2+ reactive astrocytes in the
peri-infarct area at 1, 3, and 14 d after stroke, but did not detect the RC2 antigen by
immunohistochemistry at 28 d after stroke (i.e. within the glial scar when proliferation
has subsided) (Figure 3-1). At 3 d after distal middle artery occlusion (dMCAO), the
majority (73%) of proliferating GFAP+/Ki67+ reactive astrocytes co-expressed RC2
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(RC2+/GFAP+/Ki67+, 1857 ± 321.0 cells/mm2; RC2-/GFAP+/Ki67+, 698.6 ± 195.0
cells/mm2; mean ± SEM, n=3; Figure 3-2A). RC2+ reactive astrocytes stained strongly
for ETBR, a receptor expressed at a comparatively low level in distal parenchymal
GFAP+ cells and other cortical cell types (Figure 3-2B). Nearly all RC2+ reactive
astrocytes in the cortical peri-infarct area expressed ETBR (99 ± 1%, n=3).

Notch1 signaling regulates the number of RC2+/ETBR+ reactive astrocytes
Tamoxifen (TM)-inducible GFAP-CreERTM mice express CreER under control of the 2.2
kb human GFAP promoter. Using this mouse strain to target reactive astrocytes, we
reported previously that Notch1 determines, in part, reactive astrocyte proliferation after
stroke . To examine whether Notch1 signaling affected proliferation specifically in
RC2+/ETBR+ reactive astrocytes, we performed dMCAO surgery on GFAP-CreERTMNotch1-cKO mice and performed double immunohistochemistry for RC2 and ETBR. At
30 d after tamoxifen (TM) administration and 3 d after dMCAO, there was a significant
reduction in the number of RC2+/ETBR+ cells in TM-treated mice compared with corn oil
(vehicle)-treated mice (Vehicle, 5254 ± 557.5 cells/mm2; TM, 2685 ± 60.75 cells/mm2;
mean ± SEM, n=3 mice per group, p < 0.05; Figure 3-2C). To determine if Notch
signaling regulated proliferating RC2+/ETBR+ reactive astrocytes in other models of brain
injury, we counted the number of RC2+ reactive astrocytes in cortical tissue 3 d after
stereotaxic injection of dibenzazepine (DBZ), a Gamma secretase inhibitor (GSI) that
inhibits cleavage of Notch1. In the brain stab model, we observed significantly less RC2+
reactive astrocytes surrounding the stab injury in DBZ-injected mice compared with
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vehicle-injected control mice (DBZ, 602.7 ± 118.1 cells/mm2; DMSO, 1835.0 ± 209.7
cells/mm2; mean ± SEM , n=3, p=0.01; Figure 3-8).
To further investigate Notch1 signaling in RC2+/ETBR+ reactive astrocytes, we
next asked whether they expressed Jagged-1, a Notch1 ligand presented on the cell
surface that induces Notch1 signaling in adjacent cells. We isolated reactive astrocytes
from peri-infarct tissues by magnetic-activated cell sorting (MACS) with antibodies
against Glutamate Aspartate Transporter-1 (GLAST)(Shimada et al., 2012). At 3 d after
stroke, FACS phenotyping of GLAST+ reactive astrocytes from cortical tissues of
C57BL/6J mice demonstrated that cell surface Jagged-1 expression was markedly
upregulated on cells from the ischemic ipsilateral side of the brain compared with cells
from the contralateral side (Figure 3-3A and Figure 3-9). Depending on the absence or
presence of injury, we observed that cortical GLAST+ cells partitioned into Jagged-1Neg
and Jagged-1Lo cells or Jagged-1Neg, Jagged-1Lo, and Jagged-1Hi cells, respectively
(Figure 3-3A). These results demonstrated that Jagged-1 levels could be used to segregate
3 major subpopulations of reactive astrocytes after brain injury.
As RC2 is a cytoskeletal protein and FACS-compatible antibodies for ETBR were
not available, we fixed and stained cells post-sort that were allowed to adhere for 24 hr in
culture. Notably, GLAST+/ Jagged-1Neg cells adhered initially but did not survive the 24
hr of culture (data not shown). GLAST+/Jagged-1Lo and GLAST+/Jagged-1Hi cells
adhered, survived, and expressed RC2, ETBR, and nestin (Figure 3-3B and data not
shown).
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Differential Jagged-1 expression on reactive astrocytes from the peri-infarct area
suggested that the GLAST+ subpopulations varied in their level of Notch1 signaling.
Based on their close proximity to the infarct core and their dependence on Notch1
signaling, we hypothesized that proliferating RC2+/ETBR+ reactive astrocytes belonged to
the GLAST+/Jagged-1Hi category of GLAST+ cells isolated from the peri-infarct area. To
test this idea, we pooled live cell isolates from peri-infarct cortical tissue (n=3 animals
per group) and employed the above MACS/FACS strategy to assay GLAST+/Jagged-1+
cells from GFAP-CreERTM-Notch1-cKO mice. Compared with control (vehicle)-treated
GFAP-CreERTM-Notch1-cKO mice, we observed ablation of the GLAST+/Jagged-1Hi cell
population in TM-treated GFAP-CreERTM-CreERTM-Notch1-cKO mice (Figure 3-3C).
Injured (ipsilateral) cortex from C57BL/6J mice and GFAP-CreERTM-Notch1-cKO
vehicle treated mice, which should be ostensibly normal, displayed similar percentages of
GLAST+/Jagged-1Hi cells (C57BL/6J: 6.89%; GFAP-CreERTM-Notch1-cKO [vehicle]:
8.37%; Figure 3-9). These results suggested that Jagged-1/Notch1 signaling could occur
between adjacent astrocytes in the peri-infarct area to promote astroglial proliferation and
that Jagged-1/Notch1 signaling might interact with ETBR-based signaling in RC2+/ETBR+
reactive astrocytes.
Immobilized Jagged-1 induces ETBR and promotes proliferation in adult reactive
astrocytes
Although there is a conventional method to isolate and culture astrocytes from neonatal
mice, primary adult cortical reactive astrocytes survive poorly in culture. We recently
reported the isolation and expansion of self-renewing, multi-potent Rad-NSCs derived
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from the cortical peri-infarct area after stroke. To avoid possible differences between
neonatal and adult astrocytes, we sought to develop a method to study signaling in adult
astrocytes based on re-differentiated Reactive astrocyte-derived Neural Stem Cells (RadNSCs). After re-differentiation of Rad-NSCs in medium containing 10% FCS for 7 d, we
obtained cultures that were 80% GFAP+ /Tuj1- astrocytes (GFAP+, 82 ± 5.3%; Tuj1+, 7±
2.2%, SEM, Figure 3-4A). For clarity, we hereafter refer to the Rad-NSC-derived
astrocytes as AstroRad-NSC. When maintained in serum-containing medium, most AstroRadNSC

expressed nestin and a few expressed RC2 (Figure 3-1); this suggested that AstroRad-

NSC

might be used to model reactive astrocyte signaling after brain injury. Jagged-

1/Notch1 signaling requires mechanical tension between cell surface Jagged-1 and
Notch1 that are presented on the membranes of adjacent cells. Accordingly, to promote
Jagged-1/Notch1 signaling, we plated AstroRad-NSC onto immobilized Jagged-1. After 48
hr, immobilized Jagged-1 dramatically increased the number of RC2+/Ki67+ reactive
astrocytes (Figure 3-4C). To test whether exposure to Jagged-1 could alter expression of
ETBR, we plated AstroRad-NSCand post-natal day 2 (PND 2) astrocytes onto immobilized
Jagged-1. Exposure to immobilized Jagged-1 markedly increased the level of ETBR for
both AstroRad-NSC (Figure 3-4D) and PND 2 astrocytes (Figure 3-4E).
Regulation of EDNRB promoter activity
To investigate whether Notch Intracellular Domain 1 (NICD1)-mediated signaling might
directly influence ETBR levels through enhanced transcription of EDNRB (EDNRB =
gene for ETBR), we analyzed the DNA sequence in the EDNRB promoter. By promoter
mapping, we did not find CSL sequences within 10 kB of the ETBR coding sequence,
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indicating that the EDNRB promoter may not be directly regulated by NICD1. In
contrast, we located multiple consensus sequences for STAT3 in both the human and
murine EDNRB promoter that satisfied the TTM(N)3DAA (D: A, G, or T; M: A or C; N:
A, G, T or C) motif or the TTC(N)4GAA motif (Figure 3-5A, Table 3-1). To test for
transcriptional regulation by STAT3, a pGL4 luciferase reporter vector containing human
EDNRB promoter sequence was transfected into HEK 293 cells (-3022 bp to +160 bp;
Figure 3-5A’). We found that incubation of 293 cells in IL-6 or LIF, cytokines that bind
gp130 and signal through STAT3, led to a significant increase in EDNRB promoter
activity (ANOVA, F=8.51, n=3, p=0.0002; Figure 3-5). Notably, this effect also occurred
after exposure of cells to EGF, which signals through EGFR/JAK2/STAT3, but not via
gp130/JAK2/STAT3 (Figure 3-5). Next, we incubated the 293 cells in IL-6, LIF, or EGF
with the addition of “STATTIC”, a STAT3-specific pharmacological inhibitor that
destabilizes phosphorylated STAT3 (p-STAT3) and prevents STAT3-mediated effects.
We observed (in all cases) that STATTIC attenuated the induction of EDNRB promoter
activity expected to occur after cytokine/growth factor incubation (Figure 3-5B, left). In
some cases, a decrease in cell number due to inhibitor toxicity may appear to represent a
reduction in promoter activity. To control for this possibility, we assayed cell viability on
replicate plates under similar conditions of cytokine treatment and STATTIC. By assay
of cellular metabolism (MTS), treatment of 293 cells with STATTIC was minimally
cytotoxic (Figure 3-5B, right).
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EDNRB promoter activity is enhanced by coincident NICD1/p-STAT3 signaling
HES1 and HES5, transcription factors acting downstream of Notch1 signaling, were
shown to stabilize JAK2 and STAT3 complex formation and increase the level of pSTAT3 during glial development. Furthermore, Kamakura et al. (2004) showed that
STAT3 activity was critical for Notch-induced differentiation of embryonic radial glial
cells and astrocytes. To examine whether Notch1 signaling altered EDNRB transcription
by enhancing STAT3 activity, we next performed co-transfections of NICD1 expression
vector with the pGL4-EDNRB promoter/Luc reporter. Acknowledging that experiments
in 293 cells (embryonic kidney) could differ from glial cell responses, we examined U87
human glioma cells. By immunoblotting, U87 cells expressed low but detectable levels of
ETBR relative to AstroRad-NSC (Figure 3-5C). U87 cells transfected with pGL4-EDNRB
promoter/Luc reporter and incubated in EGF exhibited EDNRB promoter activity that
was enhanced by co-transfection with NICD1 expression plasmid (ANOVA, F=14.71
,n=3, p = 0.0001; Figure 3-5D). Furthermore, the action of EGF and EGF/NICD1 on
EDNRB promoter activity in U87 cells was attenuated in the presence of STATTIC
(Figure 3-5D). These data indicated that Notch1 signaling (NICD1) could enhance
STAT3 activity, perhaps by stabilizing p-STAT3 in the manner shown by Kamakura et
al. (2004).
Notch1 signaling stabilizes/increases p-STAT levels in adult reactive astrocytes
To examine whether increased phosphorylation of STAT3 (p-STAT3) in adult reactive
astrocytes could induce ETBR expression, we incubated AstroRad-NSC in medium
supplemented with IL-6. As expected, exposure of adult reactive astrocytes to IL-6
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increased the level of p-STAT3 and also GFAP, a protein regulated at the transcriptional
level by STAT3 (Figure 3-6A). Importantly, we also observed an increase in ETBR levels
following IL-6 exposure (Figure 3-6A). To determine whether Notch1 stabilized STAT3
signaling or promoted STAT3 activation, we performed a loss-of-function experiment by
treating AstroRad-NSC from GFAP-CreERTM-Notch1-cKO mice with 4-OH-TM (hereafter
OHTM) to remove Notch1 and blotted for p-STAT3. To test a different factor known to
stimulate gp130 and JAK2/STAT3 signaling, we first incubated both treated and control
cells with Leukemia Inhibitory Factor (LIF). In the presence of LIF, we observed reduced
NICD1 and p-STAT3 levels after 5-8 d of OHTM treatment compared with vehicle
control (Figure 3-6B).
Jagged-1/Notch1 signaling controls the level of ETBR.
To test for effects of Notch signaling on ETBR, we exposed AstroRad-NSC to GSI. By realtime quantitative reverse-transcriptase polymerase chain reaction (real-time qRT-PCR)
assays, incubation of reactive astrocytes in DBZ significantly reduced EDNRB
transcription (Figure 3-6 6C). Furthermore, separate treatment of AstroRad-NSC using two
different GSI (DAPT and L-685,485) resulted in reduced levels of ETBR (Figure 3-6D).
To more specifically evaluate the effects of Notch1 signaling on ETBR in adult reactive
astrocytes, we produced AstroRad-NSC using clonal Rad-NSCs isolated from the periinfarct areas of GFAP-CreERTM-Notch1-cKO mice (Shimada et al., 2012). By gene
expression assays, treatment of GFAP-CreERTM-Notch1-cKO reactive astrocytes with
OHTM reduced mRNA for ETBR and GFAP; this was coincident with reduced transcript
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levels for NICD1 (Figure 3-6E). Furthermore, OHTM treatment of GFAP-CreERTMNotch1-cKO reactive astrocytes also reduced ETBR protein expression (Figure 3-6F).
ETBR controls reactive astrocyte proliferation in vivo after stroke
To examine the specific role of ETBR in the proliferation and/or function of reactive
astrocytes, we generated GFAP-CreERTM-ETBR-cKO mice (Figure 3-10). To examine
whether ETBR cKO affected the reactive astrocyte population, we obtained stereological
counts within the peri-infarct area for the number of GFAP+/ETBR+ cells 30 d after TM
administration and 3 d after dMCAO. The number of GFAP+/ETBR+ cells was
significantly decreased in TM-treated GFAP-CreERTM-ETBR-cKO mice compared with
vehicle-treated control mice (Vehicle: 6703 ± 447.5 cells/mm2, TM: 4233 ± 460.4
cells/mm2, mean ± SEM, n=3 mice per group, p = 0.018; Figure 3-7A). Of interest, for
RC2-negative/GFAP+ cells, we found no difference in cell number between TM- and
vehicle-treated GFAP-CreERTM-ETBR-cKO mice (Vehicle: 1552 ± 176.1 cells/mm2, TM:
1743 ± 410.4 cells/mm2, mean ± SEM, n=5 mice per group p < 0.05; Figure 3-7B).
However, for RC2-positive/GFAP+ cells, TM-treatment led to significantly reduced cell
numbers relative to vehicle-treated controls (Vehicle: 3318 ± 372.6 cells/mm2, TM: 1335
± 353.0 cells/mm2, mean ± SEM, n=5 mice per group, p=0.01; Figure 3-7B).
Astroglial-specific deletion of ETBR prior to injury decreased the amount of
proliferating Ki67+/GFAP+ reactive astrocytes at 30 d after TM administration and 3 d
after injury (Vehicle: 2504 ± 288.9 cells/mm2, TM: 829.9 ± 111.7 cells/mm2, mean ±
SEM, n=5 mice per group, p < 0.01; Figure 3-7D and E). By triple
immunohistochemistry,

we

observed
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a

significant

decrease

in

RC2-

positive/Ki67+/GFAP+ reactive astrocytes in GFAP-CreERTM-ETBR-cKO mice at 3 d
after dMCAO (Vehicle: 1896 ± 193.4 cell/mm2, TM: 388.2 ± 115.8 cell/mm2, mean ±
SEM, n=5 mice per group, p < 0.01; Figure 3-7D). However, loss of ETBR did not affect
the number of RC2-negative/Ki67+/GFAP+ reactive astrocytes, highlighting the
importance of ETBR-based signaling for RC2+ reactive astrocytes localized in close
proximity to the site of cortical injury (Vehicle: 607.1 ± 125.4 cells/mm2, Tm: 441.7 ±
79.60 cells/mm2, mean ± SEM, n=5 mice per group, p < 0.05; Figure 3-7D). In terms of
reactive astrocyte proliferation in the peri-infarct area, the results in GFAP-CreERTMETBR-cKO mice phenocopied those observed for GFAP-CreERTM-Notch1-cKO after
stroke.
Discussion
Here we demonstrated a novel Notch1-STAT3-ETBR signaling axis that controls reactive
astrocyte proliferation after brain injury. Importantly, our findings with STAT3 and
ETBR suggest that Jagged-1/Notch1 signaling may amplify the transcription of myriad
STAT3 targets after CNS injury.
During reactive astrogliosis, gene transcription is upregulated to generate proteins
involved with reactive astrocyte formation and function(s) (Hamby et al., 2012;
Zamanian et al., 2012). For some proteins such as GFAP, CNS injury promotes signaling
through Notch1, EGFR and/or gp130 that drives gene transcription via both canonical
Notch (CSL) binding promoter elements and STAT3 binding cis-elements (Ge et al.,
2002). Notably, we did not find CSL elements in the EDNRB promoter. Instead, we
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found that Jagged-11/Notch1 signaling in reactive astrocytes acted indirectly to promote
ETBR expression by increasing the level of p-STAT3.
Gene and protein expression patterns can be unique to populations of reactive
astrocytes that form in response to different types of CNS injury (Egnaczyk et al., 2003;
Hamby et al., 2012; Zamanian et al., 2012). However, the primary signaling networks
that control reactive astrogliosis may be common to many forms of CNS injury. For
example, most brain injuries result in local release of ET-1 and ETBR-mediated signaling
as well as secretion of growth factors/cytokines with signals transduced by STAT3
(Koyama and Michinaga, 2012). ET-1 was recently shown to promote Jagged-1
expression in cultured astrocytes and also to alter Notch signaling in vivo during the first
week after a demyelinating injury (Hammond et al., 2014). When combined with those of
Hammond et al. (2012), our observations support an interesting model for reactive
astrogliosis. Hypothetically, with CNS injury and release of ET-1 from endothelial cells,
astrocytes, and other cell types, increased Jagged-1 and Jagged-1/Notch1 signaling would
increase the level of p-STAT3, EDNRB transcription and cell surface ETBR in adjacent
astrocytes. In the case of stroke, where the ischemic penumbra expands deeper into
cortical and striatal tissues during the days following the initial occlusive event, a
paracrine/autocrine system that increases ETBR levels ahead of and prior to ligand
exposure may serve to enhance tissue preservation by propagating astroglial proliferation
and inductive signaling several cell layers in front of the expanding zone of
necrosis/apoptosis.
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With a series of complementary approaches, we identified a simple cell surface epitope
profile (GLAST+/Jagged-1+) for prospective isolation of 3 different reactive astrocyte
subpopulations directly from cortical peri-infarct tissue after stroke. Of special interest,
GLAST+/Jagged-1Hi cells corresponded to the subset of proliferative RC2+/nestin+/ETBR+
reactive astrocytes lying immediately adjacent to the infarct core; these cells required
both Notch1 and ETBR for proliferation and/or survival. Notch signaling stabilizes
phosphorylated STAT3 in both healthy somatic cells and transformed cells (Kamakura et
al., 2004; Lee et al., 2009). Blockade of Notch signaling with GSIs was reported to
reduce the growth of tumor “neurospheres” and stem-like glioblastoma cells in
xenografts and to prolong host survival (Fan et al., 2010). Autocrine signaling through
ETBR is critical for self-renewal and survival of glioblastoma stem cells (tumor initiating
cells) (Liu et al., 2011) and pharmacological antagonists of ETBR were shown to decrease
proliferation and survival of glioma cells and oligodendroglioma cells (Paolillo et al.,
2010; Wan et al., 2014). Our data from adult reactive astrocytes, neonatal astrocytes, and
U87 glioma cells provides evidence that paracrine/autocrine signaling through
Notch1/STAT3/ETBR may be operative in a wide variety of proliferating cell populations
that arise after tissue injury or following cellular transformation. Mechanistic
understanding of the signaling network(s) that regulate cell proliferation after injury may
help to identify promising clinical targets for modulation of glial scarring, fibrosis and
cancer.
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Experimental procedures
Mice
All animal work was approved by the University of Vermont College of Medicine’s
Office of Animal Care in accordance with the American Association for Accreditation of
Laboratory Animal Care and National Institutes of Health guidelines. Adult male
C57BL/6J mice (6–8 wks of age) were obtained from Taconic Farms. We obtained
GFAP-CreERTM mice from Dr. Suzanne Baker (St. Jude Children’s Research Hospital,
Memphis, TN) (Chow et al., 2008). Notch1tm2Rko/GridJ mice (Notch1-flox mice,
Cat#006951) and B6;129-Ednrbtm1Nat/J (EDNRB-flox mice, Cat#011080) were from
JAX. Genotyping was performed with the REDExtract-N-Amp Tissue PCR Kit (XNAT1KT;

Sigma).

We

used

the

following

primers:

Notch1,

forward-5’-

TGCCCTTTCCTTAAAAGTGG-3’, reverse-5’-GCCTACTCCGACACCCAA TA-3’;
EDNRB, forward-5’-AGGAGACTGAATGCAGACCAGC, reverse-5’-CATGTTACA
GCTTGCTC CTGTG; GFAP-CreERTM, forward-5’-AGCGATCGCTGCCAGGAT-3’,
reverse-5’-ACCAGCGTTTTCG TTCTGCC-3’.
dMCAO surgery
Mice were anesthetized with isoflurane (1–5%; Webster Veterinary) and body
temperature was maintained with a heated pad. Focal cerebral ischemia was produced by
permanently occluding the middle cerebral artery (MCA) (Shimada et al., 2010; Bakondi
et al., 2011; Shimada et al., 2012). Under low-power magnification, the left temporoparietal region of the head was shaved, and an incision was made between the left orbit
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and the left ear in the shape of a “U.” An incision was made superiorly on the upper
margin of the temporal muscle forward. The MCA was observed through the
semitranslucent skull. A small burr hole (1–2 mm) was drilled into the outer surface of
the skull just over the MCA. The inner layer of skull was removed with fine forceps. The
MCA was then encircled with 10–0 monofilament nylon suture (7V33; S & T), ligated,
and transected superior to the ligation point. The small flap of temporo-parietal skin
covering the skull was closed with Vetbond (3M Animal Care). For conditional knockout
mouse studies, animals received 0.1 mg/g of tamoxifen (TM; T5648; Sigma) dissolved in
9:1 corn oil:absolute ethanol (vehicle) or vehicle alone by intraperitoneal injection for 3
consecutive days from d 0 to 3, followed by a 7 d or 20 d washout period, then subjected
to dMCAO. Mice were euthanized at various time points after dMCAO. Brain tissue was
then either processed for immunohistochemistry or cell isolation (see below).
Immunohistochemistry
Mice subjected to dMCAO were perfused with PBS and 4% paraformaldehyde (PFA),
fixed in 4% PFA overnight at 4°C, and then incubated in 30% sucrose for 2 d at 4°C.
Brain tissue was placed in OCT compound and cut into 30 µm frozen sections on a
cryostat (Leica). Frozen sections were dried for 30 min at 37°C, and incubated in PBS for
15 min. Sections were then blocked in blocking buffer (5% normal goat serum, 0.5%
Triton X-100 in PBS) for 1 h at room temperature. Sections were incubated in the
following primary antibodies overnight at 4°C: ETBR (1:150, SAB2700741; Sigma),
GFAP (rabbit) (1:1000, Z0334; DAKO), GFAP (mouse) (1:250, G3893; Sigma), or RC2
(1:50, University of Iowa Hybridoma Bank). Staining for Ki67 (1:500, Sp6 clone,
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ab16667; Abcam) was performed at room temperature overnight. After 3 PBS washes,
sections were incubated in secondary antisera (Alexa Fluor 488 or Alexa Fluor 594,
1:1000; Invitrogen) for 1 h at room temperature. Cell nuclei were stained with DAPI
(Vector Laboratories). Isotype stains for rabbit IgG, mouse IgG, and mouse IgM (each at
2 µg /ml) were used as negative controls for immunohistochemical stains as in Shimada
et al. (2010). Photomicrographs were obtained with a confocal microscope (Zeiss LSM
510 META; Zeiss Microimaging) or an epi-fluorescence deconvolution microscope with
an automated x,y,z stage (Leica DM6000B; Leica) and Leica FW4000 software.
Immunocytochemistry
Cells were fixed with 4% PFA at 4°C for 10 min, rinsed several times with PBS, and
blocked in blocking buffer (5% normal goat serum, 0.1% Triton X-100 in PBS) for 30
min. Primary antibodies were incubated at 4°C overnight or 1 hr at RT: β-tubulin III
(1:500, PRB-435P, Tuj1; Covance), ETBR (1:400, SAB2700741; Sigma), GFAP (rabbit)
(1:1000, Z0334; DAKO), GFAP (Mus) (1:500, G3893; Sigma), or RC2 (1:150,
University of Iowa Hybridoma Bank).
Cell counts
Infarct area was defined by tissue autofluorescence, whereas the peri-infarct area was
defined by the presence of RC2+ or GFAP+ reactive astrocytes. This area typically
extends 200 µm radially from the infarct core. One out of every ten sections was
quantified for each animal. All cell counts were performed with observers blinded to
slide (sample) identity.

Cell numbers were assessed using stereology and
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StereoInvestigator software (MBF Biosciences, Williston, VT). The Fractionator Probe
method was used in the cortical peri-infarct area. Under low magnification (100X), the
area of interest was identified and the boundary contour was drawn using the softwarepointing device. Spacing between sampling sites (grid size) was set such that 12-24
sampling sites were counted per section. Cells were then counted at high magnification
(400X). For RC2+ and GFAP+ cell quantification, cell identity was ascertained by DAPI
localization. We defined the outer peri-infarct area as the cortical tissue that covered from
200 to 400 µm radially from of the infarct core. All data were expressed as means and
standard error means (SEM). StereoInvestigator was used in conjunction with a Nikon
Optiphot 2 microscope, a Hitachi HVC20 camera, a Heidenhahn focus encoder, and a
motorized, computer-driven X–Z stage (all microscope attachments provided by MBF
Biosciences).
Isolation and culture of Rad-NSCs
For isolation of Rad-NSCs, brains were removed 3 d after dMCAO, placed into a
polyacrylic brain block (Acrylic Matrices, RBMA-200C; World Precision Instruments),
and cut coronally into 1 mm sections. The sections were transferred into alpha-MEM
(Invitrogen) in 6-well plates. The cortical peri-infarct area was dissected under a light
microscope. Tissues from the anterior lateral ventricle, posterior lateral ventricle,
hippocampal arch, dentate gyrus, white matter, and third ventricle were carefully
excluded. The tissues containing the peri-infarct area were harvested, diced into ~1 mm3
pieces, and digested in enzyme digestion solution containing 200 U papain
(Worthington), 20 ug/ml DNase (Worthington), 1.5 mM EDTA (Fisher Scientific), 1.5
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mM CaCl2 (Sigma), 2 mg L-cysteine (Sigma), and DMEM/F12 media (Lonza), at 37°C
for 20 min. Following enzymatic digestion, the tissues were triturated two times in
trituration solution: 5 ml DMEM/F12 medium containing 15 mg trypsin inhibitor
(Invitrogen) and 15 mg bovine serum albumin (BSA; Fisher Scientific). Cells were
resuspended in DMEM/F12 medium containing 0.9 M sucrose and centrifuged to remove
myelin (300 × g for 10 min). Cells were grown at a low density (10,000 cells/ml) in NSC
growth medium containing 10 ng/ml Epidermal Growth Factor (EGF; BD Biosciences),
20 ng/ml basic Fibroblast Growth Factor (bFGF; recombinant human bFGF produced in
our laboratory), 1× B27 supplement (Invitrogen), 2 mM L-glutamine (Mediatech), and
100 U/ml penicillin/100 ug/ml streptomycin, in NeurobasalA (Invitrogen) in 12-well
plates (Nunc Thermo Fisher Scientific). To generate clonal spheres, individual small
spheres (10–100 cells) were pipetted under microscopy into separate 24-well plates 1 wk
after plating. Clonally-isolated neurospheres were expanded and passaged in NSC growth
medium for further studies.
Isolation of postnatal day 2 (PND2) astrocytes
Primary astroglial cultures were prepared from C57BL/6J mice (PND 0-3) as described
previously (Shimada et al., 2011).
Isolation of reactive astrocytes or Rad-NSCs by Magnetic Activated Cells Sorting
To isolate GLAST+ cells from peri-infarct ipsilateral cortical tissue and contralateral
cortical tissue after dMCAO, we dissected and dissociated tissue to obtain a single-cell
suspension (as above). Cell suspensions were blocked for 20 min at 4°C with anti-mouse
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FCR to prevent non-specific binding of mouse antibodies to FCR+ cells (130-092-575;
Miltenyi Biotec). We then performed Magnetic-Activated Cell Sorting (MACS) using
antibody to GLAST according to the manufacturer’s instructions (130–095-822; Miltenyi
Biotec). Positive fractions from MACS isolates were lysed for immunoblotting, subject to
Fluorescence Activated Cell Sorting (FACS) or cultured in NSC medium to obtain RadNSCs.
Fluorescence Activated Cell Sorting of GLAST+ Cells after isolation by MACS
GLAST+ cells from ipsi- and contralateral cortex (1 × 106 cells/ml) were incubated in 2
µg/ml of anti-CD339 (Jagged-1) conjugated to phycoerythrin (clone HMJ1-29, NBP200234; NovusBio) or a matching isotype control (2 µg/ml, NB120-18474PE; NovusBio)
for 30 min at 4°C in DMEM containing 0.5% bovine serum albumin and 2 mM EDTA.
Cells were washed 3 times with PBS and resuspended in PBS for FACS. FACS was
performed with a BD FACSAria cell sorter equipped with a 488 nm (blue) Coherent
Sapphire laser. Forward scatter and side scatter gates were chosen to exclude debris,
doublets and cell aggregates. The remaining events were sorted based on 3 gates: Jagged
1Neg, Jagged 1Lo, and Jagged 1Hi. In some cases, cells were sorted into Complete Culture
Medium (10% CCM) consisting of 1× Alpha-Minimum Essential Medium (Corning
Cellgro) supplemented with 10% Fetal Bovine Serum (FBS), 2 mM L-glutamine
(Corning Cellgro), and 100 U/ml penicillin/100 ug/ml streptomycin (Mediatech). Isolated
cells were plated into 10% CCM at 1.66 × 105 cells/cm2 into wells containing 12 mm
glass coverslips; these were previously coated with mouse laminin and poly-D lysine (5
µg/ml each). Flow cytometry plots were generated with FlowJo software version 7.6.5.
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Immunoblotting
Total protein was extracted from cells with a RIPA cell lysis buffer containing: 1.0%
Triton-X 100, 0.1% SDS, 0.5% Deoxycholate, 50 mM Tris HCL, 150 mM NaCl, 5 mM
EDTA, 1× Protease inhibitor Cocktail (Roche), and 1× phosphatase inhibitor Cocktail
(Sigma) when required. Protein concentrations were determined with a Bio-Rad DC
Protein Assay (Bio Rad). Protein preparations were separated by SDS-PAGE and
transferred to immobilon-P membrane (PVDF; Millipore). The membrane was blocked
with 5% w/v dry milk/1× PBS and then incubated with primary antibody diluted in
blocking buffer overnight at 4°C or at room temperature for anti-GAPDH. After washes,
the membrane was incubated with a horseradish peroxidase-conjugated secondary
antibody for 1 h at room temperature. The blot was visualized with Western Lightning
Plus-ECL (NEL103001EA; Pierce), and exposed to Kodak x-ray film. Equivalence of
protein loading was verified by probing for GAPDH. We used the following primary
antibodies: GFAP (1:2000, Z0334; DAKO), GFAP (1:1000, G3893; Sigma), cleaved
NICD1 (1:1000; AB8925; Abcam), ETRB (1:500, SAB2700741; Sigma), GAPDH
(1:2500, MAB374; Millipore), and GAPDH (1:2500, G9545; Sigma). Films were
scanned at 600 dpi for densitometry (ImageJ software).
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Ex Vivo differentiation of astrocytes from Rad-NSCs
Rad-NSCs were expanded in NSC medium as neurospheres and dissociated with trypsinEDTA. Dissociated cells were plated in 10% CCM at a density of 5.5 × 105 cells/cm2 into
100 mm2 dishes (NUNC) previously coated with laminin/poly-D-lysine (5ug/ml each,
BD Biosciences). Under the above conditions, the plated cells differentiated for 7 d with
medium changes every 2 d.
Experiments with Rad-NSCs
For conditional knockout of Notch1 in reactive astrocytes that were re-differentiated from
Rad-NSCs of GFAP-CreERTM-Notch1-cKO mice, 10% CCM was removed and replaced
with 10% CCM containing 1 uM 4-OH-TM (Sigma) or ethanol (vehicle control). This
treatment was refreshed every 2 d for 5-8 days. For experiments with Gamma-secretase
inhibitors (GSI), cells were treated with (5S)-(tert-Butoxycarbonylamino)-6-phenyl-(4R)hydroxy-(2R)-benzylhexanoyl)-L-leucy-L-phenylalaninamide

(L-685,458,

L1790;

Sigma), N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT,
D5942; Sigma), Dibenzazepine (DBZ, 565789; Millipore) or dimethylsulfoxide (DMSO;
vehicle) for 2 d. For cytokine stimulation, astrocytes re-differentiated from Rad-NSCs
were treated with Interleukin-6 (IL-6, 50 ng/ml, I1395; Sigma), Epidermal growth factor
(EGF, 20 ng/ml, 354052; BD bioscience), or Leukemia Inhibitory Factor (LIF, 20 ng/ml,
Peprotech) for 2 d in 10% CCM.
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DNA constructs
NICD1 coding sequence was removed from pCLEN (Addgene plasmid: 17704) and
cloned into lentiviral vector pWPT-GFP (Addgene plasmid: 12255). For improved
efficiency we generated a translational fusion between NICD1 and GFP using a viral F2A
self-cleaving peptide (Carey et al., 2009). By PCR-based cloning we placed an F2A
sequence between the NICD1 3’-end coding sequence and the 5’-end GFP coding
sequence in such a way that bicistronic mRNA was translated into single polypeptide
chain. The single chain undergoes self-cleavage into functional NICD1 and GFP proteins
directly following translation. The human EDNRB promoter sequence including the
region from -3022 to +160 relative to the transcriptional start was subcloned into Kpn1
and Xho1 sites of vector pGL4.20[luc2/Puro] (Promega) to allow for selection of
puromycin-resistant cells.
Luciferase promoter assays
Human embryonic kidney 293 cells were grown in 10% CCM to 70% confluence and
transfected with the pGL4:hEDNRB promoter construct in 2% CCM with Lipofectamine
3000 (Life technologies). The vector pWPT-GFP (cat# 12255, Addgene) was cotransfected as an indicator of transfection efficiency. At 24 hr after transfection, more
than 75% of cells expressed GFP (data not shown). After 24 hr the cells were seeded into
96-well plates at a density of 10,000 cells/well and allowed to recover another 24 hr. At
45 hr post-transfection, 2% CCM was replaced with 2% CCM containing various
cytokines (e.g. IL-6, LIF, EGF). The plate was then allowed to incubate for a further 3 hr
before luciferase activity was assessed by adding ONE-Glo reagent (Cat# E6110,
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Promega). Luminescence was measured with an appropriately configured Synergy HT
Multimode Microplate reader (BioTek Instruments, Inc.; Winooski, VT).
MTS assay
CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit was used as per the
manufacturer’s instructions (Promega). Relative absorbance at λ = 490nm was quantified
with a Synergy HT fluorescence plate reader.
Real-time Quantitative Reverse-transcriptase Polymerase Chain Reaction
RNA was extracted from cells using a HighPure RNA Isolation kit (Roche, Cat:
11828665001). After first-strand cDNA synthesis with the SuperScript® III RT-PCR
System (Life Technologies), relative quantification real-time PCR was performed as
described by Tharp et al., (2012) with minor modifications. Several TaqMan (Life
Technologies) gene expression kits and assays for mouse were employed: Notch1-FAM,
Mm00435249_m1; GFAP-FAM, Mm01253033_m1; EDNRB-FAM, Mm00432989_m1,
GAPDH-VIC, Mm99999915_g1). The cDNA input template was diluted 1:12 and
GAPDH-VIC probe was added to each well as an internal control. All samples were run
in triplicate. Real-time qRT-PCR was performed on an Applied Biosystems 7300 RealTime PCR System with standard settings (Applied Biosystems Inc, Foster City, CA).
Gene expression was normalized to internal GAPDH controls and fold change was
calculated using the 2(-Delta Delta C[T]) method (Livak and Schmittgen, 2001).
Statistical analysis
Statistical analyses were performed with GraphPad Prism software (version 6.0e).
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Individual groups were compared by Student’s t-test (unpaired). Multiple comparisons
were made by analysis of variance (ANOVA) with Bonferroni post-hoc testing. P values
of less than 0.05 were considered significant.
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Figure 3-1. RC2+ reactive astrocytes appear within 1 day after focal ischemic
cortical injury but are undetectable 30 days later.
A, A’) RC2+ reactive astrocytes (green) at 1 d after dMCAO. Arrows: RC2+ reactive
astrocytes that co-express GFAP (red). Note “bushy” astrocyte morphology. B, B’) RC2+
reactive astrocytes have acquired a hypertrophic, stellate morphology by 3 d after
dMCAO. C,C’) At 14 days following injury, GFAP+ reactive astrocytes that express RC2
have largely lost the stellate morphology and extend processes in the direction of the
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infarct core (dotted line). D, D’) At 30 days after injury, RC2 expression is undetectable
in the GFAP+ reactive astrocytes that compose the glial scar. Scale bars (A, B, C, D)=
100 µm. Scale bars (A’, B’, C’, D’) = 50 µm.
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Figure 3-2. RC2 marks Notch1-dependent reactive astrocytes that proliferate after
injury and express high levels of ETBR.
A) At 3 d after dMCAO, the majority of GFAP+/Ki67+ reactive astrocytes surrounding
the infarct core expressed RC2 (73%), whereas a minority of astrocytes co-expressed
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Ki67 and GFAP, but not RC2 (white arrowhead). B) RC2+ astrocytes expressed high
levels of ETBR (white arrows) relative to distal astrocytes and other cell types. C)
Conditional deletion of astroglial Notch1 in GFAP-CreERTM-Notch1-cKO mice
significantly decreased the number of RC2+/ETBR+ astrocytes in the peri-infarct area 3 d
after dMCAO. *p < 0.05, n = 3. Scale bars, 50 µm.
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Figure 3-3. Cell surface Jagged-1 levels identify distinct subpopulations of GLAST+
reactive astrocytes after cortical injury.
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A) Jagged-1 phenotype of GLAST+ cells isolated by MACS from pooled contralateral
and ipsilateral cortical tissues of C57BL/6J mice 3 d following ischemic injury (n=4
mice; ipsi- and contralateral tissues dissected from the same animals). Upper-left:
Contralateral GLAST+ cells divide into 2 populations; Jagged-1Neg and Jagged-1Lo
(blue line). Note that the signal from isotype control staining (red line) overlaps the signal
for the Jagged-1Neg cells (see also lower-left panel). Upper-right: Cell surface Jagged-1
levels markedly increase on a portion of ipsilateral GLAST+ cells after stroke, forming a
3rd additional population of Jagged-1Hi cells (see signal intensity above 105). Lower-left:
We isolated the Jagged-1Hi cells by FACS (gate = black rhombus). B) Post-FACS,
Jagged-1Hi cells adhered to substrate and were cultured for 24 hours, then fixed and
stained for RC2 (green) and ETBR (red). C) GFAP-CreERTM-Notch1-cKO mice were
treated with vehicle (Corn oil) or tamoxifen (TM)(n=3 mice per treatment group, pooled
by ipsi- or contralateral cortical tissue). Left: GLAST+ cells isolated from contralateral
cortices of oil-treated GFAP-CreERTM-Notch1-cko mice lacked the population of Jagged1Hi cells, similar to C57bl/6 control animals (compare to phenotype in [A], lower-left
panel). Middle: Similar to the phenotype obtained for ipsilateral cortices of typical
C57BL/6J mice 3 d after dMCAO, a population of GLAST+/Jagged-1Hi cells (black oval)
was observed for GFAP-CreERTM-Notch1-cko mice treated with oil (compare to [A],
upper-right panel). FACS phenotype is shown for 4.06 × 105 cells. Right: Astroglial
deletion of Notch1 in TM-treated GFAP-CreERTM-Notch1-cko mice results largely
removed the GLAST+/Jagged-1Hi cell population (red oval). FACS phenotype is shown
for 4.06 × 105 cells.
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Figure 3-4. Primary reactive astrocytes proliferate and increase ETBR expression
when exposed to immobilized Jagged-1.
A) Passage 3-5 Rad-NSCs differentiated for 7 d provided enriched cultures of GFAP
(red)-positive adult reactive astrocytes, termed AstroRad-NSC. Differentiation in medium
containing 10% serum resulted in minor neuronal cell contamination (see Tuj1 stain,
green). Scale bar, 200 µm. B) Subpopulations of AstroRad-NSC expressed GFAP (left
image, red), nestin (right image, red), and RC2 (green in both). All RC2+ cells coexpressed nestin (see white arrows). Scale bar, 50 µm. C) AstroRad-NSC plated onto
immobilized Jagged 1-Fc chimera proliferated and expressed Ki67 (white circles, left
image), whereas AstroRad-NSC plated onto control surfaces did not proliferate or express
Ki67 (right image). Scale bar, 100µm. D,E) By immunoblot, ETBR protein levels
increased after cells were plated onto immobilized Jagged 1-FC for 2 d; this was
observed for both (D) AstroRad-NSC and (E) astrocytes from post-natal day 2 mice
(AstroPND2).
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Figure 3-5. Transcriptional activity at the human EDNRB promoter is increased by
NICD1 in a STAT3-dependent manner.
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A) Mouse and human promoter sequences of the EDNRB gene contain multiple putative
STAT3 binding sites. Schematic indicates relative positions of sites (arrows with labels)
upstream of the transcriptional start site (0 kb) that match STAT3 binding motif
TTM(N)3DAA (D: A, G, or T; M: A or C; N: A, G, T or C) (numbered 1 through 9) or
motif TTC(N)4GAA (N: A, G, T or C) (labeled “A”) (Table 3-1). A’) Schematic of
reporter construct for the human EDNRB promoter (pGL4-hEDNRB-prom) used for
transfection experiments and luciferase activity assays. A 3.5 kb span of the hEDNRB
promoter was cloned upstream of the firefly luciferase gene (LUC). +160bp indicates the
position of the start codon. B) Relative luciferase activity (RLA) of HEK 293 cells
transiently-transfected with pGL4-hEDNRB-prom. After 3 hrs of incubation in IL-6 (50
ng/ml), LIF (20 ng/ml) or EGF (20 ng/ml), luciferase activity significantly increased
relative to control (PBS/DMSO). STATTIC, a specific STAT3 inhibitor, abrogated these
effects. *p < 0.05 vs. DMSO/PBS; †p < 0.05 vs. with relevant DMSO/growth factor or
DMSO/cytokine, ANOVA, mean ± SEM, n=3. Right: Note that STATTIC did not affect
cell viability (MTS assay). C) Expression of ETBR by AstroRad-NSC and the U87 human
glioma cell line. D) Compared to U87 glioma cells transfected with control vector, U87
glioma cells transfected with NICD1 significantly increased RLA. However, this was not
the case for NICD1-transfected cells incubated in EGF with STATTIC or STATTIC
alone. *p < 0.05, ***p < 0.001; ANOVA, mean ± SEM, n=3. RLA: relative luciferase
Activity.
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Figure 3-6. Astroglial ETBR levels change in a correlated manner with STAT3
activation and are modified by presence/absence of Notch1.
A) Incubation of AstroRad-NSC in IL-6 (50 ng/ml) for 2 d increased the level Figure
of activated,
6!
phosphorylated STAT3 (p-STAT3), ETBR and GFAP protein. B) AstroRad-NSC generated
from Rad-NSC of GFAP-CreERTM-Notch1-cko mice exhibited decreased cleavage of
Notch1 intracellular domain (NICD1) after exposure to 4-OH Tamoxifen (OHTM) for 5
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or 8 d in comparison with vehicle-treated control cells (ethanol, EtOH). LIF (20 ng/ml)
induced p-STAT3 levels were reduced in AstroRad-NSC after conditional deletion of
Notch1 (Left: Immunoblot; Right: Normalized band densities from immunoblot [ratio of
p-STAT3 to T-STAT3]). C) Compared with vehicle (DMSO) treatment, exposure to the
Gamma-secretase inhibitor DBZ for 24 hr decreased EDNRB gene expression in AstroRadNSC

(unpaired t-test, *p < 0.001, mean ± SEM, n=3). D) ETBR levels were decreased in

AstroRad-NSC after 2 d incubation in DAPT or L-685,458 (two different GSI). E)
Conditional knockout of Notch1 significantly reduced EDNRB gene expression in
AstroRad-NSC. *p < 0.01, ANOVA, mean ± SEM, n=3. F) AstroRad-NSC differentiated from
different clonal Rad-NSC lines had decreased levels of ETBR protein after Notch1 was
conditionally deleted. Note: Rad-NSC (clone1, clone 2) were isolated from two separate
GFAP-CreERTM-Notch1-cKO animals.
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Figure 7!

Figure 3-7. Conditional knockout of ETBR depletes proliferative astrocytes in the
peri-infarct area 3 d after stroke.
A) Conditional knockout of astroglial ETBR significantly decreased the number of
GFAP+/ETBR+ reactive astrocytes in the peri-infarct area 3 d following stroke. Left:
Representative, low magnification images. Right: Cell numbers. *p < 0.05, unpaired ttest, mean ± SEM, n = 3 mice per group. Scale bar, 200 µm. B) GFAP+/RC2+ reactive
astrocytes, which make up the majority of proliferating reactive astrocytes 3 d following
stroke (see Figure 2), were significantly decreased by conditional knockout of ETBR.
GFAP+ astrocytes that were negative for RC2 expression were not reduced in number. *p
< 0.01, ANOVA with Bonferroni, mean ± SEM, n=5 mice per group. NS= not
significant. C) Conditional knockout of ETBR reduced the number of reactive astrocytes
that were actively dividing (Ki67-positive) 3 d following injury. Left column:
Representative images at low magnification. Scale bar, 100 µm. Middle column:
Representative images of the proximal peri-infarct area. Scale bar, 30 µm. Right
column: Representative images of the distal peri-infarct area. Scale bar, 30 µm. D) The
number of reactive astrocytes actively dividing in the peri-infarct area was significantly
reduced by conditional deletion of ETBR. Of interest, RC2-positive/GFAP+/Ki67+ (triplepositive) reactive astrocytes were significantly reduced in number within the peri-infarct
area, whereas the number of RC2-negative, GFAP+/Ki67+ reactive astrocytes was not
affected. *p < 0.01, ANOVA, mean ± SEM, n=5 mice per group. NS= not significant.
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Binding Motif

Species

(ID) Sequence, promoter position
(bp)

TTC(N)4GAA

Human

(A) TTCATTTGAA, -1175

Mouse

(A) TTCATGGGAA, -1512

Human

(1) TTCCCCAAA, -3012

TTM(N)3DAA

(2) TTACAATAA, -2971
(3) TTAAGTGAA, -2875
(4) TTACCTTAA, -2695
(5) TTATAAAAA, -2609
(6) TTCCATTAA, -1904
(7) TTACCTGAA, -1298
(8) TTAAAAAAA, -688
(9) TTACGTGAA, -320
Mouse

(1) TTAAAAAAA, -2973
(2) TTCCCCAAA, -973
(3) TTAGTAAAA, -330
(4) TTAGCTAAA, -155

Table 3-1. Supplementary Table 1. STAT3 DNA-binding consensus sequences are
found in the human and murine EDNRB promoter.
Promoter sites in mouse and man satisfying STAT3 binding motifs TTM(N)3DAA (D:
A, G, or T; M: A or C; N: A, G, T or C) or TTC(N)4GAA (N: A, G, T or C). Positions
are relative to the transcriptional start sequence for transcript variant 1 in both human and
mouse EDNRB. Human EDNRB sequence data was obtained from Genebank
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(http://www.ncbi.nlm.nih.gov/genbank/)

accession

ID

NG_011630

with

the

transcriptional start point (position 0) located at 61,797 bp in sequence context. Mouse
EDNRB sequence data was obtained from Genebank accession ID NC_000080.6 with the
transcriptional start point located at 5,254 bp in sequence context. See Figure 3 for the
corresponding graphic to this table.
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Figure 3-8. Supplementary Figure 1: Formation of RC2 reactive astrocytes 3 d
following cortical stab injury is attenuated by inhibition of Gamma Secretase.
+

A-A’) RC2 reactive astrocytes (green) surround injury at 3 d after needle stab. Arrows:
Supplemental Figure 1

+

+

RC2 reactive astrocytes. A’) DBZ injection reduces the presence of RC2 cells. B)
+

Quantification of RC2 cells in the peri-infarct area. DBZ treatment significantly reduced
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+

the number of RC2 cells after injury. *p < 0.05, unpaired t-test, mean ± SEM, n=3. Scale
bars, 50 µm.
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Figure 3-9. Supplementary Figure 2: GLAST+ cells isolated by MACS express cellsurface Jagged-1.
+

All plots are smoothed x-y graphs of GLAST cells subjected to flow cytometry. Cells
are plotted by PE fluorescence level and the forward scatter of light (FSC). A) GLAST+
input from MACS gated by side scatter (SSC) and FSC. B) Jagged-1 phenotype of
GLAST+ cells isolated by MACS from pooled contralateral cortical tissues of C57BL/6J
mice (n=4) at 3 d following dMCAO. Monoclonal antibody directed toward the
extracellular domain of Jagged-1 yields a population of cells that are immunoreactive in
contralateral cortex that are not observed with isotype control staining (Left). C)
GLAST+ cells from contralateral cortex of GFAP-CreERTM-Notch1-cKO mice treated
with tamoxifen (TM) or oil (vehicle) show similar populations of GLAST+/Jagged-1+
immunoreactive cells (pooled n=3 mice per treatment group). D) GLAST+ cells from
ipsilateral (injured) cortex 3 d after stroke from C57BL/6J and GFAP-CreERTM-Notch1cKO vehicle treated mice show similar percentages of Jagged-1Hi cells (gate indicated by
the black rectangle).
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Figure 3-10. Supplementary Figure 3: Representative genotyping of hGFAPCreERTM (+/-) ; Ednrbloxp/ loxp double transgenetic mice.

188

CHAPTER 4. CONCLUSIONS AND FUTURE DIRECTIONS.
The goal of this dissertation was to identify and characterize targets of Jagged-1/Notch
signaling that impart reactive astrocytes with the ability to respond and modulate the
injury environment after ischemic stroke. This was accomplished through investigation of
targets from a transcriptome analysis of adult astrocytes (AstroRad-NSC) exposed to
immobilized Jagged-1. The induction of Notch signaling in AstroRad-NSC was verified by
up-regulation of gene expression for the HES family of transcription factors and by the
antagonism of expression for transcription factors associated with oligodendrocyte and
neuronal differentiation (e.g. bHLHs). Importantly, Jagged-1/Notch signaling upregulated genes expressed by reactive astrocytes after CNS injury. Moreover, multiple
gene-members of functional groups were up-regulated together, including groups of
genes that encode proteins known to affect function extracellular solute and ion balance,
the inflammatory response, the formation of extracellular matrix typical to the glial scar,
and glutamate processing. Analysis of results from the Jagged-1 forward signaling screen
suggests that Notch signaling promotes a variety of reactive astrocyte functions.
We chose to investigate GLAST, a astrocyte-specific glutamate transporter,
whose transcription was up-regulated by Jagged-1 in our screen. The regulation of
GLAST level appears to be transcriptionally-controlled by Notch1. We confirmed that
loss of Notch1 corresponded with decreased Glast mRNA and protein expression in
cultured AstroRad-NSC. Importantly, we showed that GLAST protein levels were decreased
in acutely-isolated adult reactive astrocytes using transgenic mice with a conditional
deletion of Notch1 in astrocytes. In regard to function, cultured AstroRad-NSC were able to
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take up glutamate from the extracellular space; this action was attenuated by inhibition of
γ-secretase. Our results imply that Jagged-1/Notch1 signaling in reactive astrocytes upregulates GLAST and could be a master regulator of glutamate up take and processing: a
function of reactive astrocytes that is essential for maintaining extracellular glutamate
levels following stroke.
Further experimentation is required to establish the full role of Notch signaling in
glutamate processing in reactive astrocytes. Other genes associated with glutamate
metabolism in astrocytes, such as Glutamate synthase (Glul) and Glutamate
Dehydrogenase 1 (Glud1) were also up-regulated by Jagged-1/Notch signaling in our
screen, but these targets were not verified. We hypothesize that loss of Notch1 in reactive
astrocytes during stroke will decrease glutamate uptake and processing and increase
extracellular glutamate levels. In turn, this will promote neuronal apoptosis due to
excitotoxicity. Our group has already begun to investigate various methods to assay
extracellular glutamate in the parenchyma of mice following stroke. Microdialysis has
been used successfully to measure extracellular glutamate in the brains of mice subject to
ischemic injury (Mitani and Tanaka, 2003). Alternatively, newly-developed fluorescence
intensity-based glutamate sensors could be employed to assay intracellular of glutamate
directly in reactive astrocytes transfected with DNA-constructs for sensor expression.
Using 2-photon imaging of acute organotypic slices of injured cortex, the intensity of
fluorescent sensors, and therefore the concentration of intracellular glutamate, could be
determined in live tissue (Marvin et al., 2013). A combination of these two methods, and
perhaps the addition of glutamate metabolite analyses with mass spectrometry or NMR,
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will be essential for describing the effects that loss of Notch1 may have on glutamate up
take and processing in vivo.
The transcripts for cell surface receptors that increased after Jagged-1 exposure
included Ednrb. We chose to study ETBR further for two reasons, 1) Endothelin signaling
through ETBR is an important regulator of reactive astrocyte proliferation and function
and 2) Notch signaling was not known to affect ETBR expression in reactive astrocytes or
any other system. Loss-of-function experiments specifically-designed to remove Notch1
and gain-of-function experiments with immobilized Jagged-1 confirmed regulation of
ETBR by Jagged-1/Notch1 signaling. The regulation of ETBR by Jagged-1/Notch1
signaling was not direct, however, and required Notch-mediated enhancement of
activated STAT3. Our experiments demonstrate that STAT3 promotes the transcription
of Ednrb. Previous studies indicated that pharmacologic antagonism of ETBR reduced
reactive astrocyte proliferation after brain injury, a phenotype our group observed in
GFAP-Notch1-conditional KO (cKO) animals after stroke. We observed that the radial
glial marker, RC2, co-localized with ETBR high-expressing peri-infarct reactive
astrocytes. Seventy-five percent of RC2+ reactive astrocytes expressed Ki67+ in the periinfarct area, identifying RC2+ as a suitable marker for the subset of proliferating reactive
astrocytes. Both GFAP-ETBR-cKO and GFAP-Notch1-cKO animals lost the RC2+
population and had fewer proliferating reactive astrocytes after stroke. Lastly, we
described three different populations of GLAST+ astrocytes from stroke cortex based on
their Jagged-1 surface expression. The population of Jagged-1Hi astrocytes was depleted
in GFAP-Notch1-cKO animals following stroke, suggesting that 1) Jagged-1Hi astrocytes
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require Notch1 for proliferation and/or survival, 2) Jagged-1Hi astrocytes are RC2+ and
represent the proliferative subpopulation, 3) Juxtaparacrine astrocyte-to-astrocyte Jagged1/Notch1 signaling is involved in supporting their proliferation. Based on these data we
propose three general astrocyte sub-types in stroke (Figure 2-1).
Isolation of the GLAST+ Jagged-1Hi population of reactive astrocytes and
subsequent transcriptome and epigenetic tiling analyses may elucidate many features of
these cells that distinguish them from non-proliferative reactive astrocytes. Our group has
shown proliferative RC2+ cells are required for the exclusion of CD45 cells from the
parenchyma of the brain after stroke (Shimada et al., 2011). This could be due to
numerous secreted anti-inflammatory factors produced by these cells, the physical barrier
created by proliferative astrocytes (Wanner et al., 2013), or both. Moreover, profiling of
proliferative Jagged-1Hi reactive astrocytes may provide insights into the cell signaling
pathways and epigenetic changes that allow these cells re-enter the cell cycle, and that
make them receptive to conversion into neural stem cells in culture conditions. Although
we have not formally demonstrated Jagged-1Hi reactive astrocytes create NSCs in culture,
Sirko et al. (2013) suggested that proliferating reactive astrocytes responding to Sonic
Hedgehog signaling in the peri-infarct area after stroke formed multipotent neurospheres
in culture. Their study highlights the importance of injury type in the formation of
reactive astrocyte subsets. Astrocytes responding to neuron-specific apoptosis and models
of Alzheimer’s disease adopted features of reactive astrocytes (increased GFAP
expression, hypertrophy), but failed to proliferate and did not create NSCs when isolated
and cultured. Conversely, proliferating reactive astrocytes isolated from ischemic or
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penetrative injuries readily converted to NSCs (Sirko et al., 2013). Understanding the
secretome, signaling and epigenetic profiles of these proliferative Jagged-1Hi reactive
astrocytes may advance basic knowledge of reactive astrocyte biology and also uncover
new targets for rational drug design.
We assume that Notch signaling is increased markedly in proliferative Jagged-1Hi
ETBRHi reactive astrocytes (Figure 2-1). Although we have not established direct
evidence for this here, measuring instantaneous levels of Notch signaling activity is
technically achievable. Levels of Notch signaling can be assessed with transgenic mice
that drive expression of EGFP from a CBF1-responsive element activated during
canonical Notch signaling (Mizutani et al., 2007). Cell-cycle analyses by flow cytometry
could also be used to link the level of Notch signaling to reactive astrocyte proliferation.
Furthermore, complementary immunohistochemistry experiments could be performed
with these mice to localize cells with high levels of Notch signaling with ETBR and
proliferation markers in the peri-infarct area.
Our finding that Jagged1/Notch1 signaling in reactive astrocytes influences ETBR
expression suggests a regulatory scheme for the activation and proliferation of RC2+
reactive astrocytes when viewed in the context of recent literature. Work from Hammond
et al. (2014) showed that reactive astrocytes increased their Jagged-1 expression in
response to ET-1. After chemical demyelination, ET-1 signals through ETBR, ERK and
JNK pathways, and results in the activation of the transcription factor c-jun (Gadea et al.,
2008). C-jun binds to cis-acting AP-1 DNA elements in the Jag1 promoter (Zeng et al.,
2005). Taken with our data, this suggests a putative feed-forward loop whereby ET-1
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signaling through ETBR increases Jagged-1, which then provides a ligand for Notch
signaling in adjacent astrocytes. Notch signaling increases the expression of ETBR,
through p-STAT3 activation, and in turn enhances expression of Jagged-1 through
amplified ET-1 signaling through ETBR. We predict that Endothelin, Notch, and STAT3
signaling all collaborate to drive the proliferation of reactive astrocytes in the peri-infarct
area after stroke through this hypothetical feed-forward loop (Figure 4-2). Absent from
this model is the contribution of the Sonic Hedgehog (SSH) signaling pathway, which is
also required for normal reactive astrocyte proliferation (Sirko et al., 2013). Nevertheless,
it is enough to disrupt ETBR or Notch1 signaling in reactive astrocytes to prevent normal
proliferation, independent of intact SHH signaling.
Our proposed feed-forward loop may be exploited clinically. It is now clear that
proliferative reactive astrocytes protect surrounding healthy tissue from secondary
damage mediated by extracellular glutamate, inflammatory cells and cytokines, and
ischemia after severe CNS injuries like stroke. Enhancing reactive astrocyte proliferation
could provide a novel mechanism to provide protection. Notch signaling in reactive
astrocytes could potentially be enhanced through pharmacological methods. Pinchot and
colleagues (2011) developed a luciferase-based high-throughput screening method
whereby activity of a Notch downstream effector could be measured in cells exposed to
one of 7,264 separate compounds. They found that resveratrol, a compound found in red
wine, produced the strongest reporter response of all the compounds tested. Resveratrol
treatment produced an up-regulation of Notch signaling by inducing expression of
Notch2 in carcinoid cells. This approach is sub-optimal, however, due to resveratrol’s
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potential ability induce Notch signaling in many cell types, not just astrocytes. Notch
signaling has a tumor suppressor-like effect for some cancer cell types, whereas it
supports the growth of others, making it unsuitable for general use as a signal to cells of
injured or diseased tissues (reviewed in Ranganathan et al., 2011; Lobry et al., 2014). Our
model suggests that selective stimulation of ETBR indirectly increases Notch signaling by
up-regulating Jagged-1 levels, thereby promoting juxtaparacine signaling between
adjacent reactive astrocytes. Importantly, drugs or biologics that promote reactive
astrocyte proliferation through pharmacological stimulation of ETBR could provide a
treatment for patients who are ineligible for reperfusion therapy after ischemic stroke.

195

Cortical tissue after stroke
A)!
B)!
C)!

G0

AP
GF

AP
GF

GLAST

Nestin

gp130

G0,
1!

RC

Notch1

2

ETRB

M!

Jagged-1

A)!

B)!

Protoplasmic Astrocyte
•
Mitotically quiescent
•
GLAST+
•
Jagged-1Lo or Jagged-1Neg
•
ETBR not detectable
•
GFAP not detectable

C)!

Reactive Astrocyte (RA)
•
Mitotically silent
•
GLAST+
•
Jagged-1Lo
•
ETBRLo
•
GFAP

Peri-infarct RC2 RA
•
Mitotically active
•
GLAST+
•
Jagged-1Hi
•
ETBRHi
•
GFAP, RC2, Nestin

Figure 4-1. Sub-types of astrocytes in the cortex after stroke.
A) By FACS, protoplasmic astrocytes express Jagged-1 at low or undetectable levels.
By immunohistochemistry, they express undetectable levels of ETBR, GFAP and
GLAST. These astrocytes are located distal to the infarct core and in contralateral
(uninjured) cortex. B) Outside of the peri-infarct area, reactive astrocytes up-regulated
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Jagged-1 levels 3 days after focal ischemic stroke. ETBR and GFAP levels increase and
are now detectable by IHC. These cells re-enter the first growth phase, but rarely divide.
C) Peri-infarct RC2+ reactive astrocytes are directly adjacent to the infarct core and are
mitotically active. They express high levels of ETBR by IHC and are Jagged-1Hi by flow
cytometry. By IHC, these cells express nestin and RC2 in addition to GFAP. This subtype of reactive astrocyte is depleted in ETBR or Notch1 cKO mice after stroke.
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Figure 4-2. Proposed feed-forward loop to amplify Endothelin/STAT3/Notch
signaling in proliferative RC2+ reactive astrocytes of the peri-infarct area after
stroke.
1) Protoplasmic astrocytes become activated and secrete ET-1 (Hammond et al., 2014) or
become activated through direct exposure to ET-1 (Rogers et al., 2003). 2) Autocrine and
paracrine signaling by ET-1 through ETBR activates c-jun (Gadea et al., 2008) and drives
the expression of Jagged-1 (Zeng et al., 2005). 3) gp130-associated cytokine receptors,
such as the IL-6 receptor, or non-gp130 receptors (e.g. EGFR), bind ligands and stimulate
the phosphorylation of STAT3. Adjacent reactive astrocytes with ET-1-induced Jagged-1
expression provide ample ligands for Notch signaling. Notch intracellular domain
(NICD) increases the expression of HES1 and 5, which then physically associate with
STAT3 to stabilize its phosphorylation (Kamakura et al., 2004; see inset). 4) p-STAT3
increases the expression of ETBR, thereby increasing the cell’s receptivity to ET-1 and
further increases the expression of Jagged-1 (2). 5) The feed-forward process of ETBR
and Jagged-1 signal amplification in the presence of autocrine and paracrine ET-1 may
drive proliferation of reactive astrocytes.
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ABSTRACT
In response to stroke, subpopulations of cortical reactive astrocytes proliferate and
express proteins commonly associated with neural stem/progenitor cells, such as Glial
Fibrillary Acidic Protein (GFAP) and Nestin. To examine the stem cell-related properties
of cortical reactive astrocytes after injury, we generated GFAP-CreERTM;tdRFP mice to
permanently label reactive astrocytes. We isolated cells from the cortical peri-infarct area
3 days after stroke, and cultured them in neural stem cell medium containing EGF and
bFGF. We observed tdRFP-positive neural spheres in culture, suggestive of tdRFPpositive reactive astrocyte-derived neural stem/progenitor cells (Rad-NSCs). Cultured
Rad-NSCs

self-renewed

and

differentiated

into

neurons,

astrocytes,

and

oligodendrocytes. Pharmacological inhibition and conditional knockout mouse studies
showed that Presenilin 1 and Notch 1 controlled neural sphere formation by Rad-NSCs
after stroke. To examine the self-renewal and differentiation potential of Rad-NSCs in
vivo, Rad-NSCs were transplanted into embryonic, neonatal and adult mouse brains.
Transplanted Rad-NSCs were observed to persist in the subventricular zone and
secondary Rad-NSCs were isolated from the host brain 28 days after transplantation. In
contrast with neurogenic post-natal day 4 NSCs and adult NSCs from the subventricular
zone, transplanted Rad-NSCs differentiated into astrocytes and oligodendrocytes, but not
neurons, demonstrating that Rad-NSCs had restricted differentiation in vivo. Our results
indicate that Rad-NSCs are unlikely to be suitable for neuronal replacement in the
absence of genetic or epigenetic modification.
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INTRODUCTION
Neural Stem Cells (NSCs) are multipotent cells that self-renew and differentiate into
neurons, astrocytes and oligodendrocytes (Reynolds and Weiss, 1992, 1996; Morshead
and van der Kooy, 2004; Neumeister et al., 2009). NSCs reside as astrocyte-like cells in
neurogenic niches such as the subventricular zone (SVZ) of the lateral ventricle, and the
subgranular zone (SGZ) of the hippocampus (Ihrie and Alvarez-Buylla, 2008). Although
NSCs in neurogenic niches have been well-studied, whether stem/progenitor cells reside
in non-neurogenic niches, such as the cortex, remains under debate (Gould et al., 1999;
Palmer et al., 1999; Kornack and Rakic, 2001; Nunes et al., 2003).
Astrocytes are one of the major cell types in the Central Nervous System (CNS),
and occupy 20 - 30% of brain volume in mammals. Astrocytes contribute to numerous
homeostatic functions in the CNS (Nedergaard et al., 2003; Sofroniew, 2009). Glial
Fibrillary Acidic Protein (GFAP) is often used as a marker to identify astrocytes in the
cortex, and also astrocyte-like NSCs in neurogenic niches. Although NSCs and astrocytes
express this marker in common, GFAP-expressing adult cortical astrocytes of uninjured
animals do not have stem/progenitor cell properties (Laywell et al., 2000).
Following diverse CNS injuries, astrocytes are activated and described as
“reactive astrocytes” (Sofroniew and Vinters, 2009; Robel et al., 2011). The appearance
of reactive astrocytes is one of the most obvious phenomena observed after brain or
spinal cord injury. Subpopulations of reactive astrocytes differentially express several
stem cell-associated proteins such as Sox2, GFAP, Nestin, and RC2 (Pekny and Pekna,
2004; Buffo et al., 2008; Shimada et al., 2010; Zawadzka et al., 2010). We and others
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have demonstrated that locally-derived NSC-like cells can be generated from cortical
tissues following injuries such as stroke, brain stab injury or laser injury (Buffo et al.,
2008; Nakagomi et al., 2009; Sirko et al., 2009; Shimada et al., 2010; Nakagomi et al.,
2011; Robel et al., 2011). Following brain stab injury, it was shown that GLAST-positive
reactive astrocytes could de-differentiate, and form multipotent spheres in culture (Buffo
et al., 2008). Therefore, reactive astrocytes appear to have a greater plasticity than was
previously realized, and may provide a source of multipotent cells or a cellular target for
regenerative medicine. Importantly, however, the signaling pathway(s) that govern the
formation of injury-induced NSCs from cortical tissue remain unidentified. In addition,
whether reactive astrocyte-derived NSCs are multipotent following transplantation back
to the CNS is not known.
Here we use lineage tracing to determine the cellular origin of cortical neural
sphere-producing cells after stroke. We demonstrate the isolation of reactive astrocytederived-NSCs (Rad-NSCs) from the cortical peri-infarct area 3 days following distal
Middle Cerebral Artery Occlusion (dMCAO). Through pharmacological inhibition and
conditional knockout mouse studies, we show that Presenilin 1 and Notch 1 regulate the
generation of Rad-NSC spheres from cortical peri-infarct tissues. Following
transplantation of Rad-NSCs back to CNS, Rad-NSCs differentiated into astrocytes and
oligodendrocytes. However, we did not observe neuronal differentiation, suggesting that
unmodified Rad-NSCs are restricted from neuronal differentiation in vivo, despite their
ability to produce neurons in culture.
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Materials and Methods
Mice
All animal work was approved by the University of Vermont College of Medicine’s
Office of Animal Care in accordance with American Association for Accreditation of
Laboratory Animal Care and National Institutes of Health guidelines. Adult male
C57BL/6J mice (6-8 weeks of age) were obtained from Taconic Farms, Hudson, N.Y.
We obtained GFAP-CreERTM mice from Dr. Suzanne Baker (St. Judes Children Hospital,
Memphis, TN) (Chow et al., 2008). The GFAP-CreERTM mice express CreERTM under
control of the 2.2 kb human GFAP (hGFAP) promoter. We obtained ROSA26-tdRFP
mice from Dr. Hans Joerg Fehling (University Clinics Ulm, Germany) (Luche et al.,
2007). C57BL/6-Tg(UBC-GFP)30Scha/J mice (GFP mice, Cat # 004353), B6.129(Cg)Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J (mT/mG mice, Cat # 007676), B6;129PPsen1tm1Vln/J mice ( Presenilin 1-flox mice, Cat # 007605) and Notch1tm2Rko/GridJ mice
(Notch 1-flox mice, Cat # 006951) were obtained from Jackson Laboratory. Genotyping
was performed by PCR using REDExtract-N-Amp Tissue PCR Kit (XNAT-1KT; Sigma)
following the manufacturer’s instructions. We used the following primers: Notch 1, 5'TGCCCTTTCCTTAAAAGTGG-3', 5'-GCCTACTCCGACACCCAATA-3'; tdRFP, 5'AAGACCGCGAAGAGTTTGTCC-3',

5'-TAAGCCTGCCCAGAAGACTCC-3',

AAGGGAGCTGCAGTGGAGTA-3';
CAGGCACACTCACCCACAGA-3’,

Presenilin

1,

5'5’-

5’-GAAAATCATATCCCCTACACTA-3’;
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GFAP-CreERTM,

5’-AGCGATCGCTGCCAGGAT-3’,

5’-

ACCAGCGTTTTCGTTCTGCC-3’.
Distal Permanent Middle Cerebral Artery Occlusion (dMCAO) surgery
Adult mice (6-8 weeks) were anesthetized with isoflurane (1-5%; Webster Veterinary,
Sterling, MA) and body temperature was maintained with a heated pad. Focal cerebral
ischemia was produced by permanently occluding the middle cerebral artery (MCA)
(Bakondi and Shimada et al., 2009; Shimada et al., 2010). Under low-power
magnification, the left temporal-parietal region of the head was shaved, and an incision
was made between the left orbit and the left ear in the shape of a “U”. An incision was
made superiorly on the upper margin of the temporal muscle forward. The MCA was
observed through the semitranslucent skull. A small burr hole (1-2mm) was drilled into
the outer surface of the skull just over the MCA. The inner layer of skull was removed
with fine forceps, and the dura was opened with a cruciate incision. The MCA was then
encircled with 10-0 monofilament nylon suture (7V33, S & T, Neuhausen, Switzerland),
ligated and transected superior to the ligation point. The small flap of facial skin was
closed with Vetbond (3M animal care products, St. Paul, MN). For transgenic mouse
studies, mice received 0.1 mg/g of tamoxifen (T5648, Sigma) or corn oil by
intraperitoneal injection for 3 consecutive days from day 0 immediately following
dMCAO. Mice were euthanized 3 or 28 days after dMCAO. Brains were perfused with 4
% paraformaldehyde, fixed in 4 % paraformaldehyde overnight at 4 °C, and then
incubated in 30 % sucrose for 2 days at 4 °C. Brains were mounted with OCT compound,
and cut into 20-30 µm frozen sections.
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To label cells migrating from the lateral ventricle to the peri-infarct area after
stroke, stereotaxic surgery was performed immediately after dMCAO surgery.
Stereotaxic surgery was used to deliver 50 µmol/L DiI (CellTracker CM-DiI; Invitrogen)
in 5 µL of phosphate-buffered saline into the lateral ventricle (lateral ventricle
coordinates: anteroposterior, −0.3 mm, mediolateral ±1.0 mm, and dorsal/ventral −3.0
mm). The solution was delivered at a rate of 1 µL/min. Three days later, mice were
euthanized.

Isolation of Reactive astrocyte-derived NSCs (Rad-NSCs) and typical NSCs
For isolation of Rad-NSCs, brains were removed 3 days after dMCAO, placed into a
polyacrylic brain block (Acrylic Matrices, RBMA-200C, World Precision Instruments,
Sarasota, FL) and cut coronally in 1 mm sections. The sections were transferred into
alpha minimum essential medium (Invitrogen, Carlsbad, CA) in 6-well plates. The
cortical peri-infarct area was dissected under a light microscope. Tissues from the
anterior lateral ventricle, posterior lateral ventricle, hippocampal arch, dentate gyrus,
white matter, and third ventricle were carefully excluded. The tissues containing the periinfarct area were harvested, diced into 1 mm3 pieces, and digested in enzyme digestion
solution (200 units papain [Worthington, Lakewood, NJ], 20 µg /ml DNase
[Worthington], 1.5 mM EDTA [Fisher Scientific, Fair Lawn, NJ], 1.5 mM CaCl2
[Sigma], 2 mg L-Cysteine [Sigma], DMEM/F12 media [Invitrogen, Carsbad, CA]) at 37
C° for 15 min. Following enzymatic digestion, the tissues were triturated 2 times in
trituration solution in (10 mls of DMEM/F12 medium containing 15 mg trypsin inhibitor
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[Invitrogen] and 15 mg BSA [Fisher Scientific]). Cells were resuspended in DMEM/F12
medium containing 0.9 M sucrose and centrifuged to remove myelin (111 x g for 10
minutes). Cells were grown at a low density (10,000 cells/ml) in NSC growth medium
(10 ng/ml EGF [BD Biosciences, Bedford, MA], 20 ng/ml bFGF [recombinant human
bFGF produced in our laboratory], 1 x B27 supplement [Invitrogen], 2 mM L-Glutamaine
[Mediatech], and 100 units/ml Penicillin/100 µg/ml Streptomycin, in Neurobasal A
[Invitrogen]) in a 100 mm2 dishes (Nunc, Thermo Fisher Scientific, Rochester, NY). Two
weeks after plating, the number of neural spheres was counted under microscopy. To
generate clonally-derived spheres, individual small spheres (10-100 cells) were pipetted
under microscopy into separate 24-well plates a week after plating. The clonally-isolated
neurospheres were expanded and passaged in NSC growth medium for further studies.
For sphere formation assays, clonally-isolated primary spheres were dissociated, and
plated again into NSC growth medium (24-well plates, 20 cells/µl density, 500 µl per
well). Seven days after plating, the number of neural spheres was counted under
microscopy.
Post-natal day 4 neural stem cells (PD4-NSCs) and adult NSCs from the SVZ (adultNSCs) were isolated as neurospheres from whole brains or lateral ventricle of C57BL/6J
mice, GFP mice, or mT/mG mice (Neural Stem Cell Isolation Kit; StemCell
Technologies, Inc., Vancouver, BC, Canada). To isolate typical adult NSCs, 1 mm
coronal brain sections from adult mice (4-8 weeks of age) were dissected to obtain tissues
from the lateral ventricle and hippocampus under microscopy. To isolate NSCs from the
lateral ventricle, tissues were obtained from the dorsal and lateral sides of the lateral
233

ventricle. To isolate NSCs from the hippocampus, tissues were obtained from the
hippocampus that excluded the posterior lateral ventricle.
Cell transplantation
Rad-NSCs were dissociated, diluted to 25,000 cells/µl in Neurobasal A media, and 5 µl of
cell suspension was transplanted into the lateral ventricle (A/P, -0.3mm, M/L ±1.0 mm,
and D/V -3.0mm), hippocampus (A/P, -2.3 mm, M/L ±1.3 mm, and D/V -2.0mm) or
RMS (A/P, -2.5mm, M/L ±0.8 mm, and D/V -3.0mm) in adult C57BL/6J mice. Two µl of
the NSC cell suspension was transplanted into the brains of day 0-4 C57BL/6J mice. For
neonatal transplants, neonates were anaesthetized with cold vapor from dry ice (carbon
dioxide). The length between the posterior part of the left and right eyes was measured
and divided into 3 equi-distant sections. Rad-NSCs were injected at both edges of the
middle section, 1/3 of the distance inward from the posterior part of left and the right
eyes, and about 1 mm below the skin using 30 gauge needle (7803-07, Hamilton, Reno,
Nevada) and 10 µl Hamilton syringe (1701, Hamilton). To examine retention of
transplanted cells and their location, some mice were injected with DiI (50 µmol/L,
CellTracker CM-DiI; Invitrogen) or NSCs and the location of DiI or cells injection was
analyzed. Neonatal mice were returned to their mothers after the cell injections. They
were euthanized 28 days after injection. For embryonic transplants, 1 µl of the Rad-NSC
cell suspension was transplanted into the brains of embryonic day 15 C57BL/6J mice in
utero. Rad-NSCs were injected at both edges of the middle section of the skull, 1/3 of the
distance inward from the dorsal part of left and the right eyes, and about 1 mm below the
skin using 30 gauge needle (7803-07, Hamilton, Reno, Nevada) and 10 µl Hamilton
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syringe (1701, Hamilton). The mother was returned to the cage, and pups were
euthanized at embryonic day 20 for further analysis.
BrDU (5-Bromo-2’-deoxyuridine) administration
Mice received 50 mg/kg of BrDU (5-Bromo-2’-deoxyuridine, Sigma) by intraperitoneal
injection for 5 consecutive days from day 0 immediately after dMCAO or cell transplant.
Mice were euthanized on day 28 after dMCAO or on day 28 or day 90 after cell
transplant.
TTC (2, 3, 5-Triphenyltetrazolium chloride) staining
Three days following dMCAO, mice were euthanized. Brains were removed and coronal
sections were cut to 1 mm thickness with a polyacrylic brain block. The sections were
incubated in 10% TTC (Sigma) solution (diluted in distilled water) for 15 minutes at 37
°C. After staining, the sections were photographed with a digital camera.
Treatment of cultured cells
Twenty-four well dishes (Nunc) were coated with 5 µg/ml laminin/poly-D-lysine (both
from BD Biosciences]) for 1 hour or overnight. Cells (5,000 cells/cm2) were plated into
NSC growth medium in 24-well plates. One day after plating, the cells were incubated in
various treatments. For the gamma-secretase inhibitor study, cells were treated with
L685-485 (Calbiochem) or DMSO (vehicle) for 2 days. For the 4-OH-Tamoxifen (4-OHTM) study, cells were treated with 0.5 µM 4-OH-TM (Sigma) or ethanol (vehicle) for 2
days.
CyQUANT assay
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Cells (5,000 cells/cm2) were grown in NSC medium in 24-well plates. Two days after
plating, the cells were washed with PBS and plates were frozen at −80 °C (n=4 for each
time point). Cell numbers were quantified by dye labeling of nucleic acids (CyQUANT;
Invitrogen) using a fluorescence plate reader (Biotek Synergy HT; BioTek Instruments,
Winooski, VT).
MTS assay
Cells (5,000 cells/cm2) were grown in NSC medium in 24-well plates. Cell number was
assayed 2 days after plating (CellTiter 96 AQueous One Solution Cell Proliferation
Assay, Promega, Madison, WI). Relative intensity was quantified using a fluorescence
plate reader.
Neural stem/progenitor cell differentiation
Twelve mm2 round cover glasses (Electron Microscopy Sciences, Hatfield, PA) were
coated with 5 µg/ml laminin/poly-D-lysine in 24-well plates for 1 hour. Clonally-isolated
single dissociated cells (5,000 cells/cm2/500 µl passage 3-5) were plated into 24-well
plates, and cultured in NSC growth medium for 1 day. For differentiation, single
dissociated cells were cultured in differentiation medium (1 % FBS, 100 units/ml
Penicillin/100 µg/ml Streptomycin, B27 supplement, 2 mM L-Glutamine in Neurobasal
A) for 7 days. The number of cells that differentiated into neurons, astrocytes, and
oligodendrocytes was determined after immunocytochemistry. To examine the
multipotency of clonal spheres, clonal spheres were plated into 24-well plates, and
cultured in NSC growth medium for 1 day. For differentiation, the spheres were cultured
in differentiation medium for 7 days.
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RT-PCR assays
Total RNA was prepared from Rad-NSCs and PD4-NSCs with a commercially available
kit, according to the manufacturer’s protocol (PureLink RNA Mini Kit, Invitrogen).
DNAse I (Turbo DNase, Invitrogen) was used to remove genomic DNA from RNA
samples. cDNA was synthesized from 1 µg of total RNA with SuperScript III RT
(Invitrogen) and an oligo-dT primer. As a negative control, no-RT samples were made
by omitting SuperScript III from duplicate RT reactions. The cDNA was used for PCR
with the following primers: Sox2, 5’-GGCAGCTACAGCATGATGCAGGAGC-3’ and
5’-CTGGTCATGGAGTTGTACTGCAGG-3’;Pax6,

5’-

AGTTCTTCGCAACCTGGCTA-3’ and 5’-TGAAGCTGCTGCTGCTGATAGGA-3’;
Mash1, 5’-CGTCCTCTCCGGAACTGA-3’ and 5’-TCCTGCTTCCAAAGTCCATT-3’;
Olig2, 5’-TCATCTTCCTCCAGCACCTC-3’ and 5’-CCGTAGATCTCGCTCACCAG3’;

and

GAPDH,

5’-CGGAGTCAACGGATTTGGTCGTAT-3’

and

5’-

AGCCTTCTCCATGGTGGTGAAGAC-3’.
qRT-PCR
Real-time quantitative PCR was performed using SYBR Green I detection Taq
ReadyMixTM (S4438, Sigma, St. Louis, MO, USA) containing 5 mM MgCl2 and 400 nM
of each primer in a final 24 ul reaction volume. We ran reactions with an Applied
Biosystems 7500 Fast real-time PCR system (Applied Biosystems, Foster City, CA,
USA).

The cDNA was used for PCR with the following primers:

CGGAGTCAACGGATTTGGTCGTAT-3’
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and

GAPDH, 5’5’-

AGCCTTCTCCATGGTGGTGAAGAC-3’;

Hes1,

5’-

TGAAGGATTCCAAAAATAAAATTCTCTGGG-3’

and

5’-

CGCCTCTTCTCCATGATAGGCTTTGATGAC-3’;

Deltex1,

5’-

TGAGGATGTGGTTCGGAGGT-3’ and 5’-CCCTCATAGCCAGATGCTGTG-3’; and
RBPJ,

5’-

TGGCACTGTTCAATCGCCTT-3’

and

5’-

AATCTTGGGAGTGCCATGCCA-3’.
Flow cytometry analysis
Cells (500,000 cells/ml) were suspended in 0.5 ml alpha MEM and analyzed by closed
stream flow cytometry (Epics XL; Beckman Coulter; LSR II; Becton Dickinson, Franklin
Lakes, NJ).
Magnetic-Activated Cell Sorting (MACS)
To isolate GLAST-positive cells from whole brains, we performed magnetic-activated
cell sorting using GLAST antibody (130-095-822, Miltenyi Biotec, Auburn, CA)
according to the manufacturer’s instructions.
Immunoblotting
Total proteins were extracted from the sorted cells using a cell lysis buffer (0.1 % SDS,
1x complete protein inhibitor cocktail [Roche, Basel, Switzerland] in PBS). Protein
concentrations were determined with a Bio-Rad DC Protein Assay (Bio-rad, Hercules,
CA). Protein preparations were separated by SDS-PAGE and transferred to an
immobilon-P membrane (PVDF, Millipore, Boston, MA). The membrane was blocked
with 5 % BSA (BP1605, Fisher) and then incubated with a primary antibody. After
washing, the membrane was incubated with an HRP-conjugated secondary antibody for 1
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hour at room temperature. The blot was visualized with Western Lightning Plus-ECL
(NEL103001EA, Pierce, Waltham, MA), and exposed to Kodak X-ray film. Equivalence
of protein loading was verified by probing for GAPDH or β-actin. The antibodies used
were against GFAP (Z0334, DAKO, Glostrup, Denmark), NICD1 (Notch 1 Intracellular
Domain, ab8925, Abcam), Presenilin 1 (MA1-752, Thermo Scientific) GAPDH
(MAB374, Millipore) and β-Actin (A5441, Sigma).
Immunohistochemistry
Frozen sections were dried for 30 minutes at 37 °C, and incubated in PBS for 15 minutes.
Sections were then blocked in blocking buffer (10 % normal goat serum, 0.4 % Triton X
in PBS) for 1 hour at room temperature. For BrDU staining, sections were treated with 2
N HCl for 30 minutes at 37°C and washed before the incubation with blocking buffer.
For Galactocerebroside (GalC) staining, sections were treated with proteinase K (20
µg/ml, Invitrogen) for 5 minutes at 37°C. Sections were incubated in the following
primary antibodies overnight at 4 °C: β-tubulin III (1:1000, PRB-435P, Tuj1; Covance),
BrDU (1:500, A21300; Molecular Probes), Calbindin (1:1000, CB38; Swant, Marly,
Switzerland), Calretinin (1:1000, AB149; Millipore), Doublecortin (1:1000, AB5910;
Millipore), GalC (1:200, MAB342; Millipore), GFAP (1:1000, Z0334; DAKO), GFAP
(1:500, G3893; Sigma), GFP(1:1000, A11122; Invitrogen), GSTπ (1:1000, MSA-102E;
Stressgen, Ann Arbor, MI), Hu C/D (1:1000, A21271; Invitrogen), NG2 (1:200,
MAB5384; Millipore), NG2 (1:200, AB5320; Chemicon), Nestin (1:500, PRB-315C;
Covance), Nestin (1:500, ab81755; Abcam), NeuN (1:1000, MAB377; Millipore), NICD
1 (1:500, ab8925; Abcam), RC2 (1:40, University of Iowa Hybridoma Bank), RFP
239

(1:250, 632496; Clontech), Sox2 (1:1000, AB5603; Millipore), S100B (1:500; S2532;
Sigma), and Tyrosine Hydroxylase (TH, 1:1000, TYH; Aves labs inc). Antibodies against
RFP (1:250, 5F8; Chromotek) and Ki67 (1:500, ab1667; Abcam) were incubated
overnight at room temperature. After 3 PBS washes, sections were incubated in
secondary antisera (Alexa Fluor 488 or Alexa Fluor 594, 1:500; Molecular Probes) for 1
hour at room temperature. Cell nuclei were stained with DAPI (Vector Laboratories,
Burlingame, CA). Isotype controls: Rabbit IgG (2 µg/ml), Mouse IgG (2 µg/ml), and
Mouse IgM (2 µg /ml) were used as negative controls for immunohistochemical stains as
in Shimada et al. (2010). Photomicrographs were obtained using an epifluorescence
deconvolution microscope with an automated x,y,z stage (Leica DM6000B, Leica,
Wetzlar, Germany) and Leica FW4000 software. For deconvolution, images were
obtained every 0.1 µm under 100 X magnification, and de-convolved using Leica Deblur
software. For some photomicrographs, images were obtained using a confocal
microscope (Zeiss LSM 510 META, Zeiss Microimaging, Thornwood, NY).
Immunocytochemistry
Cells were fixed with 4 % paraformaldehyde for 15 min at room temperature and washed
3 times with PBS. Some cells were treated with methanol at 4 °C for longer than 1 hour
to eliminate endogenous GFP or tdRFP expression. Cells were blocked as above, and
incubated with primary antisera overnight at 4 °C: Nestin (1:1000, Covance), RC2 (1:40,
University of Iowa Hybridoma Bank), Sox2 (1:1000, Chemicon), β-tubulin III (1:1000,
PRB-435P, TUJ1; Covance), and GFAP (1:500, Sigma). Non-fixed, live cells were
stained for O4 (1:50, O7139; Sigma) and then post-fixed for analysis. After 3 PBS
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washes, cells were incubated in secondary antisera for 1 hour at room temperature. The
coverglasses were mounted onto slides with DAPI or Citifluor (100496-532, VWR
International).
Cell quantification and statistics
The infarct area was defined by tissue autofluorescence, whereas the peri-infarct area was
defined by the presence of GFAP-positive reactive astrocytes. One out of every ten
sections was quantified. Cell counts were performed by observers blinded to slide
(sample) identity. Cell numbers were determined with Optical Fractionator of Stereo
Investigator in the cortical peri-infarct area (MBF Biosciences, Williston, VT). Stereo
Investigator was used in conjunction with a Nikon Optiphot 2 microscope, a Hitachi
HVC20 camera, a Heidenhahn focus encoder, and a motorized, computer-driven X–Z
stage (all microscope attachments provided by MBF Biosciences). Under low
magnification, the area of interest was identified and boundary contours were drawn
using the software-pointing device. Spacing between sampling sites (grid size) was set
such that 6-12 sampling sites were counted per section. For GFAP, RC2, Nestin or
S100B-positive cell quantification, cell identity was ascertained by DAPI localization.
We defined the inner peri-infarct area as cortical tissue that covered 200 µm radially
outside the edge of the infarct core where proliferative reactive astrocytes were typically
located (Shimada et al., 2010). All data were expressed as means and standard error
means. Comparisons made between any two groups were performed by 2-tailed Student’s
t-test. Values of P < 0.05 were considered significant.
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RESULTS
GFAP-positive reactive astrocytes express NSC-related proteins after cortical
stroke.
To study reactive astrocytes following stroke, we induced cortical infarcts by distal
permanent middle cerebral artery occlusion (dMCAO) (Shimada et al., 2011). Three days
following stroke, mice were euthanized and brains were prepared for analysis. TTC
staining revealed that the infarct caused by dMCAO occurred exclusively in the cortex,
but not in the striatum (Figure 1A). Immunohistochemical studies identified numerous
GFAP-positive reactive astrocytes on the ipsilateral side of the cortical infarct area, but
not on the contralateral side of the cortex (Figure 1B, B’). GFAP-positive reactive
astrocytes adjacent to the infarct core expressed the cell proliferation marker, Ki67, and
several NSC-associated proteins such as Nestin, RC2 and Sox2 (Figure 1C-E) (Shimada
et al., 2010). We did not observe Nestin or RC2 expression on the contralateral side of
the brain after stroke. In agreement with recent studies, we observed that GFAP-positive
reactive astrocytes did not express the oligodendrocyte progenitor cell marker, NG2
(Dimou et al., 2008; Barnabe-Heider et al., 2010; Zawadzka et al., 2010). As reported, the
NSC-associated protein, Sox2, was expressed by many reactive astrocytes and astrocytes
in the cortex (Komitova and Eriksson, 2004). After stroke, we observed that GFAPpositive reactive astrocytes and Nestin-positive reactive astrocytes expressed Sox2 in the
peri-infarct area (Figure 1F,G). To examine whether stroke induced a greater number of
cells that expressed NSC-associated proteins, we examined the number of Sox2-positive
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cells after stroke. We observed a significantly increased number of Sox2-positive cells on
the ipsilateral side of the brain compared with the contralateral side of the brain (n=3, p <
0.01; Figure 1H).

Heterogeneous populations of reactive astrocytes are observed in the peri-infarct
area of GFAP-CreERTM;tdRFP mice after stroke.
To examine GFAP-positive reactive astrocytes, we generated GFAP-CreERTM;tdRFP
mice. In GFAP-CreERTM;tdRFP mice, tdRFP was induced permanently in GFAPpositive cells after tamoxifen (TM) administration (Luche et al., 2007; Chow et al.,
2008). Focal cortical stroke was induced by the dMCAO surgery on GFAPCreERTM;tdRFP mice. Mice received 0.1 mg/g of TM by intraperitoneal injection for 3
consecutive days starting immediately after stroke. Three days after dMCAO, mice were
euthanized and brains were prepared for analysis. tdRFP-positive cells were observed in
the peri-infarct area (Figure 2A). By immunohistochemistry, 58.7% of GFAP-positive
cells were positive for tdRFP, and 74.5% of tdRFP-positive cells expressed GFAP in the
peri-infarct area of the cortex (n=3 mice; Figure 2A). To analyze further the
characteristics of tdRFP-positive cells in the peri-infarct area, we stained for the presence
of other proteins expressed by reactive astrocytes. Nestin is a marker of NSCs and neural
progenitor cells, and its expression is observed in a subpopulation of reactive astrocytes
after stroke (Shimada et al., 2010; White et al., 2010). Three days after stroke, 63.3% of
Nestin-positive cells were positive for tdRFP, and 78.9% of tdRFP-positive cells
expressed Nestin in the peri-infarct area of the cortex (n=3 mice; Figure 2B). RC2 is a
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commonly used marker of radial glial cells during development and is expressed by a
subpopulation of reactive astrocytes after stroke that reside directly adjacent to the infarct
core (Shimada et al., 2010). We observed that 41.5% of RC2-positive cells were positive
for tdRFP, and 24.2% of tdRFP-positive cells expressed RC2 in the peri-infarct area of
the cortex (n=3 mice; Figure 2C). S100B is a commonly used marker of astrocytes and
reactive astrocytes (Sellers et al., 2009). We observed that 31.1% of S100B-positive cells
were positive for tdRFP, and 28.4% of tdRFP-positive cells expressed S100B in the periinfarct area of the cortex (n=3; Figure 2D).

Isolation of tdRFP-positive spheres from the cortical peri-infarct area after stroke.
Previously, we reported the isolation of locally-derived NSC-like cells from the periinfarct area 3 days after stroke (Shimada et al., 2010). In that work, we observed neural
sphere formation from peri-infarct tissues after stroke, but the cellular origin of the neural
sphere-forming cells from the cortical peri-infarct area was not determined. To study the
origin of locally-derived neural spheres after stroke, we isolated cells from the periinfarct area of GFAP-CreERTM;tdRFP mice 3 days following the dMCAO surgery
(Figure 3A). To prevent contamination of typical NSCs residing in neurogenic niches,
tissues from the anterior lateral ventricle, posterior lateral ventricle, hippocampal arch,
dentate gyrus, white matter, and third ventricle were carefully excluded from the
dissected peri-infarct tissues. We cultured cells in NSC growth medium with EGF and
bFGF. After 2 weeks in culture, we observed tdRFP-negative spheres and tdRFP-positive
spheres (n=3; Figure 3B,C). As a negative control, cortical tissues from the contralateral
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side of the brain were harvested. From the contralateral side of cortical tissues, we did not
observe sphere formation (n=3; Figure 3D).

Lack of neuroblast migration from the SVZ to the cortex after stroke.
To determine whether the cells that generated tdRFP-positive neural spheres had
migrated from the SVZ after stroke, migrating neuroblasts were analyzed by
immunohistochemistry. Doublecortin-positive migrating neuroblasts did not migrate into
the peri-infarct area from the SVZ 3 days following stroke (Figure 3E, F). Moreover, the
staining pattern for doublecortin in the SVZ on the ipsilateral and contralateral sides of
the brain was similar. Since there could be doublecortin-negative neuroblasts migrating
from the SVZ to the peri-infarct area, we also stained to localize PSA-NCAM-positive
immature neuroblasts. However, we did not observe PSA-NCAM-positive cells in the
peri-infarct area 3 days following stroke (data not shown). To examine whether any cells
from the lateral ventricle migrated into the peri-infarct area, DiI was injected into the
lateral ventricle to label cells in the SVZ immediately after the dMCAO surgery. As a
positive control for DiI labeling, we examined whether DiI-positive cells migrated in the
rostral migratory stream (RMS) from the SVZ. We observed the migration of DiIpositive cells from the lateral ventricle to the RMS, demonstrating that our DiI injection
was successful (data not shown). However, we found that DiI-positive cells did not
migrate into the peri-infarct area 3 days after stroke (Figure 3G, H). These data indicated
that cells from the lateral ventricle niche did not migrate into the cortical peri-infarct area
within 3 days after MCA ligation in the dMCAO stroke model.
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We also examined tdRFP-positive cells in the SVZ. Similar to a report that used
the same GFAP-promoter strain (Chow et al., 2008), we found that most GFAP-positive
cells on the striatal side of the lateral ventricle did not express tdRFP in GFAPCreERTM;tdRFP mice (Figure 3I,J). We then isolated cells from the dorsal and lateral
(striatal) sides of the lateral ventricle 3 days after dMCAO, and cultured them in NSC
growth medium. After 1 to 2 weeks of culture, numerous lateral ventricle-derived neural
spheres were observed (Figure 3K,L). However, most spheres did not express tdRFP
(n=3). Therefore, the lack of tdRFP-labeled neural spheres from the lateral ventricle
appeared to relate to mosaicism in the transgenic mouse model. As a positive control,
cells from the hippocampus were also cultured. Many tdRFP-positive cells were observed
in the SGZ of the hippocampus (data not shown). We then isolated cells from the
hippocampus and cultured them in NSC growth medium. As expected, hippocampusderived neural spheres expressed tdRFP (data not shown). In agreement with previous
reports, we failed to passage the hippocampus-derived neural spheres in culture (Seaberg
and van der Kooy, 2002; Clarke and van der Kooy, 2011). Altogether, these data
indicated that the tdRFP-positive neural spheres isolated from the cortical peri-infarct
area after stroke had originated from tdRFP-positive reactive astrocytes of the peri-infarct
area, and not from cells that had migrated from the SVZ. Hereafter, we call the injuryinduced tdRFP-positive neural sphere-forming cells “Reactive astrocyte-derived NSCs”
or Rad-NSCs.

Rad-NSCs self-renew and are multipotent in culture.
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To examine the self-renewal and multipotential capacities of Rad-NSCs in culture, clonal
Rad-NSC spheres were derived. To obtain clonal spheres, individual spheres from low
density cultures were pipetted under microscopy into separate 24-well dishes. To confirm
whether the isolated clonal sphere population was homogenous in terms of tdRFP
expression, we analyzed the passaged clonal spheres by flow cytometry. As a negative
control, we used postnatal day 4-derived NSCs (PD4-NSCs) that were negative for
tdRFP. We confirmed that the clonal tdRFP-positive sphere population was homogenous
for tdRFP expression (n=2; Figure 4A). To examine the self-renewal capacity of RadNSCs ex vivo, sphere formation assays were performed with the clones. As a positive
control, we used PD4-NSCs. As expected, PD4-NSCs formed secondary and tertiary
spheres in culture. Clonal Rad-NSC spheres were also able to form secondary and tertiary
spheres in culture. The number of Rad-NSC spheres was significantly less than that of
cultures from PD4-NSCs, and the Rad-NSC spheres were smaller in size (number of
spheres: secondary; p < 0.01, tertiary; p < 0.01, size of spheres: secondary; p < 0.01,
tertiary; p < 0.01, n=3; Figure 4B,C). We observed that Rad-NSCs grew slower than
PD4-NSCs (day 2; p < 0.01, day 4; p < 0.01, day 6; p < 0.01, n=4; Figure 4D). Rad-NSCs
expressed several mRNAs commonly expressed by NSCs such as Sox2, Pax6, Mash1 and
Olig2 (Figure 4E). To determine whether Rad-NSCs also expressed NSC-associated
proteins,

we

performed

immunocytochemistry.

Immunocytochemical

analysis

demonstrated that tdRFP-positive Rad-NSCs expressed several stem cell-associated
proteins, such as Sox2, Nestin, RC2 and GFAP in culture (Figure 4F-J).
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To examine the multipotency of Rad-NSCs, dissociated Rad-NSCs were
differentiated for 7 days. Immunocytochemistry demonstrated that cultured Rad-NSCs
differentiated into neurons, astrocytes, and oligodendrocytes (Figure 4K-N). About 89%
of Rad-NSCs differentiated into astrocytes. Since dissociated cell analysis does not fully
examine the multipotency of spheres, we also used a more stringent test to examine
multipotency. To examine the multipotency of Rad-NSC spheres and PD4-NSC spheres,
clonal spheres were plated into 24-well dishes and differentiated for 7 days and then
examined

by

triple

immunocytochemistry

(Figure

4O-Q).

Following

immunocytochemistry, the number of unipotent (astrocytes), bipotent (astrocytes and
neurons, or astrocytes and oligodendrocytes) and tripotent (astrocytes, neurons and
oligodendrocytes) spheres was quantified. Interestingly, Rad-NSC cultures contained
significantly more tripotent spheres than did PD4-NSC cultures (unipotent, p= 0.32;
bipotent, astrocytes and neurons, p=0.10; astrocytes and oligodendrocytes p=0.17;
tripotent, p < 0.05; Figure 4Q).

Control of Rad-NSC self-renewal by Presenilin 1- and Notch 1-dependent signaling.
The Notch signaling pathway has critical roles in development and NSC maintenance.
Notch is cleaved by gamma-secretase, and the intracellular domain is transported to the
nucleus and interacts with DNA via DNA-binding proteins. Notch signaling maintains
the undifferentiated state of NSCs, and also enhances gliogenesis from NSCs (Borghese
et al.; Furukawa et al., 2000; Satow et al., 2001; Ge et al., 2002; Hitoshi et al., 2002; Iso
et al., 2003; Eiraku et al., 2005; Alexson et al., 2006; Androutsellis-Theotokis et al.,
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2006; Patten et al., 2006) . Therefore, we examined whether reactive astrocytes in cortical
peri-infarct tissues expressed the cleavage product of the Notch 1 receptor after stroke.
By immunohistochemistry, GFAP-positive reactive astrocytes expressed Notch1
Intracellular Domain (NICD1) in the cortical peri-infarct area after stroke (Figure 5)
(Shimada et al., 2011). tdRFP-positive Rad-NSCs also expressed NICD1 in culture
(Figure 5A). Based on the requirement for Notch signaling to maintain NSCs, we
hypothesized that this gamma-secretase-mediated pathway also regulates Rad-NSCs.
First, to determine whether gamma-secretase-mediated cleavage was required for
proliferation, cultured Rad-NSCs were plated and treated with a gamma-secretase
inhibitor (GSI) for 2 days. The number of Rad-NSCs decreased significantly following
GSI treatment compared with vehicle control (p<0.01; Figure 5B), suggesting that a
gamma secretase-mediated pathway regulated the proliferation of Rad-NSCs.
Presenilin 1 is thought to act as the catalytic subunit for gamma secretase (Fortini,
2002). To determine whether gamma secretase itself was important for self-renewal of
Rad-NSCs, we generated GFAP-CreERTM;Presenilin 1 inducible conditional knock out
(GP cKO) mice. In GP cKO mice, Presenilin 1 is deleted after TM treatment in GFAPpositive reactive astrocytes. To determine if Presenilin 1 expression levels were
decreased in astrocytes in GP cKO mice following TM treatment, we isolated astrocytes
by MACS using an antibody against GLAST, a cell surface protein commonly expressed
by astrocytes (Mori et al., 2006). We confirmed that sorted GLAST-positive cells
expressed GFAP by western blotting, indicating that GLAST-positive cells were enriched
for astrocytes (Figure 5C). GLAST-positive astrocytes were isolated and used for further
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analysis. We treated GP cKO mice with TM for 3 days and isolated astrocytes. By
immunoblotting, we observed decreased Presenilin 1 expression levels in TM treated
mice compared with vehicle treated mice 14 days after TM treatment but not 3 days after
TM treatment, suggesting that residual Presenilin 1 was present in a proportion of
GLAST-positive cells at 3 days after TM treatment (Figure 5D and data not shown). It is
noteworthy that by analysis of GFAP-CreERTM;tdRFP mice, not all GFAP-positive cells
expressed Cre enzyme (Figure 2A). Therefore, we did not expect to observe knockout of
Presenilin 1 in all astrocytes of GP cKO mice. To determine whether reduction of
Presenilin 1 affected neural sphere formation from reactive astrocytes after stroke, RadNSCs were isolated from cortical peri-infarct tissues 3 days after stroke from GP cKO
mice that were treated with TM for 3 consecutive days after MCA ligation. As negative
controls, Rad-NSC spheres were isolated from the brains of GP cKO mice that were
treated with corn oil, and also from littermate control mice (GFAP-CreERTM;Presenilin 1
heterozygous mice or Presenilin 1-loxp mice) that were treated with TM. After 2 weeks
in culture, the number of neural spheres generated decreased significantly for GP cKO
mice treated with TM compared with both negative control groups (n=6-8 for each group;
Figure 5E). To understand whether cell proliferation affected neural sphere formation
from GP cKO-derived Rad-NSCs, we isolated clonal Rad-NSCs from GP cKO mice 3
days after stroke. Clonal Rad-NSCs were treated with either ethanol (vehicle control) or
4-OH-TM to flox Presenilin 1 in culture. Two days following treatment, the proliferation
of Rad-NSCs was examined by CyQUANT assay and MTS assay. We observed that
conditional knockout of Presenilin 1 significantly reduced the proliferation of cultured
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Rad-NSCs (n=4 for each group; Figure 5F,G). Therefore, gamma-secretase mediated
signaling controlled both the generation of Rad-NSCs from cortical reactive astrocytes
after stroke injury as well as the proliferation of Rad-NSCs in culture.
To determine whether Notch1 signaling was important for self-renewal in RadNSCs, inducible GFAP-CreERTM;Notch 1 conditional knockout (GN cKO) mice were
generated. In the GN cKO mice, Notch 1 is deleted after TM treatment in GFAP-positive
reactive astrocytes. To examine Notch 1 expression levels in astrocytes, we performed
western blotting using sorted GLAST-positive cells. We observed decreased Notch1
expression levels in TM treated mice compared with oil treated mice (Figure 5H). Next,
we examined expression of NICD1 in reactive astrocytes. By immunohistochemistry, we
observed lack of NICD1 expression in reactive astrocytes in TM-treated mice, but not
corn oil-treated mice 3 days after stroke (Figure 5I,J). To determine whether Notch 1
reduction affected proliferation of reactive astrocytes, the number of proliferating
reactive astrocytes was quantified in the peri-infarct area 3 days following dMCAO.
Three days after stroke, the number of total GFAP-positive astrocytes or the overall
number of Ki67-positive proliferating cells did not differ among treatment groups (data
not shown). However, in agreement with our previous study, the number of proliferating
reactive astrocytes was significantly decreased in TM-treated GN cKO mice compared
with TM-treated GN heterozygous cKO mice and the corn oil-treated group (Shimada et
al., 2011). The number of proliferating reactive astrocytes was also significantly
decreased in TM-treated GN heterozygous cKO mice compared with corn oil-treated
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mice of the same genotype (n=3-4; Figure 5K-N). These data indicate that Notch 1
knockout affects reactive astrocyte proliferation in vivo.
To determine whether Notch 1 signaling affected neural sphere formation by
reactive astrocytes after stroke, Rad-NSCs were isolated from cortical peri-infarct tissues
of GN cKO mice that were treated with TM for 3 consecutive days after dMCAO. The
number of neural spheres generated in culture decreased significantly for GN cKO mice
treated with TM compared with corn oil-treated mice. Interestingly, the number of neural
spheres was significantly decreased for GN heterozygous mice too (n = 4; Figure 5O). To
understand whether cell proliferation affected neural sphere formation in GN cKOderived Rad-NSCs, we isolated clonal Rad-NSCs from GN cKO mice 3 days after stroke.
Clonal Rad-NSCs were treated with either ethanol or 4-OH-TM to reduce Notch1 levels
in cultured cells. Two days following treatment, the number of Rad-NSCs was examined.
By CyQUANT assay and MTS assay, we observed that reduction of Notch1 significantly
reduced the number of cultured Rad-NSCs (n = 4; Figure 5P, Q). Therefore, Notch 1
signaling controlled both the generation of Rad-NSCs from reactive astrocytes as well as
the proliferation of Rad-NSCs in culture. To examine whether downstream aspects of the
Notch 1 signaling pathway was altered in TM-treated GN cKO-derived Rad-NSCs, Notch
target gene mRNAs were examined by quantitative real time-PCR (qRT-PCR). First, we
confirmed that Notch 1 was deleted in Rad-NSCs derived from TM-treated GN mice by
RT-PCR. We did not observe Notch 1 expression in Rad-NSCs derived from TM treated
GN mice (data not shown). qRT-PCR results also demonstrated that Hes1, Deltex and
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Rbpj mRNA levels were all significantly decreased in Rad-NSCs derived from TM
treated GN mice compared with corn oil treated GN mice (n=3-6; Figure 5R).

Transplanted Rad-NSCs self-renew in vivo.
To study the self-renewal capacity of Rad-NSCs in vivo, tdRFP-positive Rad-NSCs were
transplanted into day 0-4 mouse brains (Figure 6A). First, to examine retention of
transplanted cells and their location, we injected DiI into the day 0 mouse brains. Four
hours after injection, we observed DiI-positive cells located in the lateral ventricle. DiIpositive cells were also observed in the needle track (Figure 6B). Twenty eight days after
transplantation, we observed tdRFP-positive cells residing in the lateral ventricle walls
(Figure 6C-F). We then investigated whether transplanted tdRFP-positive cells might
reside in the lateral ventricle as NSCs. By Immunohistochemistry, tdRFP-positive cells in
the SVZ expressed GFAP and Sox2 (Figure 6C, D). However, we did not observe RadNSCs that expressed Ki67, suggesting that tdRFP-positive cells were not actively
dividing at the time of the assay (Figure 6E). To examine whether transplanted RadNSCs proliferated in vivo, we injected BrDU to the mice for 5 consecutive days
immediately after transplantation. We observed BrDU-positive Rad-NSCs in the SVZ 1
month after transplantation, indicating that tdRFP-positive Rad-NSCs proliferated in the
SVZ after transplantation (Figure 6F).
To examine whether Rad-NSCs maintained stem cell characteristics in the mouse
brain after transplantation, we repeated transplantation of Rad-NSCs to day 0-4 mouse
brains and dissected tissues from the lateral ventricle after 28 days (Figure 6G). From
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these isolates, we observed neural sphere formation after 1 week of culture in NSC
growth medium (Figure 6H,I). These data indicated that Rad-NSCs transplanted to the
SVZ self-renewed and maintained their multipotency for differentiation. Notably, we
observed both tdRFP-positive and tdRFP-negative neural spheres in culture, indicating
that some neural spheres were obtained from host-derived NSCs of the SVZ, whereas
some had derived from transplanted tdRFP-positive Rad-NSCs.
To determine the self-renewal capacity and multipotency of secondary-transplanted
tdRFP-positive Rad-NSCs (hereafter called 2nd Rad-NSCs), clonal tdRFP-positive
spheres were isolated from mixed sphere cultures and analyzed. The purity of tdRFP cells
in the clones was examined by flow cytometry. We found that clonally-isolated 2nd RadNSCs were homogeneous in terms of tdRFP expression (n=6; Figure 6J). To confirm that
2nd Rad-NSCs had self-renewal capacity and multipotency, sphere formation assays and
differentiation assays were performed. Similar to primary Rad-NSCs, dissociated clonal
2nd Rad-NSCs differentiated into neurons, astrocytes, and oligodendrocytes in culture
(Figure 6K-N). To examine the multipotency of clonal 2nd Rad-NSC spheres, spheres
were plated into 24-well dishes and differentiated for 7 days. Multipotency of clonal 2nd
Rad-NSC spheres was examined by immunocytochemistry (Figure 6O). Following
immunocytochemistry, the number of unipotent (astrocytes), bipotent (astrocytes and
neurons, or astrocytes and oligodendrocytes) and tripotent (astrocytes, neurons, and
oligodendrocytes) spheres were quantified (Figure 6P). We observed that 42% of spheres
from clonal 2nd Rad-NSCs were tripotent. Clonal 2nd Rad-NSCs also formed secondary
and tertiary spheres, suggesting that 2nd Rad-NSCs self-renewed ex vivo (Figure 6Q, R).
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Therefore, the primary Rad-NSCs that were transplanted into neonatal brains maintained
their ability to self-renew as NSCs in vivo for 28 days.

Transplanted Rad-NSCs generate astrocytes and oligodendrocytes in vivo.
To examine further the self-renewal and multipotency of tdRFP-positive Rad-NSCs in
vivo, we first transplanted GFP-positive PD4-NSCs that were isolated from the lateral
ventricles of healthy mice. For some transplants, the location of GFP-positive cells was
examined 4 hours after transplantation. As expected, we observed many GFP-positive
PD4-NSCs in the lateral ventricle and the needle track (Figure 7A). Other groups of
transplanted mice were examined 28 days after transplantation. In these mice, many
surviving GFP-positive cells were observed to remain in the SVZ after injection (Figure
7B). Notably, however, we also observed GFP-positive cells in the olfactory bulb (Figure
7C). To examine whether transplanted GFP-positive PD4-NSCs differentiated into
neurons in vivo, confocal imaging was performed to visualize NeuN/GFP-positive cells in
the olfactory bulb. We found that 66.6% of GFP-positive cells differentiated into NeuNpositive neurons in the olfactory bulb (n=48 cells, n=4 mice; Figure 7D). We also
observed 5% GFP-positive cells, derived from PD4-NSCs, that differentiated into GFAPpositive astrocytes in the olfactory bulb (n=20 cells, n=2 mice; Figure 7E).
To examine whether adult NSCs were multipotent following transplantation, we
isolated adult NSCs from the lateral ventricles of adult mice (4-8 weeks of age). We
obtained adult NSCs from GFP mice and also from mT/mG mice. Cells derived from
mT/mG mice express tdTomato without Cre recombination and provide a bright red
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signal to track cell lineage. We transplanted GFP-positive or tdTomato-positive cells into
the lateral ventricles of neonatal mice (Figure 7F). We observed migrating lineage-traced
cells in the RMS 1 month after transplantation (Figure 7G). Differentiated neurons and
astrocytes derived from adult NSCs were also observed in the olfactory bulb. After 1
month, we found that 16.2% of transplanted lineage-traced adult NSCs differentiated into
NeuN-positive neurons once they reached the olfactory bulb (n=482 cells, 3 mice; Figure
7H). We also observed that 14.1% of adult NSCs differentiated into GFAP-positive
astrocytes in the olfactory bulb (n=377 cells, 3 mice; Figure 7I). These data confirmed
that the multipotency of cultured adult NSCs could be evaluated by in vivo
transplantation back to mouse brains (Neumeister et al., 2009).
We then examined the multipotency of transplanted tdRFP-positive Rad-NSCs.
tdRFP-positive Rad-NSCs were transplanted into the RMS, lateral ventricle (SVZ), and
hippocampi (SGZ) of adult C57BL/6J mice. Twenty-eight days after transplantation,
brains were examined by immunohistochemistry. tdRFP-positive cells localized primarily
to the injection areas in the RMS, SVZ, and SGZ (n=3-13 mice; Figure 8A-C). In adults,
transplanted tdRFP-positive cells did not migrate to the RMS from the SVZ, and we did
not observe tdRFP-positive cells in the olfactory bulb 1 month after transplantation.
Moreover, after 1 month, no tdRFP-positive cells expressed NeuN (mature neuronal
marker) in the striatum, SVZ or SGZ, suggesting that the adult mouse brain did not
provide a suitable environment for Rad-NSCs to differentiate into neurons.
To determine if the age of the host affected the differentiation output from RadNSCs, tdRFP-Rad-NSCs were transplanted into postnatal day 0-4 mouse brains (n=15
256

mice).

Following tdRFP-positive Rad-NSC transplantation, tdRFP-positive cells

localized to the SVZ, gray matter, and white matter (Figure 8D,E and data not shown).
After 28 days, transplanted tdRFP-positive Rad-NSCs differentiated into GFAP-positive
astrocytes and GST-π-positive oligodendrocytes in both gray and white matter (n=85-198
cells; Figure 8D-G). Although we observed tdRFP-positive cells in the SVZ, we did not
observe any tdRFP-positive cells in the RMS or olfactory bulb. These data indicated that
tdRFP-positive cells did not migrate into the olfactory bulb from the SVZ 1 month after
transplantation into neonates. Additionally, tdRFP-positive cells were detected after
direct transplantation to the hippocampus. However, analysis by confocal microscopy
demonstrated that transplanted tdRFP-positive Rad-NSCs also did not differentiate into
NeuN-positive mature neurons in the hippocampus (Figure 8F). Similarly, we did not
observe tdRFP-positive cells expressing NeuN in gray or white matter 28 days after
transplantation into brains of neonates (n=489 cells; Figure 8G). Since immature
neuroblasts and some mature neurons do not express NeuN, we checked for other
markers of neurogenesis. However, tdRFP-positive cells did not express other neuronal
proteins, such as β-tubulin III, doublecortin, Hu C/D or PSA-NCAM (data not shown).
Therefore, tdRFP-positive Rad-NSCs differentiated into GFAP-positive astrocytes and
GSTπ -positive oligodendrocytes, but not neurons 1 month after transplantation into
neonates.
Because tdRFP-positive Rad-NSCs might require a longer time to differentiate
into neurons, we also examined transplanted cells 3 months after transplantation into
neonates. Three months after transplantation, tdRFP-positive cells expressed Nestin and
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Sox2 and also stained positive for BrDU in the SVZ, suggesting that self-renewing
tdRFP-positive cells could reside in the SVZ for 3 months (n=4 mice; Figure 8H-J).
Interestingly, at this time point, we observed that some tdRFP-positive cells had migrated
to the olfactory bulb. However, immunohistochemistry showed that tdRFP-positive cells
did not express NeuN in the olfactory bulb (n=117 cells; Figure 8K). Since not all
neurons in the olfactory bulb express NeuN, we also performed immunohistochemistry
using other neuronal markers, such as β-tubulin III, doublecortin, TH, Calretinin and
Calbindin (Parrish-Aungst et al., 2007; Batista-Brito et al., 2008). tdRFP-positive cells
did not express any of these additional neuronal markers (n=68-109 cells; Figure 8L and
data not shown). In contrast, we observed that 21% of tdRFP-positive cells expressed
GFAP. Thus, after 3 months, tdRFP-positive Rad-NSCs had migrated into the olfactory
bulb and differentiated into astrocytes, but not neurons (n=123 cells; Figure 8M). To
better understand the identify of the Rad-NSC-derived cells in the olfactory bulb, we
performed double stains for RFP and GalC (a marker of oligodendrocytes), NG2 (a
marker of oligodendrocyte progenitor cells and pericytes), and smooth muscle alpha actin
(SMA, a marker of smooth muscle cells and myofibroblasts). Despite confirmation of
positive staining for each marker throughout the brain, we did not observe any tdRFPpositive cells that co-expressed GalC, NG2, or SMA (data not shown).
To determine if the embryonic brain environment was more suitable for neuronal
differentiation of Rad-NSCs, we transplanted tdRFP-positive Rad-NSCs in utero into
embryonic day 15 (E15) mouse brains. Mice were euthanized at E20 to examine neuronal
differentiation. We observed many tdRFP-positive cells in both gray and white matter
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(Figure 8N). Although many tdRFP-positive cells were observed throughout the brains,
transplanted tdRFP-positive Rad-NSCs did not differentiate into NeuN-, Hu C/D-, or βtubulin III-positive neurons (n=837 cells, n=5 mice; Figure 8N,O and data not shown).
We observed that 53% of tdRFP-positive cells expressed GFAP in gray and white matter
(n=548 cells, n= 5 mice; Figure 8O). Therefore, despite their ability to generate neurons
in culture, we did not observe transplanted Rad-NSCs that differentiated into neurons in
vivo, regardless of host age.

Native reactive astrocytes are unipotent in vivo following stroke.
To determine whether endogenous reactive astrocytes are multipotent in the peri-infarct
area following stroke, we analyzed the cell types that were generated in the peri-infarct
area 1 month after stroke. We treated mice with BrDU immediately after stroke surgery
for 5 consecutive days and analyzed the mice 1 month after stroke. In agreement with our
previous study (Shimada et al., 2010), we did not observe BrDU-positive mature neurons
in the cortical peri-infarct area 1 month after stroke (n=3; Figure 9A). We observed
BrDU-positive newly-generated astrocytes and oligodendrocytes, (Figure 9B,C), but the
origin of these cells was not clear. To determine whether native reactive astrocytes were
multipotent in the cortical peri-infarct area in vivo after stroke, we performed a lineage
tracing study with GFAP-CreERTM;tdRFP reporter mice. Lineage tracing demonstrated
that tdRFP-positive reactive astrocytes did not differentiate into NeuN-positive mature
neurons or GSTπ-positive oligodendrocytes, but remained as GFAP-positive reactive
astrocytes in the peri-infarct area 28 days following stroke (n=3; Figure 9D-F). Therefore,
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endogenous tdRFP-positive reactive astrocytes were unipotent, and not multipotent in the
cortical peri-infarct area following stroke.

DISCUSSION
Our data demonstrate that cortical GFAP-expressing reactive astrocytes isolated from the
stroke injury environment can de-differentiate into Rad-NSCs that self-renew and are
multipotent. Lineage tracing demonstrated that reactive astrocytes are a cell of origin for
NSCs derived from in the cortical peri-infarct tissues after stroke. Our data also showed
that Rad-NSCs did not originate from cells that had migrated from the SVZ after stroke.
Previously, there were several possibilities regarding the cellular origin of cortical neural
sphere-forming cells after stroke: (1) neuroblasts or progenitor cells that migrated from
the SVZ to the cortex in the absence of stroke, (2) neuroblasts or progenitor cells that
migrated from the SVZ to the cortex after stroke, (3) bona fide stem cells that resided in
non-neurogenic niches, (4) oligodendrocyte progenitor cells, (5) pericytes, and (6)
reactive astrocytes. However, several of the possibilities were unlikely candidates for the
origin of Rad-NSCs. For example, in the brains of uninjured adult rodents, NSCs from
the SVZ are not known to migrate to the cortex after the completion of development
(Chen et al., 2009). In addition, NSCs or progenitors from the SVZ do not migrate to the
damaged cortex following brain stab injury or focal cortical stroke (Buffo et al., 2008;
Nakagomi et al., 2009; Shimada et al., 2010). Notably, we and others have not been able
to generate neural spheres from healthy adult cortical tissue (e.g. contralateral, uninjured
side of the cortex after stroke). In our hands, cells that reside in healthy cortex such as
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NG2-expressing oligodendrocyte progenitor cells, or other adult stem/progenitor cells
that potentially reside in non-neurogenic niches do not form neural spheres in NSC
growth medium. Furthermore, Buffo et al. (2008) sorted NG2-positive cells from cortical
tissue after stab injury and found that they did not give rise to neural spheres. In
agreement with our GFAP lineage tracing studies after stroke, GLAST-positive reactive
astrocytes were reported to form multipotential neural spheres in culture after brain stab
injury (Buffo et al., 2008). Therefore, reactive astrocytes are the most plausible candidate
for the cells that produce neural spheres from cortical tissue, regardless of type of injury.
It is noteworthy that we also obtained tdRFP-negative spheres from the peri-infarct area.
Although it is of interest to study the origin of these cells, we focused on GFAP-CreERpositive cell populations. Because inducible lineage tracing mice do not tag all relevant
cells (we found that Cre was not expressed by 100% of GFAP-positive cells), some of the
tdRFP-negative neural spheres could have derived from GFAP-expressing reactive
astrocytes that were not labeled. Since reactive astrocytes are phenotypically
heterogeneous in the peri-infarct area, generating other types of transgenic mice to track
subpopulations of reactive astrocytes would likely provide valuable tools to improve
understanding of reactive astrogliosis and also possibly neurogenesis (Li and Chopp,
1999; Ganat et al., 2006; Shimada et al., 2010; White et al., 2010; Bi et al., 2011).
Hematopoietic stem cell self-renewal capacity is generally tested in vivo using
transplantation studies (Kiel and Morrison, 2008; Nakada et al., 2011). Recently, the
Taylor group reported transplantation assays in mice to examine NSC self-renewal
capacity (Neumeister et al., 2009). They found that transplantation of typical mouse
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NSCs into embryonic or neonatal brains could generate neurons (Neumeister et al.,
2009). With a similar transplantation model, we showed that cultured PD4-NSCs and
adult NSCs that both were derived from the SVZ could migrate to the olfactory bulb in 1
month and produce mature neurons (NeuN-positive). To test the self-renewal and
multipotency of Rad-NSCs, we transplanted Rad-NSCs into the RMS, SVZ, or SGZ, in
adult mice, and also into the brains of neonatal mice and embryonic mice. Following
transplantation, Rad-NSCs in the SVZ expressed Sox2 and GFAP and BrDU
incorporation assays showed that Rad-NSCs proliferated in the SVZ after neonatal
transplantation. Transplanted Rad-NSCs could be re-isolated from the SVZ and grown as
NSCs, even after remaining 28 days in vivo. These data suggest that some Rad-NSCs
may maintain their capacity to self-renew as multipotent NSCs in the SVZ after
transplantation.
Despite their tri-potent capacity and ability to produce neurons in culture, Rad-NSCs
differed from SVZ-derived PD4-NSCs and adult NSCs in their ability to migrate to the
olfactory bulb and also in their ability to generate neurons once they reached the olfactory
bulb. The restriction for Rad-NSCs to produce neurons in vivo did not appear to involve
age-related changes in environmental (neurogenic) cues from the host; Rad-NSCs did not
differentiate into neurons in the brains of adult, neonatal or embryonic hosts.
Transplanted

Rad-NSCs

were

at

most,

bipotent,

producing

astrocytes

and

oligodendrocytes, but not neurons. Based on the similarities between Rad-NSCs and
bona fide NSCs from the SVZ in culture, and their differences following transplantation
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in vivo, Rad-NSCs may provide a valuable system to identify epigenetic and/or other
regulators of neurogenesis.
We identified Presenilin1-based Notch 1 signaling as a mechanism that controlled the
generation, proliferation, and self-renewal of Rad-NSC neural spheres. Consistent with
our study, other groups have shown that Notch 1 plays a critical role in the proliferation
and self-renewal of embryonic and adult NSCs (Borghese et al.; Hitoshi et al., 2002;
Androutsellis-Theotokis et al., 2006; Breunig et al., 2007; Ables et al., 2010;
Veeraraghavalu et al., 2010). Therefore, both Rad-NSCs and typical NSCs utilize a
common pathway that regulates stem cells.
The mechanisms that control de-differentiation of reactive astrocytes into Rad-NSCs, will
be interesting to study. Because we did not obtain any neural spheres from the
contralateral side of the cortex after stroke, our data indicate that the cortical peri-infarct
area contains signals that are permissive to the de-differentiation of reactive astrocytes.
Importantly, however, de-differentiation did not appear to occur in vivo. Lineage tracing
demonstrated that GFAP-positive reactive astrocytes were unipotent in the peri-infarct
area 28 days after stroke. Therefore, the combination of signals from the injury
environment after stroke, (e.g. hypoxia, reactive oxygen species, cytokines, growth
factors, Notch ligands, etc.) and signals during culture in NSC growth medium (e.g.
bFGF and/or EGF) are both important for the generation of Rad-NSCs.
All reactive astrocytes may not have the capacity to de-differentiate after stroke injury.
Reactive astrocytes are heterogeneous after injury, composed of subpopulations of cells
that differentially express proteins associated with stem/progenitor cells (White et al.,
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2010). Some reactive astrocytes proliferate, but many do not (Robel et al., 2011). We
recently identified RC2/Nestin/GFAP-positive reactive astrocytes in the cortical periinfarct after stroke (Shimada et al., 2010). The RC2-positive subpopulation of reactive
astrocytes also expressed Sox2 and NICD1, proliferated, and was located immediately
adjacent to the infarct core. We found that the RC2 antigen was undetectable in uninjured
adult cortex, or in the contralateral cortex after stroke. RC2 is an antigen commonly used
to label radial glial cells during development, and is not expressed by astrocytes in
uninured adults (Misson et al., 1988; Hartfuss et al., 2001; Dromard et al., 2007). We
found that cultured RAD-NSCs as well as typical NSCs express RC2. Based on their
unique appearance in injured cortical tissue, their proliferation, and their protein
expression, the subpopulation of RC2-positive reactive astrocytes may contain the cell of
origin for Rad-NSCs. Because neuroblast migration from the SVZ is limited or absent in
strokes that do not involve the striatum (Shimada et al., 2010), proliferating RC2-positive
reactive astrocytes may provide a target cell population for in vivo reprogramming to
enhance neurogenesis in cortical peri-infarct tissues after stroke.
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Figure 1. Emergence of reactive astrocytes in the peri-infarct area after stroke. (A)

Figure 1

Representative TTC staining of an infarct in C57BL/6J mouse brain. The infarct region is
white. (B, B’) GFAP-positive reactive astrocytes (green) were observed surrounding the
infarct area on the ipsilateral side of the cortex, but not on the contralateral side of the
cortex. (C-E) Some GFAP-positive reactive astrocytes (red) expressed Ki67 (C, green)
and Nestin (D, green), but did not express NG2 (E, green) in the peri-infarct area. (F, G)
GFAP- and Nestin-positive reactive astrocytes (red) expressed Sox2 (green). (H) The
number of Sox2-positive cells was significantly greater on the ipsilateral side of the
cortex compared with the contralateral side of the cortex after stroke. Arrows indicate
colocalizations. Scale bars indicate 50 µm unless otherwise noted. Dotted lines indicate
border of stroke infarct core. Cell nuclei are shown by DAPI staining (blue). ** p < 0.01.
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Figure

2.

Heterogeneous

tdRFP-positive

reactive

astrocytes

in

GFAP-

CreERTM;tdRFP mice.
(A-D) Three days after stroke and TM treatment, tdRFP-positive reactive astrocytes (red)
expressed GFAP (A, green), Nestin (B, green), RC2 (C, green), and S100B (D, green) in
the peri-infarct area in GFAP-CreERTM;tdRFP mice. The percentage of colocalization
was quantified in the peri-infarct area. Arrows indicate colocalizations. Scale bars
represent 50 µm. Cell nuclei are shown by DAPI staining (blue). TM: Tamoxifen.
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Figure 3. tdRFP-positive reactive astrocyte-derived NSCs (Rad-NSCs) isolated from
the cortical peri-infarct area. (A) Schematic illustration of cell isolation from the
Figure 3

cortical peri-infarct area 3 days after stroke. Tissue was dissected from the area
delineated by the black box. (B, C) Clonally-isolated cells formed neural spheres that
expressed tdRFP (TRITC filter) in culture. (D) We were unable to generate neural
spheres from tissues of the contralateral side of the cortex. (E, F) Neuroblasts
(Doublecortin, DCX) did not migrate from the SVZ to the peri-infarct area in the cortex 3
days after stroke. Note that the relative staining areas for contralateral (F) and ipsilateral
(E) DCX-positive cells did not differ. (G) Schematic illustration of DiI injection
immediately after stroke to label migrating cells derived from the lateral ventricle. (H)
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DiI-labeled cells (red) did not reach the cortical peri-infarct area 3 days after stroke. (I, J)
Most GFAP-positive cells (green) on the lateral side of the LV did not express tdRFP
(red), but colocalization was observed in the medial side of the LV in GFAPCreERTM;tdRFP mice. (K, L) Most neural spheres isolated from the dorsal and lateral
sides of the LV of GFAP-CreERTM;tdRFP mice did not express tdRFP. Cell nuclei are
shown by DAPI staining (blue). Scale bars represent 200 µm where indicated, otherwise
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Figure 4. Cultured Rad-NSCs have characteristics of NSCs, self-renew, and are
multipotent ex vivo. (A) Clonally-isolated Rad-NSCs were homogenous in terms of
tdRFP expression (gray). Post-natal day 4 (PD4)-derived NSCs (blue) were used as a
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negative control. (B, C) By sphere formation assays, Rad-NSCs formed fewer and
smaller spheres compared with PD4-derived NSCs. (D) Rad-NSCs proliferated at a
slower rate compared with PD4-NSCs. (E) By RT-PCR assays, Rad-NSCs expressed
different transcription factor mRNAs associated with NSCs. (F-J) Stem cell-related
proteins and the cell proliferation marker, Ki67 (green), were also expressed by RadNSCs (tdRFP, red). (K-N) Cultured Rad-NSCs (red) were dissociated and differentiated
into Tuj1-positive neurons (K, green), GFAP-positive astrocytes (L, green) and O4positive oligodendrocytes (M, green). Note that most Rad-NSCs differentiated into
astrocytes. (O-Q) Multipotency of clonal Rad-NSC spheres and clonal PD4-NSC spheres.
(O, P) Tuj1-positive neurons (red), O4-positive oligodendrocytes (green), and GFAPpositive astrocytes (blue) were stained by immunocytochemistry. Side panels provide
magnified view of neurons (red), oligodendrocytes (green) and astrocytes (blue) in
separate channels. (Q) The number of unipotent (A, astrocytes only), bipotent (A+N,
astrocytes and neurons; A+O, astrocytes and oligodendrocytes) and tripotent (A+N+O,
astrocytes, neurons and oligodendrocytes) spheres was quantified. Rad-NSCs produced
more tripotent spheres than PD4-NSCs. Side panels (F-M) show FITC and TRITC
channels. Arrows indicate co-localizations. Cell nuclei are shown by DAPI staining
(blue). Scale bars represent 200 µm where indicated, otherwise 50 µm. * p < 0.05. ** p <
0.01.
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Figure 5. Notch 1 signaling regulates self-renewal of Rad-NSCs. (A) NICD1 (green)
was expressed in tdRFP-positive Rad-NSCs (red) in culture. (B) Gamma-secretase
inhibitor (GSI) treatment reduced the number of Rad-NSCs compared with DMSO
treatment. (C) GLAST-positive cells were sorted from mouse brains by MACS. GLASTpositive cells were enriched with GFAP compared with GLAST-negative cells (as
determined by immunoblotting). β-Actin levels were used as an internal loading control.
(D) Following TM treatment of GFAP-CreERTM;Presenilin 1 cKO mice (GP mice),
Presenilin 1 expression levels decreased compared with levels in oil-treated GP mice.
GAPDH was used as an internal loading control.

(E) TM treatment of GP mice

significantly reduced the number of neural spheres formed in culture compared with
control groups. (F, G) The number (F) and growth (G) of Rad-NSCs from GP mice were
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both significantly reduced following 4-OH-TM treatment compared with vehicle control.
(H) Following TM treatment of GFAP-CreERTM;Notch 1 cKO mice (GN mice), NICD1
expression levels in sorted GLAST-positive cells were decreased compared to levels in
control oil-treated mice. (I, J) TM treatment of GN mice (I), but not oil treatment (J)
removed NICD1 (green) expression in GFAP-positive reactive astrocytes (red). (K-M)
The numbers of Ki67 (green)-positive proliferating reactive astrocytes (GFAP, red) were
compared in oil- or TM- treated GN mice and TM-treated GN heterozygous mice. (N)
TM treatment of GN mice and TM treatment of GN heterozygous mice significantly
reduced the number of proliferating reactive astrocytes compared with oil treatment of
GN mice. TM treatment of GN mice significantly reduced the number of proliferating
reactive astrocytes compared with TM treatment of GN heterozygous mice. (O) TM
treatment of GN mice and TM treatment of GN heterozygous mice significantly reduced
the number of neural spheres formed in culture compared with oil treatment of GN mice.
(P, Q) 4-OH-TM treatment significantly reduced the proliferation of Rad-NSCs from GN
mice and GN heterozygous mice compared with vehicle control (EtOH). (P) CyQUANT
assay. (Q) MTS assay. (R) mRNA levels for proteins expressed downstream of Notch
signaling were decreased in Rad-NSC spheres derived from TM -treated GN mice
compared with oil-treated GN mice. Cell nuclei are shown by DAPI staining (blue). TM:
Tamoxifen. Arrows indicate co-localizations. Scale bars represent 50 µm. * p < 0.05. **
p < 0.01, *** p < 0.001
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Figure 6. Self-renewal capacity of transplanted Rad-NSCs in vivo. (A) Schematic
illustration of tdRFP-positive Rad-NSC transplantation into post-natal day 0-4 C57BL/6J
mouse brain. (B) DiI staining shown 4 hours after transplantation of labeled cells into
post-natal day 0 mouse brain. DiI was observed in the lateral ventricle and the needle
track. (C-F) tdRFP-positive Rad-NSCs (red) located in the SVZ 28 days after
transplantation. (C, D) tdRFP-positive cells expressed stem cell markers, GFAP (C) and
Sox2 (D). (E) tdRFP-positive cells did not express Ki67, suggesting that these cells were
not actively dividing. Side panels show type B cell-like shape of engrafted tdRFPpositive cells. (F) tdRFP-positive cells expressed BrDU, suggesting that these cells selfrenewed in the SVZ after transplantation. Insets (C, D, F) show deconvolution for colocalization (x,y,z planes). (G) Schematic illustration of cell isolation from lateral
ventricle 28 days after transplantation. (H, I) Cells isolated from the SVZ generated both
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Rad-NSC-derived, and typical C57BL/6J-derived neural spheres ex vivo. Arrow: RadNSC-derived neural sphere.

Arrowhead: host-derived neural sphere. (J) Clonal

secondary-isolated Rad-NSCs (2nd Rad-NSCs) were homogenous in terms of tdRFP
expression (gray). Post-natal day 4 (PD4)-derived NSCs (blue) were used as a negative
control. (K) Most 2nd Rad-NSCs differentiated into astrocytes. (L-N) 2nd Rad-NSCs (red)
differentiated into neurons (L), astrocytes (M) and oligodendrocytes (N) ex vivo. Arrows
indicate co-localizations. Side panels show FITC and TRITC channels. (O, P) Tuj1positive neurons (red), O4-positive oligodendrocytes (green), and GFAP-positive
astrocytes (blue) were stained by immunocytochemistry. Side panels show magnified
views of neurons (red), oligodendrocytes (green) and astrocytes (blue) in separate
channels. The numbers of unipotent (A, astrocytes only), bipotent (A+N, astrocytes and
neurons; A+O, astrocytes and oligodendrocytes) and tripotent (A+N+O, astrocytes,
neurons and oligodendrocytes) spheres were quantified. (Q, R) Clonally-isolated 2°RadNSCs continued to form spheres ex vivo. Cell nuclei are shown by DAPI staining (blue).
Scale bars represent 500 µm or 200 µm where indicated, otherwise 50 µm.
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Figure 7. NSCs from the SVZ are multipotent and neurogenic in vivo after
transplantation. (A) GFP-positive PD4-NSCs (green) 4 hours after transplantation into
post-natal day 0 mouse brains. (B) GFP-positive cells (green) were observed in the lateral
ventricle 1 month after transplantation. (C) GFP-positive cells (green) with neuronal
morphology were observed in the olfactory bulb 1 month after transplantation. (D,E)

Figure 7

Confocal imaging demonstrated that GFP-positive PD4-NSCs (green) differentiated into
NeuN-positive neurons (D, red) and GFAP-positive astrocytes (E, red) in the olfactory
bulb. (F) tdTomato-positive adult NSCs (red) derived from the SVZ were observed in the
lateral ventricle 1 month after transplantation. (G) tdTomato-positive cells (red) with the
morphology of migrating neuroblasts were observed in the RMS 1 month after
transplantation. (H, I) tdTomato-positive adult NSCs (red) differentiated into NeuN282

positive neurons (H, green) and GFAP-positive astrocytes (I, green) in the olfactory bulb
1 month after transplantation. Scale bars represent 500 µm where indicated, otherwise
200 µm.
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Figure 8. Rad-NSCs differentiate into astrocytes and oligodendrocytes in vivo after
transplantation, but not neurons. (A-C) Transplanted Rad-NSCs (tdRFP, red) did not
differentiate into NeuN-positive neurons in the striatum (A, NeuN, green) or
hippocampus (B, NeuN, green) in adult brains. (C) Transplanted Rad-NSCs were
observed in the lateral ventricle in adult brains, but did not migrate in the RMS. (D, E)
Transplanted Rad-NSCs (tdRFP, red) differentiated into GFAP-positive astrocytes (D,
green) and GSTπ-positive oligodendrocytes (E, green) in the both white and gray matter
of neonatal mice after transplantation. (F) Transplanted Rad-NSCs (red) did not express
NeuN (green) in the hippocampus. (G) Quantification of Rad-NSC differentiation 1
month after neonatal transplantation into whole brain. (H, I) Three months after
transplantation, tdRFP-positive Rad-NSCs (red) expressed Sox2 (H, green) or Nestin (I,
green) in the SVZ. (J) Three months after transplantation, tdRFP-positive Rad-NSCs
(red) stained for BrDU (green) in the SVZ. (K, L) tdRFP-positive Rad-NSCs (red) that
migrated by the RMS did not express NeuN (K, green) or DCX (L, green) in the olfactory
bulb 3 months after transplantation. (M) tdRFP-positive Rad-NSCs (red) differentiated
into GFAP-positive astrocytes (green) in the olfactory bulb 3 months after
transplantation. (N) Transplanted Rad-NSCs (red) were observed to engraft in embryonic
day 20 brains. (O,P) Transplanted Rad-NSCs (tdRFP, red) did not differentiate into
NeuN-positive (O, green) or Hu C/D-positive (P, green) neurons in embryonic day 20
brains. (Q) Transplanted Rad-NSCs (red) expressed GFAP protein in embryonic day 20
brains. Cell nuclei are shown by DAPI staining (blue). Insets are magnified
deconvolution views of the white boxes. Scale bars represent 200 µm.
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Figure 9. Native reactive astrocytes are unipotent in vivo after stroke.
(A-C) BrDU (green) tracing studies revealed newly-generated cells in the peri-infarct
area 28 days after stroke. (A) No BrdU-positive neurons (NeuN, red) were observed in

Figure 9

the peri-infarct area 28 days after stroke. (B, C) Newly-generated oligodendrocytes
(GSTπ, red) and astrocytes (GFAP, red) were observed in the peri-infarct area 28 days
after stroke. (D-F) Lineage tracing revealed that tdRFP-positive reactive astrocytes (red)
did not differentiate into NeuN-positive mature neurons (D, green) or GSTπ-positive
oligodendrocytes (E, green), but remained as GFAP-positive reactive astrocytes (F,
green) in the peri-infarct area 1 month after stroke. Cell nuclei are shown by DAPI
staining (blue). Insets show magnified deconvolution view of the white boxes. Scale bars
represent 50 µm.
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